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SUMMARY
Cachexia is commonly seen in patients with cancer, 
and there is evidence to suggest that these 
debilitated cancer patients are at an increased risk 
of morbidity and mortality following surgical 
procedures.
This thesis is concerned with two main avenues of 
investigation. In the first part, various mechanisms 
implicated in the development of cancer cachexia have 
been investigated in weight stable and weight losing 
patients with cancer and nonmalignant illness. The 
second part is concerned with ways of influencing the 
metabolic response in cancer patients undergoing 
moderate and major surgical procedures.
Energy and substrate metabolism have been 
investigated in weight stable and weight losing 
patients with recently diagnosed cancer and 
nonmalignant illness. Colorectal, gastric and 
non-small cell bronchial cancer were the commonest 
types of tumour present in the patients with malignant 
disease. Cholelithiasis, peptic ulceration and benign 
colorectal polyps were the commonest benign diseases.
These studies involve the measurement of resting 
energy expenditure (REE) using an accurate indirect 
calorimeter designed and built in the Department of 
Surgery in 1979- Measurements of oxygen consumption, 
carbon dioxide production and urinary nitrogen
31
excretion provided the rates of fat and carbohydrate 
oxidation. Protein turnover was measured using a 
primed, continuous 24 hour infusion of ^^N-glycine.
The studies have shown that patients with cancer 
do not have significant elevations of REE compared 
with patients with nonmalignant illness. Abnormalities 
of REE appear to be more closely related to weight 
loss than to the presence of cancer, suggesting that 
the h o s t ’s response to illness is a more important 
determinant of REE than the presence of cancer.
Patients with different types of tumour appear to 
show differing relationships between REE and body 
size, highlighting the possible disadvantages of using 
heterogeneous groups of cancer patients in studies of 
REE. The longitudinal study of patients before and 
after surgery for colorectal cancer, which showed no 
significant differences in REE either following a 
curative resection or progression of hepatic 
metastatic disease, provides further evidence that REE 
is not affected by cancer or increasing tumour 
burden.
The inability of commonly used predictive formulae 
to provide an accurate estimate of REE in many 
patients has been demonstrated. It is concluded that 
subtle differences in body composition of ill patients 
compared with healthy individuals from which these
formulae were derived is responsible for these 
inaccuracies. An alternative method of estimating 
REE, namely, the anthropometric measurement of mid-arm 
muscle circumference, has been investigated. This 
measurement has been found to correlate closely with 
REE, but prospective evaluation of the derived 
equations is required.
The inaccuracies associated with expressing REE in 
terms of body weight have been discussed. It is 
stressed that REE should be expressed in terms of the 
metabolically active portion of body weight. However, 
the possible errors associated with using either total 
body water or total body potassium measurements to 
estimate the mass of metabolically active tissue have 
been discussed.
Abnormalities in the metabolism of endogenous 
carbohydrate, fat and protein have been demonstrated 
in cancer patients. Decreased carbohydrate oxidation 
and increased fat oxidation occurs in patients with 
cancer, and are more pronounced in those patients with 
hepatic métastasés. The increased fat oxidation rates 
may contribute significantly to the development of 
cancer cachexia, and may be related to the production 
by the tumour-bearing host of cachectin, which has 
been shown to interfere with fat metabolism. Patients 
with colorectal and bronchial cancer have increased 
rates of whole body protein turnover (WBPT) compared
with pat ients who have gast
illness. Howe v e r , this incr
related to weight loss and
REE.
The possibility that an acute phase protein 
response is responsible for some of these metabolic 
abnormalities has been discussed. This phenomenon 
would be consistent with the finding that 
abnormalities of REE appeared to be related more 
closely to weight loss than to the presence of 
cancer. It would also be consistent with the 
abnormalities seen in fat metabolism, possibly 
mediated through cachectin production.
In the second part of the thesis, the effects on 
the metabolic response to surgery of 
peripherally-administered intravenous nutrition and 
pharmacological manipulation have been investigated in 
patients undergoing surgery for colorectal or gastric 
cancer.
The postoperative administration of a peripheral 
intravenous nutritional regimen containing glucose, 
amino acids and fat to patients with colorectal cancer 
results in a positive nitrogen balance with minimal 
phlebitic complications. Although the administration 
of amino acids alone results in body fat mobilisation, 
it has only a transient effect on postoperative
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nitrogen balance, and has little to offer compared 
with a standard dextrose-saline regimen. It is 
concluded that where the provision of postoperative 
peripherally-administered intravenous nutrition is 
desired, the use of a nutritional mixture containing 
glucose, amino acids and fat should be used.
The use of the anabolic steroid stanozolol appears 
to improve postoperative nitrogen balance in patients 
receiving amino acid solutions following colorectal 
surgery. There is also a trend towards improved 
postoperative nitrogen balance in patients receiving a 
combination of glucose, amino acids and fat.
In patients receiving a dextrose-saline regimen 
following gastric surgery, stanozolol appears to 
result in a late improvement in postoperative nitrogen 
balance. While naftidrofuryl had no demonstrable 
effect on postoperative nitrogen balance, both this 
agent and stanozolol may have some infuence on 
endogenous fat metabolism. It is possible that 
alteration of the dose or timing of administration of 
stanozolol and naftidrofuryl may enhance their effects 
on the metabolic response to surgery and it is 
recommended that further investigation of these agents 
is warranted.
In conclusion, various abnormalities in the
metabolism of patients with cancer have been 
identified, some of which may contribute to the 
development of cancer cachexia. It has been shown that 
postoperative nitrogen losses can be reduced in cancer 
patients using peripherally-administered intravenous 
nutritional support. There is also some evidence to 
suggest that pharmacological manipulation of the 
metabolic response to surgery using stanozolol and 
naftidrofuryl may improve postoperative nitrogen 
balance and influence substrate metabolism in these 
patients.
CHAPTER 1
INTRODUCTION AND AIMS OF THE THESIS
INTRODUCTION
Cachexia is commonly seen in patients with cancer 
(1,2), and various contributing factors have been 
implicated in its development. Anorexia is often 
present and inevitably contributes significantly to 
the wasting process (3,4), but there are some cancer 
patients who exhibit severe weight loss despite a 
reasonable dietary intake (5). Abnormalities of energy 
and substrate metabolism may play an important role in 
the development of the cachectic state (6-9), although 
there are many poorly controlled studies and 
conflicting reports in the literature (10-12).
There is some evidence to suggest that debilitated 
cancer patients undergoing surgery are at increased 
risk of morbidity and mortality (13-14), and 
consequently many studies have investigated ways of 
improving the nutritional status or minimising the 
deleterious effects of the catabolic response to 
surgery in these patients. Intravenous nutrition has 
been shown to improve nutritional status 
preoperatively and postoperatively, but no consistent 
benefit to clinical outcome has been demonstrated 
(15-17). An alternative approach involves the 
pharmacological manipulation of the metabolic response 
to trauma, in an effort to minimise postoperative 
nitrogen and protein losses. Anabolic steroids 
(18 , 19), growth hormone (20), and naftidrofuryl (21)
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have been shown in some studies to improve 
postoperative nitrogen balance but, as with 
nutritional support, there is little evidence to 
suggest that this confers significant benefit to the 
patient in terms of clinical outcome.
The aims of this thesis, therefore, are:
a) To assess the effects of cancer, weight loss, 
tumour type and tumour burden on the resting 
energy expenditure of patients with malignant 
disease.
b) To assess the accuracy of predictive formulae and 
anthropometric measurements in the assessment of 
REE.
c) To assess the effects of cancer and weight loss 
on the metabolism of endogenous protein, 
carbohydrate and fat in patients with malignant 
disease.
d) To assess the effects of different peripherally- 
administered intravenous nutritional regimens
in patients following surgery for colorectal 
cancer.
e) To assess the effects of pharmacological 
manipulation of the metabolic response to trauma 
in patients undergoing surgery for colorectal and 
gastric cancer.
CHAPTER 2
HISTORICAL REVIEW OF THE LITERATURE
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CANCER CACHEXIA
Cachexia, characterised by marked asthenia with 
loss of both body fat and protein, is a common finding 
in cancer patients (1,2). Indeed, in a study of 500 
autopsies on cancer patients, Warren (22) reported 
that cachexia was the commonest single cause of death. 
It accounted for more than 22% of the deaths, 
particularly in patients with breast, colon and 
gastric cancer. Several causes have been implicated. 
For example, anorexia and mechanical obstruction of 
the gastrointestinal tract result in a decreased food 
intake which leads to weight loss (3,4,23). However, 
many cancer patients maintain a reasonable intake but 
continue to lose weight (5).
Several causes for this weight loss have been 
suggested. Alterations in energy metabolism of the 
tumour-bearing host have been implicated, with many 
reports (6-8) suggesting that cancer patients have a 
raised resting energy expenditure (REE). Abnormalities 
of protein, carbohydrate and fat metabolism have been 
noted in tumour-bearing patients (2,9). It has also 
been postulated that tumours may produce metabolites 
which may interfere with normal enzyme function (2). 
These abnormalities of substrate metabolism may lead 
directly to weight loss, or they may affect REE by 
involving the host in wasteful metabolic pathways 
which deplete the energy resources of the
tumour-bearing host.
Energy metabolism
The basal metabolic rate (BMR) is defined as the 
energy output of an individual who is bodily and 
mentally at rest, more than 12 hours after a meal and 
in a neutral thermal environment (24). Since these 
conditions are difficult to achieve, particularly in 
hospitalised patients, resting metabolic rate (RMR) or 
resting energy expenditure (REE) is more commonly 
measured. REE is determined in an individual lying at 
rest, two to four hours after a light breakfast (25). 
This measurement represents energy which is produced 
by the combustion of body fuels for the metabolic 
processes involved in the maintenence of body cell 
function and the integrity of the host.
A raised REE has been implicated repeatedly as a 
factor in the development of cancer cachexia (6-8). 
However, many of these reports, particularly the 
earlier ones, were anecdotal, and some more recent 
studies of REE in cancer have omitted the use of 
control groups (8,26). In many instances where 
controls have been studied, they have been young, 
healthy individuals not strictly comparable with the 
older hospitalised cancer patients (27). Furthermore, 
the methods of measuring REE have changed considerably
over the years and even today some of the techniques 
employed have considerable disadvantages (see Chapter 
3).
One of the earliest studies of REE in cancer 
patients was published in 1914 by Wallersteiner (28), 
who measured the exchange of oxygen and carbon dioxide 
in 33 patients, most of whom had gastric cancer. 
Fifteen patients had REE values greater than his 
chosen reference value (30kcal/kg body weight/day), 16 
patients had values between 26-30kcal/kg body 
weight/day, and two patients had low REE values. REE 
fell in one patient following surgical removal of the 
tumour, but increased when the tumour recurred.
Many of the early reports suggesting that cancer 
was associated with a raised REE involved patients 
with leukaemia (29-31). Shortly thereafter, other 
malignancies were reported to have similar effects on 
REE (32,33). However, there were few controlled 
studies until recently. In 1978 Warnold and 
colleagues (34) compared ten heterogeneous cancer 
patients with nine hospitalised patients with 
nonmalignant illness who were of a comparable age. REE 
was calculated from measurement of heart rate and was 
related to separate measurements of oxygen uptake at 
different levels of heart rate. They reported a mean 
REE in the cancer patients of 1630 kcal/day compared 
with 1170 kcal/day in the control patients. When a
further study was performed at the same centre using a 
more sophisticated indirect calorimeter (35), a small 
(148 kcal/day) but significant increase in REE was 
found in cancer patients, particularly in those who 
had lost weight.
Macfie and colleagues (27) also reported a small 
increase in REE but only patients with metastatic 
disease had an REE significantly greater (289 
kcal/day) than that of their younger control group. 
Other workers have also reported an association 
between increased REE and metastatic disease or tumour 
load. For example, in 1921 Gunderson (36) found that 
the elevation in REE correlated with the proportion of 
immature cells in the circulation of patients with 
leukaemia. Arbeit and colleagues (11) compared 11 
healthy controls with nine patients who had localised 
malignancies and four patients who had métastasés.
They found that all the cancer patients had a raised 
REE, especially those with metastatic disease. 
Furthermore, they claimed that REE fell following 
surgical excision of the tumour in four patients. A 
fall in REE following tumour removal or regression, 
and a rise following tumour recurrence, have been 
reported previously (6,28,37).
Some authors (26,38,39) have compared REE in 
cancer patients, not with control groups, but with a 
value predicted by the Harris-Benedict formula, which
was derived from the metabolic investigation of young 
healthy volunteers (40). Shike and colleagues (26), in 
a study of 31 patients with small cell bronchial 
cancer, found the mean REE to be significantly higher 
than predicted values, especially in those patients 
with métastasés. Those patients who responded to 
chemotherapy showed a fall in REE. Dempsey and 
colleagues (39), in a study of 173 patients with 
gastrointestinal malignancies, made similar 
comparisons with the Harris-Benedict formula and found 
a wide range of values, with some patients apparently 
markedly "hypometabolic" and others "hypermetabolic". 
They concluded that tumour type was a major
determinant of REE, with pancreatic and hepatic cancer
patients tending to have low values and gastric cancer
patients tending to have raised values. However, the
accuracy of predictive formulae in estimating REE has 
been questioned. Roza and Shizgal (41) found the 
Harris-Benedict formula to be inaccurate in predicting 
REE in malnourished patients while Mullen and 
colleagues (42) found a wide error in prediction using 
the Harris-Benedict and Kleiber (43) predictive 
formulae.
Very few authors have reported an unchanged REE in 
cancer-bearing patients. Burke and colleagues (44) 
found no difference in REE between 42 patients with 
gastrointestinal cancer and 24 with benign 
gastrointestinal disease. They were also unable to
find any differences in dietary intake between the two 
groups. This relationship between dietary intake and 
REE has been studied extensively. There appear to be 
fundamental differences in the responses of REE to 
simple starvation compared with the anorexia 
associated with neoplastic disease. The usual response 
to a reduction in food intake in a patient with a 
nonmalignant illness is a reduction in oxygen 
consumption and hence REE (45). This occurs through a 
decreased requirement for ATP, the formation of 
triglycerides, fatty acids and glycogen which normally 
follow a transient excess of food intake being 
diminished. There is some evidence to suggest that 
there is loss of this starvation adaption in cancer 
patients who decrease their food intake and 
consequently lose weight (7,46,47). These patients 
therefore will have a relative increase in REE, since 
they have a decreased mass of body tissue.
It has also been suggested that in patients with 
cancer the REE actually increases in the presence of a 
decreased food intake (35,48). Indeed, Waterhouse (47) 
reported that glycolysis and oxidative metabolism 
persisted at increased rates in the postabsorptive 
state in cancer patients. It was suggested, however, 
that this relative or real increase in REE probably 
failed to account for all the observed calorie 
deficit. An increase in the amount of energy required 
to metabolize ingested nutrients and an increase in
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the energy cost of performing routine daily activities 
have been proposed as possible factors which 
contribute to the increased REE in cancer patients 
(46). Furthermore, Fenninger and Mider (7) suggested 
that the normal REE and absence of weight loss seen in 
some patients with cancer may indicate that at certain 
stages of tumour growth REE was not increased, or that 
dietary intake could keep pace with an increased REE 
for some time during tumour growth.
Animal studies have provided evidence in support 
of some of the above hypotheses. For example, an 
increase in host REE following tumour transplantation 
in rats has been demonstrated (49). Furthermore, this 
increase can occur almost immediately following tumour 
transplantation and therefore before any significant 
tumour growth has occurred (50).
Resting energy expenditure is obviously related to 
the metabolism of protein, carbohydrate and fat (2), 
and various abnormalities in their metabolism have 
been identified in cancer patients. It has been 
suggested that these disorders could be responsible 
for at least a proportion of the supposed increase in 
REE seen in some patients with cancer (51).
Protein metabolism
The important relationship between protein 
metabolism and REE has been stressed repeatedly 
(28,51,52). The early studies of protein metabolism 
involved mainly measurements of nitrogen balance and 
the nitrogen content of tumours and other organs. For 
example, Mider and colleagues (53,54) and White (55) 
showed that the carcasses of rats in which Walker 256 
carcinoma had been growing contained less nitrogen 
than matched controls. Furthermore, they showed that 
the total nitrogen content of the tumour was greater 
than the amount of ingested nitrogen, leading to the 
conclusion that some of the nitrogen in the tumour 
must have come from the tissues of the host. This 
theory was supported by Sherman and colleagues (56) 
who demonstrated a loss of nitrogen from most tissues 
during the growth of Walker 256 carcinoma in rats. The 
liver and spleen appeared to be exceptions to this 
phenomenon, initially gaining nitrogen.
Patient studies tended to agree with the 
conclusions drawn from the animal work. As early as 
1914, Wallersteiner (28) reported nitrogen balances in 
12 patients with advanced cancer which suggested that 
nitrogen retention occurred as tumour growth 
continued. Thirty four years later, Mider and 
colleagues (53) postulated that tumours acted as 
"nitrogen traps", whereby the incorporation of amino
acids into the tumour was a one-way mechanism, unlike 
the dynamic interchange between the amino acid pool 
and other host tissues. Various studies shortly 
thereafter supported this theory (6,57-59). Other 
workers suggested, however, that during tumour 
regression the nitrogen stored in the tumour could be 
used by the host (60). The limitations of nitrogen 
balance studies have been emphasised by the 
observation that some tumour-bearing patients could be 
in positive nitrogen balance but in negative energy 
balance, suggesting that tumours could perhaps store 
nitrogen even in the presence of a total energy 
deficit (6). Furthermore, even when nitrogen balance 
was positive, this did not necessarily imply that 
nitrogen was being stored uniformly in the host 
tissues (37).
Nitrogen balance studies, therefore, are a very 
crude way of determining the various aspects of 
protein metabolism. In contrast, the stable isotopes 
of nitrogen in leucine and glycine have provided 
estimates of protein metabolism in terms of protein 
turnover, synthesis and breakdown, not only for the 
body as a whole, but also for individual organs such 
as the liver and skeletal muscle (52,61-63). Young 
(51) emphasised the important association between 
protein metabolism and REE, estimating that protein 
turnover could account for as much as 50% of the 
h o s t ’s REE. The response of protein turnover to a
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reduced energy intake is similar to the response of 
REE, namely, it falls as energy intake falls (64). It 
has been suggested that this adaptive mechanism may be 
impaired in patients with malignant disease (1,65). 
Indeed, it has been reported that in some cancer 
patients the rate of whole body protein turnover is 
elevated (52,61,62,66,67). However, not all studies 
have shown this increase in patients with cancer
(68,69).
The presence of a tumour affects protein 
metabolism differently in different organs. For 
example, decreased protein synthesis and increased 
protein breakdown have been demonstrated in skeletal 
muscle biopsies of patients with cancer (63,70), while 
an increase in liver protein synthesis was observed 
(63). Similarly, protein turnover studies in the 
liver and skeletal muscles of rats showed a decreased 
synthesis in skeletal muscle (71-71) and an increased 
synthesis in the liver (74). These results may explain 
the increased liver weight seen in tumour-bearing rats 
(75) and also the finding that the liver appeared not 
to lose nitrogen as readily as the other organs of 
rats with Walker 256 carcinoma (55). However, not all 
the increased protein synthesis in the liver is due to 
the synthesis of hepatic tissue protein. Scherstén and 
colleagues (76) suggested that a considerable 
proportion of the increased hepatic protein synthesis 
was due to the synthesis of acute phase reactants and
other proteins.
The nitrogen-retaining properties of tumours, 
referred to earlier in this section, have been 
confirmed by protein turnover studies, which showed 
that protein synthesis in rat tumours was greater than 
that of any other tissue studied (77), accounting for 
25% of the total body protein synthesis. This 
increased protein synthesis in the tumour may be at 
the expense of protein synthesis in skeletal muscle, 
which accounts for over 50% of the whole body protein 
synthesis (74). Scherstén and colleagues (76) 
estimated that the increased protein synthesis in the 
liver and tumour of sarcoma-bearing mice accounted for 
approximately 20% of the energy deficit seen in these 
animals, and concluded that other metabolic 
abnormalities must contribute significantly to the 
development of cancer cachexia.
Carbohydrate metabolism
It has been recognised for many years that 
neoplastic cells have high rates of glucose 
utilisation associated with increased production of 
lactic acid (78,79). Waterhouse and colleagues (6) 
suggested that this disordered glucose metabolism may 
cause wasteful energy expenditure and contribute to 
the increased REE which she observed in patients with
leukaemia and Hodgkin's disease. Some years later 
Waterhouse (47) measured exogenous glucose utilisation 
following the administration of trace amounts of 
glucose, and showed enhanced production of glucose in 
cancer patients compared with controls. When 
exogenous glucose was administered over a prolonged 
period, the normally accelerated rate of disappearance 
of blood glucose (80) was slower in patients with 
cancer, due either to a slower rate of entry of 
glucose into cells or else a persistent increase in 
Cori cycle activity (8l), which would be expected to 
decrease following glucose loading in normal subjects. 
It was concluded from these studies that cancer 
patients had a fixed rate of glucose utilisation which 
was unaffected by the ingestion of nutrients (47).
The lactic acid produced by glycolysis can either 
be utilised by host tissues or else resynthesised to 
glucose in the liver. This cyclical metabolism of 
glucose is known as the Cori cycle (8l). If the 
glucose is utilised by host tissues, maximal energy 
production is achieved, whereas its resynthesis to 
glucose in the liver is an energy-consuming pathway 
(7 ,82). Increased Cori cycle activity has been 
reported frequently in cancer patients (47, 82-84) and 
some authors have claimed that this futile cycling 
significantly increases the REE of the tumour-bearing 
patient (7 ,83,85). Holroyde and colleagues (82), 
using radiolabelled glucose, studied glucose
metabolism in 14 patients with metastatic cancer, six 
of whom had lost no weight and eight of whom had 
progressive weight loss. The six weight stable 
patients had normal glucose metabolism, whereas those 
with progressive weight loss had increased glucose 
turnover, increased glucose oxidation and increased 
Cori cycle activity. These findings agree with other 
studies of glucose metabolism (47,82-84, 86). REE was 
greatest in three of the four patients with high Cori 
cycle activity, and they concluded that the energy 
loss associated with this increased futile cycling 
contributed to the development of cachexia. However, 
Young (51), reviewing Holroyde's data (82), calculated 
that Cori cycle activity accounted for less than 10% 
of daily REE.
Abnormalities of glucose metabolism other than 
disordered Cori cycle activity have been reported in 
tumour-bearing patients and animals. Increased glucose 
turnover has been demonstrated in patients (83,87) and 
rats (88) with cancer. Kokal and colleagues (89), in a 
study of 11 patients with colorectal cancer, concluded 
that glucose turnover was increased in Dukes C and D 
tumours compared with Dukes B tumours, but found no 
difference between the groups with respect to Cori 
cycle activity. Lundholm and colleagues (83) claimed 
that 80% of the increased glucose turnover was due to 
increased Cori cycle activity, the remainder being due 
to increased glucose oxidation, ketone formation and
lipid synthesis. They estimated that the increased 
glucose turnover accounted for 30-40% of the increased 
oxygen consumption seen in weight losing cancer 
patients compared with weight stable patients without 
cancer. Increased rates of gluconeogenesis from 
alanine (90) and glycerol (91) as well as lactate (92) 
have been reported in cancer patients. Of these three 
precursors lactate appears to be used most commonly 
for gluconeogenesis.
Impaired glucose tolerance (93-96) and abnormal 
insulin responses (93,95,97,98) have been reported in 
tumour-bearing patients and rats. Kisner (99) 
attributed the abnormal glucose tolerance to abnormal 
insulin production and insulin resistance, rather than 
to a reduction in peripheral insulin receptors. Low 
insulin production has been reported in tumour-bearing 
rats (100) and patients with metastatic breast cancer 
(101). In a study of substrate flux across the 
forearms of six patients with localised oesophageal 
cancer and weight loss, Burt and colleagues (102) 
found increased glucose utilisation compared with six 
healthy controls, despite significantly lower serum 
insulin levels. They suggested that the increased 
glucose utilisation may be due to the presence of 
non-suppressible insulin-like activity (NSILA) (103), 
a substance possibly produced by the tumour itself 
(104). They supported the hypothesis of the "tumour 
trap” mechanism (87,90,105) characterised by increased
glucose utilisation both in the tumour and in 
peripheral tissues. This results in a fall in plasma 
glucose which stimulates glucose production by 
gluconeogenesis, Cori cycle activity and 
glycogenolysis. This in turn could lead to a depletion 
of protein in the peripheral tissues and hence could 
contribute to the development of cachexia.
Fat metabolism
The cachectic cancer patient exhibits a profound 
loss of body fat. Adipose tissue is a readily 
available energy source (46), and there is evidence 
that mobilisation of free fatty acids from host 
adipose tissue can occur less than 12 hours after 
tumour transplantation in rats (106). Free fatty acid 
mobilisation can also occur when a tumour is very 
small, and at this stage increased plasma lipid 
concentrations, as well as changes in plasma 
lipoprotein composition and plasma lipase activity are 
found in tumour-bearing animals (107,108). In 1949 
Mider and colleagues (109) showed that rats bearing 
Walker 256 carcinoma had a significantly greater loss 
of body fat than did well matched controls. They also 
reported that this progressive loss of body fat 
commenced only when anorexia developed (110). 
Furthermore, Haven and colleagues (111) stated that 
the total lipid in tumour-bearing rat carcasses was
inversely proportional to the size of the tumour.
Lipaemia is a common finding during tumour growth 
in rats (111,112), but a fall in plasma lipid levels 
has been reported as tumours increase in size (113). 
Fenninger and Mider (7) interpreted this as an initial 
increase in fat mobilisation in order to meet the 
increased energy demands of the host, followed by a 
fall in plasma lipids as the fat stores were 
exhausted. This finding would be consistent with the 
fall in lipid content of various tumours which occurs 
as the tumours grow (53), indicating a lack of 
available lipid for storage within the tumour. An 
alternative theory for the development of lipaemia is 
that clearance mechanisms may be defective (114). This 
has been confirmed in rats (115), where a decrease in 
the amount and rate of fat absorption was also found.
In contrast to the lipaemia seen in tumour-bearing 
animals, serum lipids are usually normal in patients 
with cancer (46). Increased fasting free fatty acid 
levels have been reported (116) and were said to be 
proportional to the rate of tumour growth. However, 
previous dietary intake can influence fasting free 
fatty acid levels in man (117). It should be noted 
that in normal individuals who have had a high 
carbohydrate intake, fasting triglyceride levels will 
be high (118 ). However, the reverse is true in 
patients with cancer (46). Furthermore, following an
intravenous infusion of fat, cancer patients show an 
increased rate of disappearance of the infused fat 
whereas tumour-bearing animals show the opposite 
response (119). This finding may explain the 
difference between lipid levels in animals and man, 
with the latter unable to develop a significant 
lipaemia.
Cancer patients respond differently from controls 
in response to a glucose load. Waterhouse and 
Kemperman (10) showed diminished suppression of free 
fatty acid oxidation following a glucose load in five 
patients with metastatic cancer compared with 
controls. Other workers (7,9,11,46,106) have reported 
increased lipolysis in cancer patients. The increased 
mobilisation of free fatty acids from the adipose 
tissue of tumour-bearing hosts has various possible 
mechanisms: increased sympathetic tone (20), abnormal 
enzyme activation, deranged insulin/glucagon activity 
or a direct effect of tumour products have all been 
postulated (9). The isolation from tumours of 
"lipid-mobilising factors" has been reported (121), 
but the exact nature of these substances remains 
obscure. Arbeit and colleagues (11) reported increased 
fat oxidation rates in patients with metastatic cancer 
compared with controls, but found no significant 
difference between patients with localised cancer and 
controls. They also found no significant difference 
between patients with metastatic and localised cancer.
Weight losing cancer patients also have a 
significantly increased glycerol turnover compared 
with controls (12). The authors concluded that this 
probably indicated an increase in whole body 
lipolysis, perhaps related to decreased circulating 
insulin levels and increased adrenergic activity.
Recently, a protein produced by the macrophages of 
tumour-bearing hosts has been discovered (122,123). 
This protein, known as tumour necrosis factor or 
cachectin, has been shown to interfere with the 
control of fat metabolism in patients with cancer. It 
is possible that this endogenous mechanism, which 
seems to occur as a defense against the tumour-bearing 
state, may in fact contribute to the development of 
cancer cachexia by interfering with fat metabolism in 
the host.
Anorexia
Anorexia is a common symptom in the cancer 
patient, and inevitably leads to an inadequate dietary 
intake (9,124,125). It therefore plays a significant 
role in the development of cancer cachexia.
Mechanical obstruction of the gastrointestinal tract 
will lead to an inadequate food intake, while altered 
taste sensation and the effects of chemotherapy and 
radiotherapy can contribute to the development of
anorexia (4,9,125). However, many patients with 
cancer exhibit profound anorexia in the presence of 
very small tumours which are distant from the 
gastrointestinal tract and causing no other obvious 
secondary effects on the host (9).
Retrospective assessment of dietary intake is 
inaccurate (126) and is influenced by such factors as 
the intelligence of the patient (127) and the mode of 
questioning of the interviewer (128). Wesdorp and 
colleagues (9) demonstrated the inaccuracies of 
retrospective dietary assessment by asking cachectic 
cancer patients to complete a dietary questionaire, 
showing that many of these patients were unaware of 
their anorexia.
The mechanisms controlling food intake are complex 
(124), yet normal individuals maintain a reasonably 
steady body weight over prolonged time intervals. It 
has been postulated that this normal physiological 
regulatory mechanism may be upset in the presence of 
cancer, either by a direct effect of the tumour or 
secondary to a host response to the tumour (129). 
Wurtman and colleagues (130) noticed that the dietary 
content of precursors of central neurotransmitters 
could affect behavioural patterns. Studies in rats had 
suggested that the neurotransmitter serotonin was 
involved in the regulation of food intake, whereby 
increased serotonin turnover was associated with a
decreased food intake (131,132) and vice versa 
(133,134). Tryptophan, the only amino acid precursor 
of serotonin is an essential amino acid and therefore 
is dependent on dietary intake for adequate levels in 
the host. Furthermore, the ingestion of carbohydrate, 
protein and fat increases plasma tryptophan levels 
(9). These findings support the theory that serotonin 
may be involved in the regulation of dietary intake.
Krause and colleagues conducted studies to assess 
serotonin status in tumour-bearing (Walker 256 
carcinoma) anorexic rats (135,136) and found that 
brain levels of tryptophan and serotonin were 
increased in these rats compared with control animals. 
They found similar results when rats with a chronic 
tumour (methylcholanthrene-induced sarcoma) resulting 
in prolonged anorexia were studied (137). They 
concluded that the observed biochemical disorders were 
not tumour specific, and suggested that the increased 
levels of serotonin were caused by an increase in 
plasma free and brain tryptophan secondary to a 
reduced number of binding sites due to the decreased 
albumin and increased free fatty acid levels seen in 
patients with cancer.
There is some evidence that serotonin is involved 
in feeding behaviour, circadian rhythms, mood and pain 
sensation (9). The low food intake and vegetative 
depression seen in many cachectic cancer patients is
therefore in keeping with a possible serotonin effect. 
In a pilot study of over 20 patients with anorexia and 
cancer, the administration of the serotonin antagonist 
BC 105 resulted in improved food intake, weight gain 
and a decrease in depressive symptoms (9), further 
supporting the contention that serotonin may be 
involved in the anorexia of cancer.
Enzyme abnormalities
The growth of a tumour is associated with changes 
in the activity of many enzymes in host tissues 
distant from the site of the tumour (2), for example, 
in the activity of liver enzymes in tumour-bearing 
animals (138). There are also alterations in the 
activity of enzymes involved in gluconeogenesis (139), 
amino acid catabolism (140), and an increased activity 
of certain muscle peptide hydrolases (141). Many of 
these biochemical abnormalities were present when the 
tumour was very small and had not caused any obvious 
secondary effects in the host (142). The type of 
tumour present and the stage of tumour growth appeared 
to influence the observed biochemical changes.
Alterations in enzyme activity of tumour-bearing 
patients have also been reported. There is increased 
activity of hydrolysing enzymes in the liver of 
patients with renal tumours (143), and significantly
decreased activities of various skeletal muscle 
glycolytic and mitochondrial enzymes (95).
It is difficult to determine the association 
between these disordered enzyme activities and the 
development of cancer cachexia, many of which may be 
secondary to the cachexia, rather than the causative 
factor. However, these disordered enzyme activities 
are in keeping with the hypothesis offered by 
Theologides in 1972 (49), who suggested that tumours 
produced low molecular weight polypeptides which could 
interfere with the function of many host enzymes, 
thereby resulting in chaotic metabolic pathways in the 
tumour-bearing patient. This could result in a wastage 
of energy and thus render the patient hypermetabolic. 
This hypothesis could explain the metabolic 
abnormalities which have been reported in patients who 
have very small tumours which have not metastasised or 
resulted in secondary effects within the host.
INTRAVENOUS NUTRITIONAL SUPPORT IN THE PERIOPERATIVE
PERIOD.
The metabolic response to trauma is characterised 
by an increase in urinary nitrogen excretion and loss 
of body protein (144,145). These changes are tolerated 
well in adequately nourished patients undergoing 
surgical procedures, who regain weight and positive 
nitrogen balance in the anabolic phase. However, 
debilitated patients who have lost weight prior to 
surgery may tolerate the catabolic phase less well, 
and may be at risk of increased morbidity and 
mortality (13,14).
In an attempt to reduce postoperative 
complications in these patients, various forms of 
nutritional support have been administered either 
prior to or following surgery. Where the 
gastrointestinal tract is functioning normally, 
dietary supplements or nasogastric feeding can 
overcome the problems of inadequate food intake or 
anorexia. However, in many patients the 
gastrointestinal tract cannot be utilised adequately 
either due to pathology therein or the need to fast 
patients for various preoperative investigations. The 
administration of total parenteral nutrition (TPN) in 
the preoperative period has resulted in a reduction in 
postoperative complications and mortality in some 
studies. For example, Dudrick and colleagues (146,147)
reported a reduction in postoperative complications 
and mortality in cancer patients who received 7-14 
days of TPN preoperatively. Muller and colleagues (16) 
reported a reduction in mortality and major 
postoperative complications such as intra-abdominal 
abscess, peritonitis and anastomotic leakage in 
patients with gastrointestinal cancer receiving ten 
days of TPN preoperatively compared with similar 
patients receiving normal hospital diet. Other studies 
of preoperative TPN have yielded less convincing 
results (15,17) and some clinicians would argue that 
its use merely delays operative intervention. The case 
for preoperative TPN therefore remains unproven.
The use of postoperative nutritional support has 
also been studied extensively in patients with 
gastrointestinal disease. In the early postoperative 
period the gastrointestinal tract is frequently unable 
to tolerate intra-luminal nutrition and consequently 
the emphasis has been on intravenous nutritional 
support. As with preoperative TPN, the use of TPN in 
the postoperative period has yielded conflicting 
results. Hill (148) and Blackburn (149) have reported 
a reduction in postoperative complications and 
catabolism in patients receiving postoperative TPN, 
and although other studies have demonstrated 
improvements in postoperative nitrogen balance 
(65,150), the evidence showing that this in turn 
reduces postoperative morbidity and mortality is less
6 4
convincing (17,152,153).
Furthermore, the administration of TPN is not 
without significant hazard. The venotoxicity of 
hyperosmolar TPN solutions necessitates the use of the 
central veins for their delivery. Cannulation of the 
subclavian vein is associated with significant 
complications including pneumothorax, haemothorax, 
subclavian artery puncture and brachial plexus injury 
(154,155). Consequently, an experienced clinician is 
required for the safe insertion of these catheters 
(156). Once catheterisation is established, the main 
complication of TPN administration is catheter-related 
sepsis (154,157). Reported catheter sepsis rates vary 
from 0-41% (158,159). It is now well established that 
catheter sepsis rates can be minimised if the 
adminstration of TPN is supervised by clinicians and 
nurses who have a specific interest in nutritional 
support (160,161 ).
The lack of convincing evidence proving the 
benefit of TPN administration, together with the 
associated hazards and expense, have led many workers 
to investigate the role of peripheral intravenous 
nutrition in surgical patients. The advantages of 
peripheral intravenous nutrition are that little 
expertise is required in the placement of the 
peripheral venous cannula and the problem of 
catheter-related sepsis is considerably less. The main
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disadvantage, however, is that it is not usually 
possible to administer as much nitrogen and energy due 
to the phlebitis which occurs due to the hypertonicity 
of TPN solutions (162).
Although isotonic dextrose solutions have been 
shown previously to spare nitrogen (163,164),
Blackburn and colleagues (165) have challenged the 
rationale behind the use of these solutions in 
postoperative patients. They hypothesised that infused 
glucose stimulated insulin secretion and hence 
inhibited lipolysis, thus depriving the body of 
endogenously produced energy substrates such as free 
fatty acids, glycerol and ketones. They also 
suggested that the administration of isotonic amino 
acids, in the absence of infused glucose, conserved 
body protein stores by encouraging the mobilisation 
and utilisation of body fat stores, and claimed that 
the low insulin levels which occurred in the absence 
of infused glucose enhanced lipolysis, and hence 
prevented the breakdown of body protein for 
gluconeogenesis. However, various workers (166-168), 
comparing amino acid infusions alone with a 
combination of amino acids plus dextrose, have shown 
that the protein sparing effects of
peripherally-administered amino acids are due to the 
infused amino acids alone, and are independent of 
plasma insulin levels and ketosis. Indeed, Elwyn and 
colleagues (169) reported that the addition of glucose
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to peripheral amino acid infusions actually reduced 
nitrogen excretion.
More recently, Garden and coworkers (170) reported 
a significant improvement in nitrogen balance on only 
the first postoperative day in patients receiving 
amino acid infusions providing lOg nitrogen per day 
compared with patients receiving dextrose-saline 
infusions. Other studies have shown a more prolonged 
improvement in nitrogen balance in patients receiving 
amino acid solutions containing 10-l4g nitrogen per 
day (169,171). The type of amino acid used, and the 
balance of essential to non-essential amino acids, may 
be partly responsible for these differences in 
nitrogen balance. Indeed, Tweedle and colleagues (172) 
have shown that solutions low in glycine and alanine 
produce better nitrogen balance than solutions with 
high non-essential amino acid concentrations in 
patients receiving TPN.
The high osmolarity of nutrient solutions 
containing large amounts of nitrogen and calories has 
prevented the administration of these solutions 
through a peripheral vein. However, Burnham and 
colleagues (173) have administered a combination of 
amino acids, fat and carbohydrate providing 
approximately 14g nitrogen and 3000 non-protein 
calories per day via the peripheral veins of patients 
with gastrointestinal disease and reported positive
nitrogen balance and only a few episodes of mild 
phlebitis. Silberman and colleagues (174) also 
reported a low incidence of phlebitis in patients 
receiving a hyperosmolar solution of amino acids, 
dextrose, vitamins, heparin and fat. Anecdotal 
evidence has suggested that the addition of fat 
emulsions to peripheral nutrition solutions in some 
way protects the vein and decreases the incidence of 
phlebitis. However, recently Daly and colleagues (175) 
found no difference in the incidence of phlebitis 
whether a dextrose/amino acid solution was 
administered alone or with fat emulsion.
There is thus no consistent evidence to show that 
the use of preoperative or postoperative nutritional 
support, whether administered via a central or 
peripheral vein, significantly improves postoperative 
morbidity or mortality. Furthermore, it is difficult 
to define the "at risk" patients who may benefit from 
some form of nutritional support, despite the various 
prognostic indices which have been identified (13). 
Until the precise indications for the use of 
intravenous nutritional support in the perioperative 
period are established, its administration should be 
confined to clinical trials designed to assess the 
possible biochemical and clinical benefits of this 
therapy.
MANIPULATION OF THE METABOLIC RESPONSE TO SURGERY
The loss of body protein which occurs following 
surgical trauma (144,176,177) may have deleterious 
effects on debilitated patients (13,14). The early 
hopes that total parenteral nutrition (TPN) would 
reduce postoperative complications in many of these 
patients have been dampened by conflicting evidence 
from many studies (15-17,153). These findings, 
together with the hazards and expense (154,157,178) 
associated with the administration of TPN, have led to 
the investigation of alternative ways of influencing 
the metabolic response to surgery.
Raising the environmental temperature has been 
shown to modify heat production and protein catabolism 
following burn injury (179) and long bone fracture 
(180,181). Davies and Liljedahl (179) demonstrated a 
30% reduction in metabolism in patients with extensive 
burn injuries when the environmental temperature was 
raised from 22 degrees centigrade to 32 degrees 
centigrade, but observed that this effect became less 
as the severity of the burn decreased. Sir David 
Cuthbertson and colleagues (I80,l8l) demonstrated a 
reduction in the metabolic response to trauma when 
patients with long bone fractures were transferred to 
a warm environment, whereas patients undergoing major 
or moderately severe elective surgery appeared to 
derive no significant metabolic benefit from a similar
o9
rise in environmental temperature (182). The mechanism 
of the reduction in metabolism seen when burned 
patients are nursed in a high environmental 
temperature appears to be related to the evaporation 
of water from burned tissues. When the environmental 
temperature is high, the energy required to evaporate 
this water can be derived from the environment rather 
than the energy-rich nutritional stores of the host. 
Noradrenaline concentrations are persistently raised 
in these patients (I83) and the temperature control 
centre in the hypothalamus appears to be reset to a 
supranormal level (184). These features are not seen 
in fracture patients or those undergoing elective 
surgery, where any metabolic benefit of a raised 
environmental temperature is probably related only to 
the maintenence of core temperature thereby reducing 
the utilisation of endogenous fuels for this purpose.
Manipulating the metabolic response to surgery by 
neurogenic blockade has also been investigated. Brandt 
and colleagues (185) demonstrated a significant 
improvement in postoperative nitrogen balance when 
epidural analgesia was administered to patients 
undergoing abdominal hysterectomy. Although Traynor 
and colleagues (I86) reproduced the abolition of the 
glycaemic response to surgery when thoracic epidural 
analgesia and vagal blockade were combined during 
upper abdominal surgery, they failed to show any 
effect on the plasma cortisol levels. It is also known
that paraplegic patients undergoing surgery for the 
repair of lower limb fractures show the same increased 
catabolism of plasma albumin as found in 
non-paraplegic patients undergoing the same surgical 
procedures (187). Thus, the role of local analgesic 
techniques in influencing the metabolic response to 
surgery remains in doubt.
Pharmacological manipulation of the metabolic 
response to surgery has also been investigated. The 
reduced insulin secretion which occurs following 
trauma has led some workers to investigate the effects 
of insulin administration following surgery. It 
appears to reduce nitrogen losses in severely burned 
patients (188,189), but has little effect on nitrogen 
balance in the absence of an increased catabolic rate 
(189). Growth hormone has also been shown to improve 
nitrogen balance (20), but neither insulin nor growth 
hormone appear to diminish the release of catabolic 
hormones postoperatively. Injury may modify reactions 
which control the entry of fat and carbohydrate into 
the tricarboxylic acid cycle, thereby promoting 
oxidation of endogenous amino acids and thus 
increasing nitrogen excretion. Burns and colleagues 
(21 ) demonstrated improved nitrogen balance after 
surgery when naftidrofuryl was administered by slow 
bolus intravenous injection and suggested that this 
may be due to improved efficiency of endogenous 
carbohydrate and fat metabolism in the tricarboxylic
acid cycle. However, other workers (190,191) have 
found no significant improvement in nitrogen balance, 
whether naftidrofuryl was administered as a continuous 
infusion (190) or by slow bolus (191).
Anabolic steroids have been shown to reduce 
post-traumatic protein catabolism but their virilising 
effects have limited their use, especially in females 
(18). Their mode of action in influencing the 
metabolic response to injury is uncertain, although 
changes in nitrogen excretion are evident in both 
anabolic and catabolic phases of the response (192) 
and follow both minor and major trauma (193). 
Methandienone does not affect the rise in plasma 
cortisol or the excretion of urinary steroids 
following injury suggesting that anabolism may result 
from a direct effect on the tricarboxylic acid cycle 
(18). Norethandrolone and methandienone have been 
shown to reduce nitrogen excretion and weight loss in 
some postoperative patients (18,19) but not in others 
(194,195). Blamey and colleagues (196) showed that a 
single preoperative intramuscular 50mg dose of the 
anabolic steroid stanozolol reduced postoperative 
nitrogen balance in patients receiving a simple 
dextrose-saline regimen, and Michelsen and colleagues 
(193) reported a reduction in nitrogen excretion 
following total hip replacement in patients receiving 
nandrolone decanoate and isotonic amino acids.
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There has been conflicting evidence regarding the 
effects of anabolic steroids on nitrogen excretion in 
postoperative patients receiving TPN. For example, 
Tweedle and coworkers (192) showed that a combination 
of nandrolone decanoate and TPN improved nitrogen 
balance moreso than nandrolone decanoate alone, 
whereas Yule and colleagues (197) showed anabolic 
steroids to have no significant effect on nitrogen 
balance in patients receiving postoperative TPN,
To date there have been few studies involving the 
use of anabolic steroids in groups of cancer patients 
Most studies have involved either groups of patients 
with benign disease only (18,192,194,195,198,199) or 
where the majority of patients had benign disease 
(196,200-203).
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CHAPTER 3
METHODS
PATIENTS
The patients studied in this thesis presented to 
the University Department of Surgery between October 
1983 and December 1985. Informed consent was obtained 
from each patient prior to inclusion in the studies. 
In some instances patients have been included in more 
than one of the studies reported. All patients had 
been admitted for elective surgery or investigation. 
Patients who had clinical or bacteriological evidence 
of infection or obvious oedema or ascites, and those 
who had undergone surgery, radiotherapy or cytotoxic 
chemotherapy in the preceding year were not included. 
None of the patients studied had received nutritional 
support previously.
Patients were weighed wearing light night attire 
on beam balance standing scales (Weylux 424, U.K.). 
Patients were classified as weight stable or weight 
losing depending on the degree of weight loss 
reported. The patient’s usual body weight (prior to 
the onset of their presenting illness) was compared 
with the value recorded at the time of study. Each 
patient was questioned carefully about their usual 
weight and weight loss. This method relied on each 
patient’s subjective impression of their usual body 
weight, and while a degree of error is inevitable 
using this method, it was deemed to be more relevant 
than a comparison with desirable weight. Those
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patients who had lost 10% or more of their usual body 
weight were classified as weight losing.
.. 7
MEASUREMENT OF RESTING ENERGY EXPENDITURE
Studies of heat loss and heat production 
associated with the metabolism of man and animals have 
been performed for over two centuries (204). Energy 
expenditure can be derived either by measurement of 
heat loss (direct calorimetry) or estimation of heat 
production (indirect calorimetry). In direct 
calorimetry, the subject is completely enclosed within 
a chamber, which is either surrounded by water (205, 
206) or ventilated by a controlled air flow (207). 
Energy expenditure is then calculated from the rise in 
temperature of the water or air. This method is 
impractical in the hospital situation, as patients 
would be denied medical and nursing care during the 
study period.
Indirect calorimetry provides a more suitable 
method of estimating energy expenditure. The 
maintenance of body cell function involves the 
constant combustion of body fuels or exogenous 
nutrients. This combustion consumes oxygen and 
produces carbon dioxide. Measurement of gaseous 
exchange through the lungs therefore provides an 
indirect estimation of the amount of energy which is 
being expended by the host. The ratio of carbon 
dioxide produced to oxygen consumed, that is, the 
respiratory quotient (RQ), is a useful indicator of 
bhe type of Fuel being utilised. The physiological
range (0.7 - 1.2) is narrow, with an RQ of 0.7 
representing net fat utilisation, an RQ of 1.0 
indicating carbohydrate utilisation and RQ values 
greater than 1.0 indicating carbohydrate synthesis and 
storage.
The accurate measurement of gaseous exchange 
requires the measured delivery of inspired gases and 
the collection of expired gases, avoiding mixing with 
atmospheric air. This can be achieved to a variable 
extent in several ways. The subject can breath 
directly into a mouthpiece (while wearing a noseclip) 
or facemask. However, this technique is uncomfortable 
and can be tolerated for only a short duration. 
Furthermore, the discomfort can result in 
hyperventilation, especially in ill subjects (208).
The development of the rigid transparent head canopy 
has enabled gaseous exchange to be measured for long 
periods, even in critically ill patients (209,210).
In this closed system, the canopy is placed around the 
subject’s head and sealed around the neck using a 
flexible collar. An indirect calorimeter based on this 
design was used throughout the present studies. The 
calorimeter was built and developed in the Department 
of Surgery in the late 1970s (see Appendix) and has 
been used for clinical studies since that time.
Room air of a known oxygen and carbon dioxide 
concentration is delivered at a controlled rate to the
canopy. A mixture of this air and the subject's 
expired gases is extracted from the canopy at a 
controlled rate. Following dehumidification the mixed 
air is delivered to a wall mounted dual cell 
paramagnetic oxygen analyser (Servomex Ltd, 
Crowborough, Sussex, U.K.) and a single channel 
infra-red carbon dioxide analyser (Sieger Ltd, Poole, 
Dorset, U.K.). The concentration of oxygen and carbon 
dioxide in the mixed air, corrected for temperature 
and barometric pressure, is measured, and by 
comparison with the oxygen and carbon dioxide 
concentrations of the room air, which have been 
measured in the same way, the oxygen consumption (VOg) 
and carbon dioxide production (VCOp) of the subject 
can be derived. The analysers were calibrated 
regularly using oxygen-free nitrogen, 0.80% carbon 
dioxide and air of a known barometric presssure. The 
sensitivity and accuracy of the calorimeter was 
checked regularly by burning butane gas in the canopy 
(see appendix). The whole system provides measurements 
of VOg and VCO^ which have an overall error of less 
than +5%. Estimates of VO2 and VCOg were made every 
30 seconds during each patient study which lasted for 
40 minutes. Recording of data did not commence until a 
steady rate of oxygen consumption and carbon dioxide 
production was obtained, usually after 5-10 minutes. 
The 80 estimates of VO2 and VCO2 collected were 
processed on line by a microprocessor (PET 2001,
C.B.M. Ltd.) and converted to mean energy production
(Watts) and RQ using the abbreviated formula of Weir 
(2 1 1):
REE (kcal/day) = (3.9V02 + 1.1VC02)1440
kcal/day = Watts X
VO2 = oxygen
VCO2 = carbon
VCO2
RQ
VO2
The measurement period of 40 minutes was preceded 
by 30 minutes acclimatisation in the calorimeter 
canopy. No acclimatisation period was used in 
postoperative studies, as these patients were already 
familiar with the procedure. Each study began at 
approximately 09.00 hours, the patients having 
remained in bed since wakening. Physiotherapy, 
bed-baths and other nursing procedures were not 
permitted prior to a calorimetry run. Patients 
undergoing postoperative calorimetry received 
intravenous fluids as described in the relevant 
studies. For all other calorimetry runs patients 
received nil by mouth for 12 hours prior to the 
calorimetry run but received an intravenous infusion 
of 5% dextrose solution providing 80 ml of fluid 
(I6kcal) per hour to maintain hydration.
CALCULATION OF SUBSTRATE OXIDATION RATES
From the measurements of oxygen consumption and 
carbon dioxide production obtained by indirect 
calorimetry, together with measurements of 24 hour 
urinary nitrogen excretion, the oxidation rates of fat 
and carbohydrate were calculated using the formulae of 
Frayn (212):
Carbohydrate oxidation (g/d) =
(4.55VC02 - 3.2IVO2 - 2.87n) 1440
Fat oxidation (g/d) =
(I.67VO2 - I.67VCO2 - 1.92n) 1440
where VO2 = oxygen consumption (1/min)
VCO2 = carbon dioxide production (1/min) 
n = urinary nitrogen (g/min)
These formulae are similar to others which have been 
used in studies of substrate oxidation (25,213).
It is important to realize that in most cases the 
above formulae give net rates of "utilisation" rather 
than true oxidation rates. Frayn points out that 
small errors in the calculation of fat and 
carbohydrate oxidation rates will occur in the 
presence of metabolic processes which result in the 
accumulation or excretion of intermediary or end 
products other than carbon dioxide and water. Such 
examples include the processes of lipogenesis and
gluconeogenesis. Lipogenesis can occur during the 
infusion of high concentrations of dextrose and 
results in RQ values greater than 1.00. No RQ values 
in excess of 1.00 occurred in the studies reported in 
this thesis. Gluconeogenesis will upset slightly the 
calculation of oxidation rates only if the glucose 
formed is not subsequently oxidised. It should be 
noted that Cori cycle activity, which tends to be 
increased in cancer patients (47,82-84), does not 
affect these calculations since the conversion of 
glucose to lactate and reconversion to glucose does 
not involve gaseous exchange. Frayn concludes that the 
net rates of oxidation calculated by these formulae 
may in fact be more useful than true rates in clinical 
practice, and emphasises that the errors involved are 
small.
CALCULATION 0^  LEAN BODY MASS
Lean body mass (LBM) was derived from measurements 
of total body water using the isotope dilution 
technique (214). Initiated water (Amersham 
International pic, Buckinghamshire, U.K.) was diluted 
with 6ml of isotonic saline for intravenous 
injection. On the day of calorimetry, the tritiated 
saline (4MBq) was injected intravenously and serum 
samples obtained three and four hours after injection. 
Aliquots of 4ml were stored at -40 degrees centigrade 
and processed in batches. Immediately prior to 
injection patients voided urine, which was discarded. 
For the four hours following the injection, all urine 
passed was collected in sterile containers to measure 
the loss of tritium in the urine. The volume of urine 
was determined and a 20ml aliquot was stored at -40 
degrees centigrade for subsequent analysis.
The serum and urine samples were allowed to thaw, 
and a 1ml aliquot was diluted with 10ml of liquid 
scintillation phosphor solution, made in the 
Department of Surgery. An aliquot of the solution 
injected, which also had been stored, was diluted 
1:10,000 with normal saline. The radioactivity (counts 
per minute - cpm) of these specimens was measured in 
an Auto-gamma 500C liquid scintillation counter 
(Packard, Berkshire, U.K.). The patient samples were 
analvsed in duplicate and the injection samples were
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analysed in quadruplicate. A mean value of the three 
and four hour samples was calculated.
Total body water was calculated by comparison of 
the radioactivity in the injection and serum samples:
injection sample (cpm)
= total body water
serum sample - urine sample (cpm)
(litres )
Total body water x 100 = LBM (kg)
73.2
This calculation assumes that lean tissue contains 
approximately 73% water. Where total body water 
measurements were repeated on the fourth postoperative 
day, a serum sample was obtained prior to the tritium 
injection to measure the amount of residual tritium in 
the serum. This "background" count was subtracted from 
the plasma samples during calculation of the 
postoperative total body water. Repeated measurements 
of total body water using this technique have shown a 
coefficient of variation of +2.3% (214).
The assumption that lean tissue contains 73% water 
may not be justified in all cases. Shizgal (215) 
observed that malnourished patients have an expanded 
extracellular fluid volume which will result in an 
overestimation of LBM using the isotope dilution 
technique. Correction of this overestimation would 
result in a small increase in the value of caloric 
expenditure, where REE has been expressed in terms of
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kilograms of LBM.
An alternative method for deriving LBM is the 
measurement of total body potassium. However, 
Burkinshaw and colleagues (216) have reported that 
weight loss can result in a reduction in the 
intracellular potassium content, which in turn would 
lead to an error in the estimation of LBM in weight 
losing patients.
The most accurate method of deriving LBM would be 
by neutron activation analysis. This facility, 
however, was not available in this centre, and the use 
of this technique would have been unacceptable in many 
of the patients studied.
DIETARY HISTORIES AND ANTHROPOMETRIC MEASUREMENTS
One research dietician, unaware of each patient's 
diagnosis, was responsible for all dietary histories 
and anthropometric measurements. The dietician 
obtained a diet history by asking each patient about 
changes in appetite and food intake which had occurred 
immediately prior to admission to hospital. The amount 
and type of food and fluid ingested in a typical day 
was noted. This was converted into a daily caloric and 
protein intake using standard tables (217).
Mid-arm circumference (MAC) was measured by 
marking the midpoint between the acromion and 
olecranon processes in the dependent non-dominant arm 
with the elbow joint flexed to 90 degrees. A skinfold 
1 centimetre above this point overlying the triceps 
muscle was pinched between finger and thumb and three 
readings of the triceps skinfold thickness (TST) were 
obtained using skin calipers. The mean of the three 
readings was taken as the TST measurement. Mid-arm 
muscle circumference (MAMC) was calculated using the 
f o rmula:
MAMC = MAC - (0.314 x TST)
where MAMC is in centimetres 
MAC is in centimetres 
TST is in millimetres
MAMC and TST were expressed as percentages of expected
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standard values (218) where:
MAMC - male = 25.3 cm
- female = 23.2 cm
TST - maie = 12.5 mm
- female = 16.5 mm
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b i o c h e m i c a l MEASUREMENTS
Urine was collected over a 24 hour period in 
storage cans containing thymol/isopropanol as 
preservative. The volume of urine was determined and 
20ml aliquots were stored at -20 degrees centigrade 
and processed in batches. Total urinary nitrogen was 
measured with an automated micro-Kjeldahl method which 
uses the Berthelot reaction for quantitation, as 
described by Fleck (219).
Plasma glucose was measured enzymatically on a 
Beckman Glucose II analyser. Plasma insulin samples 
were stored at -20 degrees centigrade and analysed in 
batches using an antibody radioimmunoassay technique, 
using as standard MRC 66/304 insulin. Albumin was 
measured using the bromo-cresol green dye binding 
method. Serum transferrin samples were stored at -20 
degrees centigrade and measured by immunoturbidity on 
a Centrifichem centrifugal analyser (Baker 
Instruments, U.K.).
MEASUREMENT OF WHOLE BODY PROTEIN TURNOVER
Whole body protein turnover (WBPT) was measured by
the method based on that described by Waterlow and
colleagues (220) and Sim and colleagues (221). On the
day prior to measurement patients ate a standard
hospital diet. After an overnight fast, patients
remained in bed from the time of wakening. The
baseline enrichment of ^^N in ammonia and urea was
obtained from a urine sample taken at 08.00 hours. At
09.00 hours, a primed, constant 24 hour infusion of 
1 5
N-glycine was commenced. During the 24 hour infusion
patients were allowed free access to water, but not to
1 5food. The mean priming dose of N-glycine was 0.3 
mg^^N/kg (99 atom% ^^N - Amersham International pic, 
U.K.) and this was followed by a continuous 24 hour 
infusion at a mean rate of 0.28mg ^^N/kg/24 hours, 
delivered using a peristaltic infusion pump (Ivac,
1 c
Harrow, U.K.). The N-glycine was dissolved in NaCl 
(150mM) and sterilised by microfiltration. During the 
infusion, urine was collected over two consecutive 12 
hour periods into storage cans containing 20ml HCl 
(6mmol/l) and 8mg chlorhexidine gluconate (ICI Ltd., 
Macclesfield, Cheshire, U.K.).
The urine samples were prepared for mass 
spectroscopy using a sodium/potassium cationic 
ion-exchange resin (222). The resin-ammonia complex 
was treated with alkaline hypobromite to liberate
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molecular nitrogen, and ^ a b u n d a n c e  was measured 
using a double collector mass spectrometer (V.G. 
Micromass 602B, Cheshire, U.K.) with a precision of 
0.0008 atom /> excess. These measurements were made by 
Dr. T. Preston at the Scottish Universities Research 
and Reactor Centre, East Kilbride.
The isotopic enrichment of urinary ammonia and 
urea was measured in urine collected during the 12-24 
hour period of the infusion. This timed collection 
has previously been shown to concur with plateau 
isotopic enrichment of urinary ammonia and urea 
(223).
Rates of WBPT were calculated using the stochastic 
model of Picou and Taylor-Roberts (224). The basic 
assumption of this model is that in the steady state, 
and at isotopic equilibrium, the proportion of isotope 
excreted in the chosen end-product of nitrogen 
metabolism (ammonia or urea) is the same as the 
proportion of the nitrogen turnover excreted in that 
same end-product. Nitrogen turnover was calculated 
using the formula;
d
Q = - 
E
where Q = nitrogen turnover,
d = the quantity of isotope infused,
E = the isotopic enricnment of tne 
chosen urinary end-product.
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The assumptions of the stochastic model mean that 
in the steady state Q is equal to the rate of protein 
synthesis (S) plus the rate of nitrogen excretion (E). 
This also equals the rate of protein breakdown (B) 
plus the rate of nitrogen intake (I). Thus:
Q = I + B = S + E
Since this study was performed with patients in 
the fasting state, the rate of protein turnover should 
be equal to the rate of protein breakdown. Rates of 
whole body protein synthesis were calculated by 
subtracting 24 hour urinary nitrogen excretion from 
Q.
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STATISTICS
All statistics were performed on an Apple II 
computer using a statistical tests package developed 
and tested in the Department of Surgery. Where 
several groups of data were compared, an analysis of 
variance was used initially to test whether there were 
any significant differences between groups. However, 
the nonparametric Mann-Whitney U test and Wilcoxon 
Rank Sign test were used for pairwise comparisons in 
order to minimise the risk of detecting spurious 
differences in data which were not normally 
distributed. For descriptive purposes, data have been 
expressed as mean ± s.e.m. to facilitate comparison 
with other published results. Linear regression 
analysis was performed using the method of least 
squares and correlation coefficients (r) determined. 
Linear regression equations are in the form:
y = a + bx
where a is the intercept on the y axis 
and b is the gradient of the line
The slopes of the linear regression lines were 
compared using Student's t test. All confidence 
intervals (Cl) quoted are 95% CIs. Other statistical 
tests were used as indicated in the text.
Differences were considered significant when the 
probability of their arising by random sampling error
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was less than 1 in 20 (P<0.05). Differences were 
considered highly significant when this probability 
was less than 1 in 100 (P<0.01).
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CHAPTER 4
THE RELATIONSHIP BETWEEN RESTING ENERGY EXPENDITURE 
AND WEIGHT LOSS IN BENIGN AND MALIGNANT DISEASE
94
INTRODUCTION
During the past 70 years, many authors 
(6-8,26-28,30,33-35,82,225) have suggested that an 
increased resting energy expenditure (REE) may be a 
contributing factor in the development of cancer 
cachexia. The early reports were anecdotal (28,30,33), 
while many of the recent studies have been poorly 
controlled. For example, Macfie and colleagues (27) 
compared cancer patients with younger weight stable 
controls, while others (8,26) have studied patients 
with cancer but have offered no control data.
The aim of this study was to determine whether REE 
was increased in cancer patients who were losing 
weight. These patients were compared with three other 
groups: cancer patients without weight loss and groups 
of weight losing and weight stable patients with 
nonmalignant illness. The relationship between REE and 
various expressions of body size has been 
investigated, and the effects of cancer and weight 
loss on these relationships have been determined.
95
PATIENTS & METHODS
One hundred and thirty six recently diagnosed 
patients were included in the study. Cancer was proven 
histologically in 98 patients, and a control group of 
38 had nonmalignant disease (Table 1). Of the 98 
cancer patients, 56 were weight stable and 42 were 
weight losing. The controls were similarly divided 
into 22 weight stable and 16 weight losing patients. 
The mean weight loss expressed as a percentage of the 
mean pre-illness weight and the mean weight loss per 
month during the period of illness are shown in Table 
2.
In the cancer patients, the presence of hepatic 
métastasés was assessed by ultrasound and computerised 
tomography in all patients and confirmed 
histologically in those who underwent laparotomy. 
Eleven of the weight stable patients and eight of the 
weight losing patients had hepatic métastasés.
The methods used are as described in Chapter 3-
TABLE 1 PATHOLOGICAL DIAGNOSES IN WEIGHT STABLE AND 
WEIGHT LOSING CANCER PATIENTS AND CONTROLS
Diagnosis Cancer
Weight stable Weight losing
(n = 56) (n = 42)
Colorectal cancer 36 19
Gastric cancer 12 12
Bronchial cancer 5 7
Oesophageal cancer 3 2
Pancreatic cancer - 2
Control
Weight stable Weight losing
(n = 22) (n = 16)
Gastric ulceration 1 1
Duodenal ulceration 2 4
Pyloric stenosis - 3
Cholelithiasis 14 3
Diverticular disease 3 1
Benign colorectal polyp 2
Ulcerative colitis 1 -
Crohn's disease -
2
Hiatus hernia
RESULTS
Clinical and nutritional details are shown in 
Tables 2 and 3 respectively. There was no significant
difference in mean age between the groups. There were 
more males in the weight stable cancer group and more 
females in the weight stable control group. The 
weight losing cancer patients had a significantly 
lower mean body weight and LBM than their weight 
stable counterparts. The weight losing controls had a 
significantly lower mean body weight and LBM compared 
With their weight stable counterparts. The weight 
losing controls had a significantly lower mean body 
weight but no difference in LBM compared with the 
weight stable controls. In both the weight losing 
groups, the mean weight loss was in excess of 15% of 
pre-illness weight. The rate of weight loss in these 
groups was 2.7 kg per month. Mean measurements of MAMC 
and TST were significantly lower in both weight losing 
groups compared with their weight stable counterparts. 
No significant differences could be detected in mean 
total energy intake between the groups, although the 
weight losing controls had a significantly lower mean 
protein intake compared with the weight stable 
controls. When compared with their weight stable 
counterparts, both the weight losing groups had 
significantly reduced mean serum albumin and 
transferrin levels. In addition, weight stable cancer 
patients had lower mean serum transferrin levels than
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weight stable controls.
Measurements of REE are shown in Table 4. When 
REE is expressed in kcal/kg body weight/day, the 
weight losing cancer patients have a significantly 
increased REE compared with both the weight stable 
groups. There is no significant difference between the 
groups when REE is expressed in terms of LBM. When REE 
is expressed in terms of kg^*^^, referred to by 
Kleiber (43) as metabolic body size, weight stable 
control patients have a significantly reduced REE 
compared with the other three groups. Significant 
correlations between REE and body weight, metabolic 
body size and lean body mass are shown in Figures 1-3. 
For reasons of clarity, the scatter of points around 
each line has been omitted. The strongest correlation 
was found between REE and LBM. The gradient of the 
cancer weight losing (CWL) regression line is 
significantly steeper than both the weight stable 
groups when REE is plotted against body weight and 
LBM. When plotted against metabolic body size, the CWL 
regression line differs signficantly only from the 
weight stable cancer group (CWS).
There were no significant differences in RQ 
between the groups (Table 4). No significant 
differences in REE were found when patients with 
hepatic métastasés were compared to those without,
irrespective of weight loss (Table 5). There were no
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Figure J_
The relationship between resting energy expenditure 
and body weight in each of the groups
CWL (cancer weight losing) 
n = 42; r = 0.790; P<0.01
CWS:(cancer weight stable) 
n = 56; r = 0.648; P<0.01
y = 406 + 16.4x 
95% Cl (12.4,20.4)
y = 712 + 11.2x 
95% Cl (7.7,14.7)
NCWL (control weight losing) y = 543 + 13-4x
n = 16; r = 0.749; P<0.01 95% Cl (7.0,19.8)
NCWS (control weight stable) y = 587 + 11.2x
n = 22; r = 0.768; P<0.01 95% Cl (7.0,15.4)
The CWL slope is significantly different from the 
CWS (P<0.05) and NCWS (P<0.05) slopes.
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Figure 2_
The relationship between resting energy expenditure 
and metabolic body size in each of the groups
CWL (cancer weight losing) y = 104 + 60.Ox
n = 42, r = 0.795; P<0.01 95% Cl (45.5,74.5)
CWS (cancer weight stable) y = 477 + 42 . Ix
n = 56; r = 0.645; P<0.01 95% Cl (28.5,55.7)
NCWL (control weight losing) y = 296 + 4 9 -Ox
n = 16; r = 0.754; P<0.01 95% Cl (26.2,71.8)
NCWS (control weight stable) y = 330 + 43.Ox
n = 22; r = 0.769; P<0.01 9^& Cl (27.1,58.9)
The CWL slope is significantly different from the 
CWS slope (P<0.05).
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Figure 3
The relationship between resting energy expenditure 
and lean body mass in each of the groups
CWL (cancer weight losing) y = 299 + 21.5x
n = 42; r = 0.835; P<0.01 95% Cl (16.8,26.2)
CWS (cancer weight stable) y = 799 + 12.5x
n = 56; r = 0.662; P<0.01 95% Cl (7.2,17.8)
NCWL (control weight losing) y = 255 + 22.3x
n = 16; r = 0.873; P<0.01 95% Cl (15.7,28.9)
NCWS (control weight stable) y = 524 + l6.4x
n = 22; r = 0.896; P<0.01 95% Cl (12.8,20.0)
The CWL slope is significantly different from the CWS 
(P<0.05) and NCWS (P<0.05) slopes.
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significant differences in REE when differing tumour 
types were compared (Table 6).
When REE is related to LBM and all cancer patients 
are compared with all control patients, there is no 
significant difference between the slopes of the 
regression lines (Figure 4). However, when weight 
losing patients are compared with weight stable 
patients irrespective of the primary diagnosis, the 
slopes of the regression lines are significantly 
different (Figure 5).
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Figure ^
The relationship between resting energy expenditure 
and lean body mass for all cancer patients and all 
controls
Cancer
n = 98; r = 0.759; P<0.01
y = 542 + 17.Ox 
95% Cl (13.9,20.1)
Control
n = 38; r = 0.876; P<0.01
y = 446 + 18.1X 
95% Cl (14.8,21.4)
No significant differences between the slopes.
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Figure 5
The relationship between resting energy expenditure 
and lean body mass for all weight stable patients and 
all weight losing patients
Weight stable 
n 78; r = 0 .739; P<0.01
Weight losing 
n = 58; r = 0.837; P<0.01
y = 685 + 14.3x 
95% Cl (11.2,17.4)
y = 292 + 21.7x 
95% Cl (17.8,25.6)
The weight stable slope is significantly different 
from the weight losing slope (P<0.01).
DISCUSSION
There have been many studies of energy expenditure 
in cancer patients, and most have reported an increase 
in REE associated with the tumour bearing state 
(6-8,26-28,30,33-35,82,225). It has been suggested 
that this increased energy expenditure could 
contribute to the weight loss commonly seen in these 
patients (6,8,27,34,35,225). Other studies, however, 
have failed to show any alteration in REE when 
comparing cancer patients to controls (44). Indeed, 
Mullen and colleagues have suggested that some cancer 
patients may in fact have a reduced energy expenditure 
(39).
However, measurement of REE must take into account 
patient size, and it is apparent from this present 
study that an error can be made when energy 
expenditure is expressed as kcal/day, kcal/kg body 
weight/day or kcal/kg°'^^/day. The weight losing 
patients in- this study appear to have lost 
predominantly fat. Therefore, the proportion of total 
body weight that is represented by lean body mass 
increases. Since lean body mass contributes more to 
REE than does fat mass, any attempt to predict REE 
related to body weight will tend to underestimate 
energy expenditure in weight losing patients. This 
source of error has been ignored in earlier 
publications in this field. In this presenu study.
when energy expenditure is expressed as kcal/kg body 
weight/day, weight losing cancer patients have a 
significantly higher energy expenditure than weight 
stable cancer patients or controls. When REE is 
related to lean body mass this difference disappears.
It follows, in addition, that when formulae are 
used to predict expected energy expenditure in 
patients with altered body composition, they will 
underestimate REE if total body weight is part of the 
formula. Such formulae are the Harris-Benedict (40) 
and Kleiber (43) formulae, both of which have been 
used in the past to predict energy expenditure in 
weight losing cancer patients. Since these formulae 
do not take into account changing body composition, it 
is not surprising that they have erroneously suggested 
elevated energy expenditure when weight losing cancer 
patients are compared with control groups. In an 
attempt to minimise this error, lean body mass has 
been measured using the isotope dilution technique. As 
discussed in Chapter 3, this method will tend to 
overestimate lean body mass. However, correction of 
this error is unlikely to alter greatly the 
conclusions of the present study.
The conclusion that the weight losing cancer 
patients in this study have no detectable alteration 
in REE when compared with weight stable cancer
patients or patients with nonmalignant illness is
1 û
similar to that reached by Lindmark and his colleagues 
(35), who compared 28 cancer patients with 43 
controls. They found that weight losing cancer 
patients have an increase in REE of 148 kcal/day 
compared with weight losing controls. If it is 
accepted that complete oxidation of 1g of fat gives 
9.1 kcal, 1g of carbohydrate gives 4.1 kcal, 1g of 
protein gives 4.1 kcal, and that body tissues contain 
20% protein, Lindmark and his colleagues (35), using 
the RQ values obtained from calorimetry, estimated 
that this increase in energy expenditure could account 
for the loss of between 1 and 2 kg of body weight per 
month. Macfie and colleagues (27) found an increase in 
REE of 289 kcal/day when patients with metastatic 
cancer were compared with healthy controls. They 
suggested that this increase could account for a 
weight loss of 1 kg of fat per month. In the present 
study, neither of the weight losing groups had any 
detectable increase in REE when compared with their 
weight stable counterparts. Both goups, however, had a 
reported weight loss of almost 3 kg per month before 
coming into hospital. It is concluded, therefore, that 
an elevation in REE seems to contribute little to the 
weight loss seen in these cancer patients.
Furthermore, unlike Macfie and colleagues (27), this 
study reveals no evidence to suggest that the presence 
of hepatic métastasés significantly alters REE. 
Previous studies have suggested that advanced
seas
REE. This observation has not been confirmed in the 
present study.
When regression lines relating REE to body size 
are drawn for the four groups (Figures 1-3) the fact 
that the lines seem to converge supports the argument 
proposed by Lindmark and colleagues (35) that cancer 
patients can ultimately adapt their energy expenditure 
to the weight losing state. The patients with the 
lowest lean body masses appear best able to adapt to 
the weight losing state. However, when all cancer 
patients are compared with all control patients 
(Figure 4), there is no significant difference in the 
slope of the resulting regression lines. The most 
interesting comparison is seen when weight losing 
patients are compared with weight stable patients, 
irrespective of the presence of cancer (Figure 5). The 
fact that the slopes of the regression lines are 
significantly different suggests that the weight 
losing state is more closely associated with metabolic 
abnormalities in patients than is the presence or 
absence of cancer. It seems that some cancer patients 
and some patients who develop nonmalignant illness 
respond to their illness by producing an associated 
metabolic abnormality which leads to the weight losing 
st a t e .
To claim that the presence of a solid tumour will 
necessarily result in elevated energy expenditure is
probably an oversimplification. Some cancer patients 
respond to their illness by losing weight, as do some 
patients who develop a nonmalignant illness. It is not 
the primary pathology, but the patient's endogenous 
responses to it which determine whether weight loss 
will result. However, speaking of cancer as a uniform 
entity is also an oversimplification. It has been 
suggested that the primary site of a tumour may be 
important in determining the magnitude of the REE 
(39). In the present study, REE has been measured in 
patients with colorectal, gastric, and non-small cell 
bronchial cancer and no significant difference among 
the groups has been found. Bronchial cancers, however, 
did show a trend toward a slightly higher energy 
expenditure. Although this has not been shown to be 
statistically significant, it may be that a small 
subset of bronchial cancer patients do, in fact, have 
a higher than anticipated energy expenditure.
A possible explanation for the extent of the 
observed weight loss in the patients in the present 
study could be anorexia. Standard dietary histories 
have been used to assess energy and protein intakes of 
the patients studied. Both weight losing groups had a 
lower energy intake than the weight stable groups, but 
this difference was not statistically significant. 
Protein intakes were similar between the groups apart 
from the weight losing controls, who had a 
significantly decreased intake compared with their
weight stable counterparts. Standard dietary 
assessment techniques are inaccurate and have wide 
variability, and a small difference in intake may be 
obscured (126-128). The findings of Wesdorp and 
colleagues (9), who reported that most cachectic 
cancer patients were unaware of their anorexia, 
emphasises the limitations of this technique. While 
anorexia is likely to account for a significant 
proportion of the observed weight loss, another 
possible mechanism may be that weight losing patients 
have altered utilisation of endogenous substrates or 
of ingested nutrients. For example, the thermogenic 
response to food may be altered in cancer patients, 
leading to a reduction in the efficiency with which 
ingested substrate is stored.
The present study has yielded no evidence to 
support the hypothesis that patients who lose weight, 
whether they have cancer or not, have an increase in 
energy expenditure. There is also no evidence that 
tumour type-or tumour stage is important in 
determining REE in cancer patients, although further 
investigation in this area is warranted. It is 
possible that substrate handling in weight losing 
cancer patients may be altered. However, the evidence 
points to an altered response to illness as being the 
major determinant of increases in REE, rather than any 
factor associated with the tumour itself.
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CHAPTER 5
THE ACCURACY OF PREDICTIVE FORMULAE IN ESTIMATING 
RESTING ENERGY EXPENDITURE
INTRODUCTION
Predictive formulae are used widely to estimate 
the resting energy expenditure (REE) of patients in 
both clinical and research situations. Such 
predictors include the Harris-Benedict (40), Kleiber 
(43) and Robertson-Reid (226) formulae and the Fleisch 
tables (227). These predictors have been derived from 
calorimetric measurements in mainly young healthy 
subjects with presumed normal body composition, in 
whom the anthropometric indices of height and weight 
reflect accurately the metabolically active proportion 
of body weight. As alluded to in the previous 
chapter, body composition may be altered in various 
disease states (215), and this in turn may lead to an 
inaccurate estimation of REE when such formulae and 
tables are used. Indeed, recent studies (41,42) have 
shown the Harris-Benedict (40) and Kleiber (43) 
formulae to be inaccurate in predicting REE in a 
significant proportion of patients.
The aim of this study, therefore, was to assess 
the accuracy with which the Harris-Benedict (HB), 
Kleiber (KL) and Robertson-Reid (RR) formulae as well 
as the Fleisch (FL) tables could predict REE. The 
effects of sex, weight status and disease status on 
predictive accuracy were assessed by comparing the 
predicted REE values with those measured by indirect 
calorimetry.
PATIENTS & METHODS
The study sample consisted of 168 recently 
diagnosed patients, of whom 87 were male and 8l were 
female. These two groupings were subdivided according 
to whether a patient had benign (control group) or 
malignant (cancer group) disease. Patients were 
subdivided further into weight stable and weight 
losing groups. These subdivisions according to sex, 
disease status and weight status are shown in Table 7. 
The types of benign or malignant disease present are 
shown in Table 8.
The methods used are as described in Chapter 3 and 
b elow.
Predictive formulae
REE was predicted in four ways:
(1) Harris-Benedict formula (kcal/day)
Males: 66.473 + 13-752(W) + 5.003(H) - 6.755(A) 
Females: 655.096 + 9.563(W) + 1.850(H) - 4.676(A)
(2) Robertson-Reid formula (kcal/m^/hour)
Males: 37.405365 - 0.06944(A)
Females: 35.15375 - 0.06149(A)
(3) Kleiber formula (kcal/day)
Males: 71 .'2W^*^^(1+0.004(30-A)+0.010((H/W^'^^)-43.4) 
Females : 65.8W^'^^( 1 +0.004 (30-A)+0.0l8((H/W^'^^)-42.1)
en
Z)
E-I
H
CO
H
X
Ü
H
W
3
Q
S
<
CO
Z>
H
<
H
CO
w
co
<
[ i]
CO
M
Q
X
W
CO
O
H
Ü
Z
M
Q
PC
O
O
O
<
CO
H
Z
W
M
H
<
eu
Clj
O
z
o
M
H
Z)
CQ
M
CC
H
CO
H
Q
t> -
W
U
CQ
<
H
I—I
O
Z
c
o
o
z
(ü
ü
c
cd
CJ
bû
c
•H
en
o
-p
Z !
bû
•H
(ü
3
Z>
(d
w
-p
JZ
bû
•H
CD
S
bû
C
•H
M
O
P>
x :
bû
•H
o
3
XI
cd
X )
en
4-)
x
bû
•H
0
X
0
co
o -
cu
ITt
( \ j
vO
(\J
LO
.= r
ao
0
S
0
Cx,
TABLE 8 PATHOLOGICAL DIAGNOSES IN WEIGHT STABLE AND 
WEIGHT LOSING CANCER PATIENTS AND CONTROLS
Diagnosis Cancer
Weight stable Weight losing
Male Female Male Female
Colorectal cancer 27 14 9 14
Gastric cancer 11 4 9 8
Bronchial cancer 5 - 5 2
Oesophageal cancer 2 - 2 1
Pancreatic cancer
Control
1
Weight stable Weight losing
Male Female Male Female
Gastric ulceration - 2 - 2
Duodenal ulceration 4 4 3 2
Pyloric stenosis - - 1 3
Cholelithiasis 4 14 - 2
Diverticular disease - 1 - 1
Benign colorectal polyp 1 5 2 -
Ulcerative colitis - 1 - -
C r o h n ’s disease - - 2 -
(4) Fleisch tables (kcal/m^/hour)
where A = age in years, W = body weight in 
kilograms, H = height in centimetres.
For (2) and (4) surface area was calculated from 
height and weight using standard tables. The 
calculated REE was then multiplied by 24 to give 
kcal/day.
The REE derived from indirect calorimetry was then 
expressed as a percentage of the predicted REE:
Measured REE 
1 X 100
Predicted REE
Statistics
Male and female data were analysed separately 
throughout the study since each formula had both male 
and female versions. Thus, all analyses were made with 
patients grouped according to weight status and sex, 
and also according to disease status and sex. These 
groupings are justified as there is no interaction 
between weight status and disease status. No analyses 
were performed with patients subdivided according to 
all three indices, namely, weight status, disease 
status and sex, as this would have resulted in certain 
groups having too few patients for statistical 
analysis. One sample t tests and 95% confidence
10'
intervals were used to establish for which groups of 
patients the predictive formulae were over- or 
underestimating. An analysis of variance was used to 
identify any significant differences between the four 
formulae with regard to predictive ability. The use 
of Bonferroni’s multiple comparison procedure enabled 
the formulae to be grouped in order of predictive 
accuracy for each of the patient groups.
RESULTS
Clinical and anthropometric details are shown in 
Tables 9 and 10 respectively. Both weight stable and 
weight losing female cancer patients were 
significantly older than their corresponding controls. 
The mean body weight of each of the weight losing 
groups was significantly lower, and the mean 
percentage weight loss significantly higher, than that 
of their weight stable counterparts. Weight losing 
male patients had significantly lower mean LBM values 
compared with weight stable male patients, 
irrespective of disease status. When LBM was expressed 
as a percentage of body weight, weight losing female 
patients were found to have a significantly greater 
percentage than their weight stable counterparts, 
irrespective of disease status. Mean MAMC and TST 
measurements for each of the weight losing groups were 
significantly lower than those of their weight stable 
counterparts.
Values for measured REE, expressed as a percentage
of predicted REE, with 95% confidence intervals are 
shown in Tables 1 la and 11b. In nearly every case, the 
mean percentage predicted value is greater than 100%, 
indicating a general underestimation of REE by the 
formulae. Where the confidence intervals include 100, 
there is no signiileant over — or underestimation of 
REE. When patients are grouped according to weight
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status and sex, only the Fleisch formula used on 
weight losing males and weight stable females and the 
Harris-Benedict formula used on weight stable females 
are not significantly over- or underestimating REE. In 
every other case the mean percentage predictive values 
are significantly greater than 100% (P<0.01), 
indicating an underestimation of REE by these 
formulae.
When patients are grouped according to disease 
status and sex, all cancer patients have mean 
percentage predictive values which are significantly 
greater than 100% (P < 0.05). Thus, in these cases, 
the formulae are significantly underestimating REE. 
There is no significant over- or underestimation of 
REE in female patients with benign disease, apart from 
the Robertson-Reid formula, nor in male patients with 
benign disease when the Kleiber and Fleisch formulae 
are used.
Another aspect of the way in which these formulae 
are over- or underestimating REE is shown in Tables 
12a and 12b. The percentage of patients in each group 
whose predicted REE differed from their measured REE 
by greater than +10% ranges from 14% for females with 
benign disease where the Harris-Benedict formula is 
used to 62% for weight stable males where the 
Robertson-Reid formula is used.
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A summary of the data shown in Tables 11 and 12 
shows that:
(1) Sex affects the predictive ability of the 
Harris-Benedict formula only, predicting REE 
better in females with benign disease and 
females who are weight stable, compared with 
their male counterparts.
(2) Disease status affects the predictive ability of 
all four formulae, predicting REE better in 
females with benign disease compared with 
females with cancer.
(3) Weight status does not appear to affect the 
predictive ability of any of the formulae.
Whether patients are grouped according to weight 
status and sex or disease status and sex, an analysis 
of variance shows that significant differences exist 
between the formulae regarding their predictive 
ability. A more detailed comparison, using 
Bonferroni's multiple comparison procedure, enables 
the formulae to be grouped in order of predictive 
accuracy for each of the patient groups (Tables 13a 
and 13b). Those formulae which do not differ 
significantly using the Bonferroni method are 
indicated The Fleisch formula is the best or
equal best for all the groups studied. The 
Harris-Benedict formula is worst or equal worst for 
all male patients, irrespective of weight status or 
disease status. In contrast, the Harris-Benedict
formula is equal best for all female patients with 
benign disease, irrespective of weight status.
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DISCUSSION
This study demonstrates significant errors in the 
ability of predictive formulae to estimate REE 
accurately in hospitalised patients. The presence of 
cancer in female patients decreased the predictive 
ability of all four formulae, whereas the presence of 
weight loss did not appear to affect the predictive 
ability of any of the formulae.
The Harris-Benedict (40) and Robertson-Reid (226) 
formulae were derived from indirect calorimetry 
measurements of REE in 239 and 2,310 healthy 
individuals respectively. The Kleiber formula (43) was 
derived from the original Harris-Benedict data, and 
the Fleisch tables (227) were generated from a review 
of 24 studies involving REE measurements. All these 
predictors of REE are based on the assumption that the 
height and weight of an individual will reflect 
accurately the size of the metabolically active 
portion of the body, which in turn will reflect the 
energy expenditure of this tissue. This, however, will 
be the case only if body composition is normal. The 
presence of disease states or weight loss may lead to 
alterations in body composition (215,228), and so the 
use of these predictive formulae and tables in 
individual patients may lead to an inaccurate 
prediction of REE.
Historically, Harris and Benedict showed 12% of 
normal individuals to have a predicted REE outwith 
+10% of measured REE (40) while Boothby found only 8% 
of normal individuals to fall outwith this range 
(32,229). In contrast, in the present study 14-62% of 
patients were outwith this range, depending on the 
predictor used. In virtually all cases these 
predictors tended to underestimate rather than 
overestimate REE. This underestimation of REE has been 
reported by other workers (230,231), but it contrasts 
with the recent findings of Daly and colleagues (232) 
who reported a general overestimation of REE by the 
Harris-Benedict formula in a study of 201 healthy men 
and women. Other workers have also reported an 
overestimation of REE using predictive formulae. For 
example, Feurer and colleagues (42) reported that REE 
predicted by the Harris-Benedict and Kleiber formulae 
was greater than that measured by indirect calorimetry 
in both patients and healthy controls. It should be 
noted that in Feurer's study the percentage of healthy 
controls whose predicted REE was outwith +10% of 
measured REE was 20% for the Harris-Benedict formula 
and 33% for the Kleiber formula. These percentages are 
considerably greater than the 12% and 8% reported by 
Harris-Benedict (40) and Boothby (32,229) 
respectively. One factor which could account for these 
differing results is the different indirect 
calorimetry techniques employed. For example,
Robertson and Reid used the Benedict-Roth apparatus
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(226), Feurer and colleagues used a portable indirect 
calorimeter with mouthpiece and noseclip (42), while 
in the present study a fixed indirect calorimeter 
employing a rigid sealed canopy was used.
Irrespective of any differences in actual values 
of REE which may result due to different techniques, 
comparison of the results of the various formulae in 
the present study, where the same indirect calorimetry 
technique was used throughout, demonstrate significant 
differences in the predictive ability of these 
formulae. There were no significant differences in 
the predictive ability of the male and female forms of 
each of the predictors with the exception of the 
Harris-Benedict formula, where the female version was 
more accurate than the male version in predicting REE 
in those females who had not lost weight and who had 
benign disease. The presence of cancer had a 
significant effect on the predictive ability of each 
of the formulae when applied to females, but no such 
difference was evident when applied to males. In 
contrast, the presence of significant weight loss did 
not appear to affect the predictive ability of any of 
the formulae. This finding differs from that of Roza 
and Shizgal (41) who, comparing 33 normally nourished 
patients with 41 malnourished patients, found the 
Harris-Benedict formula to be unreliable in predicting 
REE in malnourished patients. Using a multiple isotope 
dilution technique, they demonstrated an increased
extracellular mass and a decreased body cell mass in 
the malnourished patients, and concluded that the 
inaccuracy of the Harris-Benedict formula in these 
malnourished patients was due to altered body 
composition.
In the present study, body composition was 
assessed by the measurement of LBM, as well as the 
anthropometric indices of MAMC and TST. As discussed 
in Chapter 3, the derivation of LBM from total body 
water measurements in weight losing patients is 
subject to a degree of error due to the expansion of 
the extracellular fluid volume which occurs in the 
presence of malnutrition (215). This results in an 
overestimation of LBM using this technique. It is seen 
from Table 9, however, that if an allowance is made 
for this overestimation in weight losing patients, the 
LBM/body weight percentages will fall, resulting in 
values closer to those of the weight stable patients. 
Thus, using the LBM/body weight percentage as an index 
of body composition, there appears to be no major 
difference in body composition between the groups.
The anthropometric indices of MAMC and TST, 
however, were significantly lower in the weight losing 
male and female patients compared with their weight 
stable counterparts. Reference to Table 10 shows that 
the difference between weight stable and weight losing 
j_3 more pronounced for TST measui emcnta tnan
for MAMC measurements, irrespective of disease status. 
This suggests that the weight losing patients are 
losing relatively more fat than lean tissue, which 
would lead to altered body composition.
The LBM and anthropometric measurements do not 
fully explain why prediction of REE was less accurate 
in female cancer patients yet unaffected by weight 
loss. An alternative explanation for the inaccurate 
prediction of REE in certain groups of patients could 
be that these patients have abnormalities of REE as a 
consequence of their disease. However, in the 
previous chapter it was shown that any alterations in 
REE due to disease were very small, with the subtle 
difference in the relationship of REE and lean body 
mass appearing to be related to weight loss rather 
than the type of disease present. Thus, the 
observation that the accuracy of the predictive 
formulae was affected by cancer but not by weight loss 
is unexpected. It may be that the presence of cancer 
affects body composition differently than does simple 
weight loss. It is also possible that the rate of 
loss of fat stores and lean tissue is different in 
cancer patients compared with patients who have 
nonmalignant illness. This view is supported by the 
results of a study of body composition in 23 cachectic 
patients (233), in which ten patients with malignant 
cachexia were compared with 13 patients with cachexia 
due to nonmalignant inflammatory causes. The authors
concluded that lean tissue was conserved to a greater 
extent in the cancer patients, and noted that although 
both groups were overhydrated, the distribution of 
fluid between the intracellular and extracellular 
compartments was normal. Thus, it is possible that 
changes in body composition, not detected by the 
methodology used in the present study, are interfering 
with the predictive ability of the various formulae.
The evidence of this and other studies (41,42) 
concerning the inaccuracy of predictive formulae in 
estimating REE has a significant bearing on the use of 
these formulae in both clinical and research 
practice. In the clinical situation the use of these 
formulae in assessing caloric requirements for 
nutritional support may lead to the provision of an 
inappropriate amount of calories, which has been shown 
to have adverse clinical consequences including 
hepatic dysfunction (234,235) and respiratory 
complications (236-238). In the research situation 
conclusions regarding the effects of cancer on REE 
have been made based on a comparison of measured REE 
with that predicted from the Harris-Benedict formula. 
For example, Jeejeebhoy and colleagues (26) claimed 
that patients with métastasés from small cell 
bronchial cancer had a raised REE compared with 
patients with localised disease, while Mullen's group 
(38) suggested that patients with cancer could have a 
low, normal or high REE, claiming that abnormaliuies
of REE may be related to the duration of the disease. 
In a further study from the same centre, Mullen and 
colleagues (39) suggested that different 
gastrointestinal cancers were associated with 
different REE values, with gastric cancer patients 
tending to have an increased REE while colorectal 
cancer patients had a more normal distribution of REE. 
In subsequent chapters evidence will be presented 
which will highlight the misleading results which can 
be obtained when the Harris-Benedict formula is used 
in this context.
In conclusion, this study demonstrates that the 
use of predictive formulae or tables in predicting the 
REE of individual patients or even groups of patients 
can produce inaccurate or misleading results. Thus, if 
an accurate measurement of REE is required, or if the 
metabolic characteristics of cancer patients are to be 
investigated, the use of indirect calorimetry to 
obtain this measurement is recommended.
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CHAPTER 6
ESTIMATION OF RESTING ENERGY EXPENDITURE 
BY ANTHROPOMETRY
INTRODUCTION
In addition to the inaccuracies of the predictive 
formulae highlighted in the previous chapter, there is 
the further disadvantage that estimates of REE require 
knowledge of the patient's body weight. Since the 
weighing of seriously ill or ventilated patients is 
difficult, even if expensive weighing devices are 
available, a simpler method of estimating REE would be 
of value, particularly to the clinician prescribing 
nutritional support.
Simple anthropometric measurements of triceps 
skinfold thickness (TST), mid-arm circumference (MAC) 
and calculated mid-arm muscle circumference (MAMC) 
have been used extensively to assess nutritional 
status (218). These measurements are easily performed 
irrespective of the clinical state of most patients 
and require no sophisticated equipment.
In order to assess the effectiveness of 
anthropometric measurements in estimating REE, they 
have been related to REE measured by indirect 
calorimetry in weight stable and weight losing 
patients with benign or malignant disease.
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PATIENTS & METHODS
One hundred and forty two recently diagnosed 
patients were included in the study. Cancer was proven 
histologically in 98 patients, and a control group of 
44 patients had non-malignant disease. Of the 98 
cancer patients, 54 were weight stable and 44 were 
weight losing. The controls were similarly divided 
into 27 weight stable and 17 weight losing patients. 
Pathological diagnoses are shown in Table 14.
The methods used are as described in Chapter 3-
TABLE 14 PATHOLOGICAL DIAGNOSES IN WEIGHT STABLE AND 
WEIGHT LOSING CANCER PATIENTS AND CONTROLS
Diagnosis Cancer 
Weight stable 
(n = 54)
Weight losing 
(n = 44 )
Colorectal cancer 36 20
Gastric cancer 14 15
Bronchial cancer 2 5
Oesophageal'cancer 2 2
Pancreatic cancer
Control
2
Weight stable 
(n = 27)
Weight losing 
(n = 17)
Gastric ulceration 1 1
Duodenal ulceration 3 5
Pyloric stenosis - 2
Cholelithiasis 15 3
Diverticular disease 3 2
Benign colorectal polyp 3 2
Ulcerative colitis 1 —
Crohn's disease - 1
Hiatus hernia 1 1
RESULTS
Males predominated in the weight stable cancer 
group and females predominated in the weight stable 
control group (Table 15). There were no significant 
differences in mean age and mean height between the 
groups. The weight losing cancer patients had a 
significantly lower mean body weight, body weight^ 
and LBM compared with their weight stable 
counterparts. The weight losing control patients had a 
significantly lower mean body weight and body 
w e i g h t ^ b u t  no significant difference in LBM 
compared with their weight stable counterparts. Both 
weight losing groups had lost in excess of 15% of 
their pre-illness weight.
Anthropometric and calorimetric data are shown in 
Table 16. Both weight losing groups had significantly 
lower TST, MAC and MAMC measurements compared with 
their weight stable counterparts. The weight losing 
cancer patients had a significantly lower REE and VO^ 
(unconnected for body size) than their weight stable 
counterparts, whereas no significant difference in REE 
and VO2 were found between the two control groups.
There was a significant correlation between MAMC 
and REE for each of the groups (Figure 6). The slope 
of the cancer weight stable regression line i^is
significantly different from thau of the cancer weight
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losing regression line. The significant correlation 
between MAMC and REE persisted when all cancer 
patients were compared with all control patients, with 
the slopes of the regression lines being almost 
identical (Figure 7). When all weight stable patients 
were compared with all weight losing patients (Figure
8), the correlation between MAMC and REE remained 
significant, but on this occasion there was a 
significant difference between the slopes of the 
regression lines.
MAC also correlated significantly with REE (Figure
9), but less so than did MAMC. The slopes of the 
regression lines followed a similar pattern to those 
relating MAMC to REE. The slope of the cancer weight 
losing regression line was significantly different 
from the cancer weight stable line. When all weight 
stable patients were compared with all weight losing 
patients, there was a significant difference between 
the slopes of the regression lines.
There was also a significant correlation between 
MAMC and VO?, but this correlation was not as close as 
that between MAMC and REE. The correlations between 
MAMC and VO2 were:
Cancer weight stable: r = 0.437, 95% Cl (1.6,6.0)
P<0.01
Cancer weight losing: r = 0.684, 95% Cl (6.0,11.8)
P<0.01
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Figure ^
The relationship between resting energy expenditure 
and mid-arm muscle circumference in each of the groups
CWL (cancer weight losing) y = -213 + 70.5x
n = 44; r = 0.751; P<0.01 95% Cl (51.4,89.6)
: CWS (cancer weight stable) y = 628 + 33.3x
n = 54; r = 0.511; P<0.01 95% Cl (17.8,48.8)
NCWL (control weight losing) y = 89 + 55.6x
n = 17; r = 0.728; P<0.01 95% Cl (28.6,82.6)
NCWS (control weight stable) y = 304 + 43.5x
n = 27; r = 0.539; P<0.01 95% Cl (16.4,70.6)
The CWL slope is significantly different from the 
CWS slope (P<0.01).
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Figure 7_
The relationship between resting energy expenditure 
and mid-arm muscle circumference in all cancer 
patients and all controls
Cancer
n = 98; r = 0,670; P<0.01
y = 240 + 49.3x 
95% Cl (38.2,60.4)
Control
n = 44; r = 0.619; P<0.01
y = 277 + 45.4x 
95% Cl (27.6,63.2)
No significant differences between the slopes.
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Figure 8
The relationship between resting energy expenditure 
and mid-arm muscle circumference in all weight stable 
patients and all weight losing patients
Weight stable 
n = 81; r = 0.513; P<0.01
Weight losing 
n = 61 ; r = 0.741 ; P<0.01
y = 518 + 36.8x 
95% Cl (23.0 ,50.6 )
y = -108 + 65.3x 
95% Cl (49.9,80.7)
The weight stable slope is significantly different 
from the weight losing slope (P<0.01).
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Figure £
The relationship between resting energy expenditure 
and mid-arm circumference in each of the groups
CWL (cancer weight losing) y = 178 + 45-4x
n = 44, r = 0.659; P<0.01 95% Cl (29.4,61.4)
CWS (cancer weight stable) y = 890 + 19.Ox
n = 54; r = 0.352; P<0.01 95% Cl (5.0,33.0)
NCWL (control weight losing) y = 205 -h 43.Ix
n = 17; r = 0.667; P<0.01 95% Cl (18.2,68.0)
NCWS (control weight stable) y = 698 + 21.4x
n = 27; r = 0.444; P<0.05 95% Cl (4.1,38.7)
The CWL slope is significantly different from the 
CWS slope (P<0.05).
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Control weight stable: r = 0.486, 95% Cl (1.4,9.0)
P<0.05
Control weight losing: r = 0.726, 95% Cl (3.9,11.5)
P<0.01
where Cl = confidence interval
REE correlated significantly with body weight, 
body weightO'75 ^nd LBM for each group (Table 17). No 
significant correlation was found when TST was related 
to either REE or VO2.
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DISCUSSION
This study demonstrates a significant correlation 
between mid-arm muscle circumference (MAMC) and 
resting energy expenditure (REE) in both weight stable 
and weight losing patients with benign or malignant 
disease. Although the correlations between REE and 
body weight, body w e i g h t ^ a n d  LBM were even closer 
than that between REE and MAMC, it is often 
impractical to weigh bed-bound patients, and the 
estimation of LBM requires the use of isotope dilution 
techniques (214) or total body potassium measurements 
(239).
The reason for assessing the value of 
anthropometric measurements in estimating REE is based 
on the observation that skeletal muscle mass relates 
well to basal heat production (240). Furthermore, it 
is less susceptible to the changes in extracellular 
fluid volume which occur in malnutrition (241). The 
arm is a useful site for anthropometry, as it is 
easily accessible and less affected by subcutaneous 
oedema than is the lower limb or subscapular region 
(242).
Brown and colleagues (242) reported a closer 
correlation when whole body oxygen consumption (VOg) 
rather than REE was related to MAMC. In the present 
study, although MAMC did correlate significantly with
VO2 , the correlation was not as close as that between 
REE and MAMC. The uncorrected measurement of mid-arm 
circumference (MAC) also correlated significantly with 
REE, but less so than did MAMC, which takes account of 
mid-arm fat stores. Measurements of MAC have been 
shown by others (243) to be more reproducible and to 
correlate with weight change better than MAMC, and it 
has been suggested that the error margin associated 
with TST measurement is responsible for the poorer 
performance of MAMC. However, in the present study, 
MAMC has been shown to correlate more closely with REE 
than does MAC.
A significant finding in the present study is the 
altered relationship between REE and MAMC in the 
presence of significant weight loss. The correlation 
coefficients were considerably higher in both the 
weight losing groups compared with the weight stable 
groups. Since both the weight losing groups had 
smaller TST values than the weight stable groups, it 
may be that the inaccuracy caused by the presence of 
mid-arm fat stores was responsible for this difference 
in correlation.
The significant difference in the slopes of the 
regression lines for all weight stable and all weight 
losing patients (Figure 8) should be noted. The 
significantly steeper slope of the weight losing
patients may imply that at low arm muscle
1 2'
circumferences these patients are able to lower their 
REE to a greater extent than can weight stable 
patients. This interpretation is consistent with the 
theory put forward in Chapter 4, where REE was 
correlated with LBM.
In the present study, malignant disease did not 
appear to alter the relationship between MAMC and REE 
(Figure 7), suggesting that skeletal muscle is 
unlikely to play a major role in any alteration in REE 
seen in cancer patients. The regression lines in 
Figures 7 and 8 are very similar to those in Figures 4 
and 5 (Chapter 4). This finding indicates that MAMC 
measurements reflect the metabolically active portion 
of the body.
It should be remembered that this study has been 
performed in patients who were largely unstressed, 
with no evidence of sepsis. Brown and colleagues 
(242) showed that the relationship between MAMC and 
whole body oxygen consumption was much poorer in the 
septic patient. Allowances will therefore have to be 
made for patients who have been stressed by trauma or 
surgery, and those who display any evidence of 
sepsis.
In conclusion, it would appear that mid-arm muscle 
circumference can be used to estimate resting energy 
expenditure in patients with benign or malignant
30
disease, although different relationships exist 
depending on whether the patient has or has not lost 
weight. This simple, easily performed measurement may 
therefore be of value in estimating the resting energy 
requirements of patients where access to indirect 
calorimetry facilities are unavailable. However, 
prospective evaluation of the accuracy of these 
regression equations is required.
CHAPTER 7
THE EFFECTS OF DIFFERENT TUMOUR TYPES
ON RESTING ENERGY EXPENDITURE
1 31
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INTRODUCTION
In the large group of cancer patients studied in 
Chapter 4, the type of tumour present did not appear 
to influence REE significantly. It was noted, however, 
that patients with non-small cell bronchial cancer 
appeared to show a trend towards a slightly higher REE 
than that of patients with colorectal and gastric 
cancer.
Since some authors (39) have suggested that 
differing tumour types may modify REE in different 
ways it is necessary to subdivide the heterogeneous 
group of cancer patients described in Chapter 4. This 
chapter therefore contains a closer study of the 
relationship between REE and separate groups of 
patients with colorectal, gastric or non-small cell 
bronchial cancer. This study includes some of the 
patients investigated in Chapter 3 as well as some new 
patients.
j  j
PATIENTS & METHODS
Eighty four patients with recently diagnosed, 
histologically proven cancer were included in the 
study. Patients were divided into three groups 
depending on the type of cancer present. Fifty one 
patients had colorectal cancer, 22 had gastric cancer 
and 11 had non-small cell bronchial cancer. The 
presence or absence of hepatic métastasés was assessed 
by ultrasound and computerised tomography. Patients 
with colorectal or gastric cancer found to have 
hepatic métastasés had these confirmed histologically 
at subsequent laparotomy.
The methods used are as described in Chapter 3-
RESULTS
Clinical details are shown in Table 18. There was 
no significant difference in mean age between patients 
in the different tumour groups. There were, however, 
more males than females in each group. No significant 
differences were found between the groups with respect 
to mean body weight, mean LBM and mean percentage 
weight loss. Hepatic métastasés were present in 13 
patients (25.5%) with colorectal cancer, five patients 
(22.7%) with gastric cancer and 2 patients (18.2%) 
with bronchial cancer. There were no significant 
differences in the incidence of hepatic métastasés 
between the groups.
REE has been expressed as kcal/kg body weight/day 
and as kcal/kg LBM/day (Table 19). When expressed as 
kcal/kg body weight/day the REE of bronchial cancer 
patients is significantly increased when compared with 
the other two groups. However, there is no significant 
difference between the groups when REE is corrected 
for LBM.
Significant correlations are shown between REE and 
LBM for each tumour type studied (Figures 10-12). The 
gradient of the lung cancer regression line is 
significantly steeper than that of the other two 
groups when REE is plotted against LBM (Figure 13)- 
REE also correlates significantly with body weight for
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each tumour type (Figure 14). In this case the lung 
cancer regression line is significantly steeper than 
the gastric cancer regression line, but not the 
colorectal cancer regression line.
There were no apparent differences in REE between 
patients with or without hepatic métastasés, 
irrespective of the way in which REE was expressed 
(Table 20). However, some of the subgroups were too 
small to allow statistical analysis.
Measured and predicted REE are shown in Table 21 . 
The Harris-Benedict formula underestimated REE for 
each tumour type.
Table 22 shows details of dietary intake, 
anthropometry and serum proteins. There were no 
significant differences in mean energy and protein 
intakes between the groups. Mean MAMC and TST 
measurements were all less than the expected normal 
values, -indicating a loss of both muscle and fat in 
these patients. Mean serum protein levels were all 
within normal limits with the exception of the gastric 
cancer patients who had a low mean serum albumin.
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Figure 10
The relationship between resting energy expenditure 
and lean body mass in colorectal cancer patients
n = 51 ; r = 0.682; P<0.01 y = 728 + 13.5x 
95% Cl (9.3,17.7)
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Figure 11
The relationship between resting energy expenditure 
and lean body mass in gastric cancer patients
n = 22; r = 0.767; P<0.01 y = 603 + 14.Ix
95% Cl (8.8,19.4)
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Figure 12
The relationship between resting energy expenditure 
and lean body mass in bronchial cancer patients
n = 11 ; r = 0.931 ; P<0.01 y = 320 + 22.9x 
95% Cl (16.9,28.9)
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Figure 13
The relationship between resting energy expenditure 
and lean body mass in tumour group
(See Figs. 10-12 for group data)
The bronchial cancer slope is significantly different 
from the colorectal cancer slope (P<0.05) and the 
gastric cancer slope (P<0.05).
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Figure 14
The relationship between resting energy expenditure 
and body weight in each tumour group
Colorectal
n = 51, r = 0.685; P<0.01
Gastric
n = 22; r = 0.685; P<0.01 
Bronchial
n = 11 ; r = 0.923; P<0.01
y = 571 + 13 -6x 
95% Cl (9.4,17.8)
y = 636 + 11.2x 
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The bronchial cancer slope is significantly different 
from the gastric cancer slope (P<0.05).
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IDISCUSSION
Most studies of resting energy expenditure (REE) 
in cancer have involved investigation of cancer groups 
consisting of a variety of tumour types of widely 
differing sites and histological characteristics 
(8,11,27,3^,35). These different tumours can cause a 
wide variety of symptoms and clinical effects. For 
example, an oesophageal neoplasm can affect the 
ability to ingest food due to mechanical blockage, 
whereas a sarcoma of the lower limb will have no 
direct effect on the gastrointestinal tract. These 
differences may be important, as both dietary intake 
(45) and weight loss (35) are known to influence REE. 
Despite these obvious difficulties, many workers have 
used heterogeneous groups of cancer patients for study 
and most have concluded that patients with cancer have 
an increased REE which may contribute to the 
development of cancer cachexia (6-8,11,27,34,35,225).
Mullen and colleagues (39) measured REE in 173 
patients with gastrointestinal malignancies in an 
attempt to establish if there was a relationship 
between REE and tumour type. They concluded that 
patients with pancreatic and hepatobiliary cancer 
tended to have a decreased REE, whereas gastric cancer 
patients tended to have an increased REE. In contrast, 
the patients with colorectal or oesophageal cancer 
aopeared to have a normal distribution of REE.
Unfortunately, these conclusions were reached by 
expressing measured REE as a percentage of predicted 
REE using the Harris-Benedict formula, the limitations 
of which have been highlighted in Chapter 5. In the 
present study, when REE was compared with the values 
predicted by the Harris-Benedict formula, mean 
predicted REE was lower than measured REE in each of 
the tumour types. Thus, had measured REE been 
expressed as a percentage of predicted REE, as in 
Mullen's study, each tumour type would have appeared 
to be associated with an increased REE, and colorectal 
cancer patients would appear to be hypermetabolic in 
these circumstances. Furthermore, the TST and MAMC 
measurements suggest that the gastric and bronchial 
cancer patients lost relatively more fat than muscle. 
This will alter body composition and can therefore 
lead to inaccuracies in prediction of REE when the 
formula used is dependent on total body weight.
In the present study, when REE is expressed in 
terms of kilograms of body weight, the bronchial 
cancer patients have an increased REE compared to the 
other groups. However, when REE is corrected for 
alterations in body composition and expressed in terms 
of lean body mass, there are no significant 
differences between the groups. Body composition 
therefore appears to be different depending on tumour 
type. Fat mass, calculated by subtracting lean body 
mass from body weight, was certainly lowest in the
bronchial cancer patients, and this is reflected in 
their TST measurement which was 28% less than the 
expected value.
An alternative method of comparing REE in 
different groups of patients would be to plot REE 
against either body weight or lean body mass for each 
tumour group and to compare the gradients of the 
resulting regression lines. The regression lines of 
the bronchial cancer patients (Figures 13 and 14) are 
steeper than that of the other groups, but the lines 
seem to converge as body weight and lean body mass 
falls. This finding supports the argument that some 
cancer patients can ultimately adapt their energy 
expenditure to the weight losing state (see Chapter 
4). It would appear that the bronchial cancer patients 
are more liable to do this than the other groups 
studied.
The presence of hepatic métastasés did not appear 
to alter REE in any of the tumour groups. This finding 
supports the conclusions of Chapter 4, but disagrees 
with other studies which suggest that patients with 
metastatic disease have an increased REE compared with 
patients who have localised malignancy (8,11,27).
Various metabolic abnormalities in cancer patients 
have been hypothesised to account for apparent 
alterations of REE in cancer patients. For example.
disordered cycling of substrates (51), increased Cori 
cycle activity (82), altered protein turnover (62) and 
the production by the tumour of proteins with 
metabolic effects (244) have all been offered as 
possible mechanisms for an elevation in REE. However, 
many of these studies have involved heterogeneous 
cancer groups (62,82), so it is not possible to 
attribute particular abnormalities to particular 
tumour types. In the present study, the differing 
relationships between REE and body size cannot readily 
be attributed to factors other than the type of tumour 
present. The tumour groups were well matched with 
respect to age, body weight and weight loss. No 
significant differences in energy and protein intakes 
were found, but it should be remembered that 
assessment of dietary intake by recall is subject to a 
considerable degree of error. The bronchial cancer 
patients had the lowest MAMC and TST measurements, but 
they were not significantly different from the other 
two groups. Serum albumin and transferrin levels in 
the bronchial cancer patients were within the normal 
range and were not significantly different from the 
other two groups.
In conclusion, in this study comparing patients 
with three different types of tumour, differing 
relationships between REE and indices of body size 
have been detected. These differences appear to be 
related to the type of tumour present, with bronchial
cancer having a different association between REE and 
body weight or lean body mass, when compared with 
colorectal or gastric cancer. Consequently, the use 
of heterogeneous cancer groups may be inappropriate in 
studies of resting energy expenditure and cancer.
1 4 1
CHAPTER 8
THE EFFECTS OF HEPATIC METASTASES ON RESTING ENERGY 
EXPENDITURE IN PATIENTS WITH COLORECTAL CANCER
I 4 ^
INTRODUCTION
In Chapters 4 and 7 it was observed that patients 
with hepatic métastasés had no significant differences 
in resting energy expenditure (REE) when compared with 
patients with localised malignancy. This conflicts 
with other reports which concluded that REE was 
increased in the presence of metastatic disease 
(11,27). For example, Macfie and colleagues (27) 
reported an increased REE in patients with métastasés, 
while Arbeit and colleagues (11) suggested that REE 
was increased in patients with localised cancer, was 
greater still when métastasés were present, and was 
reduced following surgical removal of the primary 
tumour.
In the present study 24 patients with colorectal 
cancer were studied before and after colorectal 
surgery in order to assess the effects of tumour 
removal or progression of metastatic disease on REE.
In using each patient as his/her own control, the 
potential errors associated with the comparison of 
different groups of patients should be minimised. 
Furthermore, by comparing one group of patients who 
had been rendered "tumour free" with the other group 
who had progressive metastatic disease, any potential 
effect of tumour burden on REE should be maximised.
PATIENTS & METHODS
Twenty four patients with recently diagnosed, 
histologically proven colorectal cancer were studied 
preoperatively and again 3-10 months after recovery 
from surgical treatment of their tumours. All patients 
were assessed preoperatively with hepatic ultrasound 
and computerised tomography and nine were found to 
have hepatic métastasés which were confirmed 
histologically at laparotomy (tumour bearing group). 
The remaining 15 patients had no evidence of hepatic 
métastasés, and these patients had a "curative" 
resection (tumour free group). Hepatic ultrasound and 
computerised tomography were repeated in all patients 
at the time of the follow up study. None of the 15 
tumour free patients had any clinical or radiological 
evidence of recurrence or progression of their 
disease. In all the tumour bearing patients, the 
presence of hepatic métastasés was confirmed once 
a g a i n .
The methods used are as described in Chapter 3.
4 4
RESULTS
There were no significant differences in age, sex 
distribution and time to follow up between the groups 
(Table 23). The type of operation performed is shown 
in Table 24.
There were no significant differences in mean body 
weight between the groups either preoperatively or at 
follow up (Table 25). However, while the mean body 
weight of the tumour free patients remained virtually 
unchanged over the study period, the tumour bearing 
patients lost on average more than 4kg. There were no 
significant differences in preoperative mean LBM 
between the groups, and although both groups 
experienced a fall in mean LBM over the study period, 
this loss of LBM was small and not statistically 
significant.
REE and RQ are shown in Table 26. REE has been 
expressed as kcal/kg body weight/day and kcal/kg 
LBM/day. Irrespective of the method used to express 
REE, there were no significant differences in REE 
between the tumour free and tumour bearing patients 
either preoperatively or at follow up. There were also 
no significant differences in REE between the 
preoperative and follow up values within each group. 
The tumour free patients had a higher follow up RQ 
than the other groups but this was not statistically
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Predicted REE using the Harris-Benedict formula 
has been compared with measured REE in Table 27. In 
each group, mean predicted REE was less than the 
measured REE. Only one patient (tumour bearing group, 
preop) had a predicted REE greater than the measured 
v a l u e .
There were no significant differences in MAMC and 
TST between the groups, although the tumour bearing 
patients had a mean TST 18% less than expected at 
follow up (Table 28). There were no significant 
differences in energy and protein intakes between the 
groups. Follow up serum albumin levels were higher in 
both groups compared to preoperative values, although 
this reached statistical significance in the tumour 
free patients only.
2
2 2
3 En
Eh 2
M 2
Q M
2 H
2 <
2 2
X
2 2
2
X O
Ü 2
2 <
2 O
2
2 2
■d
O Eh
2 O
M 2
Eh 2
CO O
2 2
2 O
O
Eh 2
O O
M
Q 2
2 2
2 3
2 O
2 2
1 Ü
2
H O
2 2
2 M
< 2
2 <
2
2
Q
2 2
Eh 3
O O
M S
Q 3
2 Eh
2
2 Q
2
Q <
2
< 2
2
Q 2
2 2
2
3 2
2 3
< O
2 2
S 3
Eh
2
O 2
3
2 En
O
2 2
H H
2
<
2 2
S 2
O 2
O
bû
C
•H
G
0
0
3
G
3
O
S
3
H
0
0
G
2
G
3
O
S
3
H
C—
CM
2
2
2
<Pu
O
d- O
a • •
3 tx d"
(X d -
3
O + J + 1
1—1
2 3 m
O IX 3
2 d" CM
0 2
> 3
0 •rH
> o 3 a :2
•H • • 0 3 o
3 O r— G I—1
0 CO 3 0 3 (—1
G a O o
0 + 1 + 1 o l—\ 2
a 0 1--1o X on G O 1
0 3 2 2 2
G d - on bû
2 (— r - 1 1 G
•H
0 0 G
0 0 0
G G 0
2 2 3
G G G
3 3 3
O O O3 S S S
3 X 3 3 3
a t • 3 3 3
3 CO o '—r'
3 d"
3 2 2 2
O + 1 + 1 2 2 2
1— 1 2 2 2
3 CO 3
O cr\ 3 3 3 3
2 d" 2 0 0 0
3 3 3
ü ü O
•rH •H •rH
3 3 3
0 0 0
0 0 G G G
> cr\ (Ti 2 a 2
•H • •
3 CO CTi
0 d- on 0 0 0
G 3 3 3
0 + 1 + 1 0 0 0
a G G G
o CO <3 0 0 0
0 ON d" > > >
G on 2
2
3 3
O O O
X O O O
X 0 V V V
0 3 2 2 2
3 \
r—i II II II
1—1 0
0 ü 0 3 O
Ü
'-H
2 •2 2 S
2 2
2 0
3 •
3 0 0
0 3
G ü + 1
3 •H
0 3 G
0 0 0
0 G 0
2 2 S
Q
S
<
OO
2
W
2
m
Eh
a
3
5
O2 1-12 < bO r—1X Eh C o<C O ■H 2Eh 2 GS 2 0M O 02 3X Offi O G 0< 3 >Eh 2 O •H2 O S 3H 3 0Q CO Eh G2 0•s 2 2X O O2 2 0Eh Ü G2 2S O
O 22 M
O 22 <
2 2Eh mS< 2
2 CO2 O Eh
O S 22 2
CO En H aH H 3S Q <2 2 2 3
S < O2 2 0 1-12 2 2 0 1—1
2 2 O G O
CO 2 2 2 2< 2 <2 O G
S 2 32 O
2 O S 02 S 3 >2 Eh •H
3 Eh 3O 02 2 G2 2 0
O EH 22 O2 0
Q H G
2 2< 2H
2 Z
> 2H mEh 2<C <
2
2 s
2 2O 22 22 CO
2
3
2
+1
m
m
en
MO
2
+1
3
3
en
o
3
+1
o
2
OO
X
X
+1
2
d"
en
X
o
m
+ 1
2
en
X
o
2
+ 1
on
3
en
00
on
+ 1
on
en
VJD
Lû 
X  
+ 1
X
d-
X
CO 
2 
+ 1
2
3
+ 1
en
3
on
X . < 2 C O O O
• T— X « • 2
CM 3
+1 -H +  1 +  1 +  1
0
on O O 3 on 0
3 G
3 X %-- d" 3 2
en C O CM X d"
G
3
O
S
0 3
d- d" d- X C O 3
• • 3 « •
CM en d- T—
CO
M -H -H + \ +  1 3
CO
d" ou 3 3 r - G
• • d" • • 0
CM d- C O en 3 >
en en 3 3
r -
\ o
/—s X •
X 0 o
0 3 V
3 \ 2
1—1
3 0 II
0 ü 1—1,—\ O 2 0
3 JX — ' bû
0 3
3 0 0
ü 3 0 2 G
0 Ü 2 0 •H S
2 0 0 3 S •
X 2 3 C 3 0
0 X C ■H 3 •
0 •H 1—1 CO
G 0
X •H +1
bO 0 S
o G 3 3 G
S Eh 0 O G 0
< CO C G 0 0H 2 2 CO S
2
3
O
G
bO
2
3
S
O
1 4 6
DISCUSSION
In the present study 24 patients with colorectal 
cancer have been investigated preoperatively when all 
were tumour bearing, and again after surgery, by which 
time 15 were potentially tumour free and nine had a 
considerable tumour burden. Despite these two groups 
of patients having very different tumour burdens 
postoperatively, there is no evidence to support the 
belief that REE is affected by colorectal cancer, or 
that an increasing tumour load increases REE.
Arbeit and colleagues (11) have suggested that 
surgical excision of tumour bulk reduces REE in 
proportion to the mass of tumour excised, but the 
study involved only four patients and REE was 
expressed only in terras of body weight. This has not 
been seen in the present study, where there was an 
upwards trend in REE in both groups of patients during 
the study period (Table 27) irrespective of the way in 
which REIE was expressed.
Mullen and colleagues (38,39), in studies of 
patients with gastrointestinal malignancies, concluded 
that REE was not dependent on tumour burden or the 
presence of hepatic métastasés. However, they 
compared measured REE with that predicted from the 
Harris-Benedict formula which has been shown to be 
inaccurate in predicting REE in many patients (see
1 4 7
Chapter 5). Indeed, within the present study the 
Harris-Benedict formula consistently underestimated 
REE in each group, and in one patient, REE was 
underestimated by 34%.
Macfie and colleagues (27) reported an increase in 
REE of 289 kcal/day in patients with métastasés 
(mainly hepatic) from gastrointestinal cancer. They 
calculated that this increment of REE could have led 
to the loss of almost 1 kg of fat per month. The 
tumour bearing patients in the present study lost on 
average 4.4 kg of body weight and this loss cannot be 
explained by an alteration in REE. An obvious 
explanation for the observed weight loss would be 
anorexia with consequent reduction in food intake. In 
the present study there were no significant 
differences in energy and protein intake between the 
groups. However, the slight increase in intake in the 
tumour free patients and the decrease in the tumour 
bearing patients over the study period are consistent 
with the observed changes in body weight and lean body 
mass, and are most likely to reflect an actual 
reduction in food intake by the tumour bearing 
patients. A small and insignificant increase in serum 
3^2.bumin levels has been observed in the tumour bearing 
group at follow up. This conflicts with other reports 
(11,150) and has failed to reflect the fall in body 
weight and lean body mass seen in these patients. It 
should be remembered, however, that many factors other
4 3
than nutritional status can affect serum albumin 
levels.
The low RQs in both groups preoperatively and in 
the tumour bearing group at follow up supports the 
evidence suggesting an increased utilisation of fat 
stores in cancer patients (11,245). Furthermore, TST 
measurements (reflecting fat stores) were less than 
expected in both groups and decreased over the study 
period, especially in the tumour bearing patients. No 
significant alteration was observed in MAMC 
measurements (reflecting muscle mass), although 
measurement of body weight and lean body mass suggests 
that tumour bearing patients lost predominantly fat 
together with a little lean tissue during the study 
period. This observation of loss of body fat warrants 
further investigation, especially in view of recent 
evidence that tumour necrosis factor or cachectin, 
produced by the host in response to the presence of 
cancer, may cause alterations in lipid metabolism 
(122,123).
In conclusion, REE and indices of body composition 
have been measured in patients before and after 
surgical treatment of colorectal cancer. Each patient 
therefore has acted as his/her own control, thus 
minimising the potential errors which can occur when 
different groups of patients are compared. It is 
concluded that neither surgical removal of the primary
1 4P
tumour nor progression of metastatic hepatic disease 
significantly alters REE in patients with colorectal 
cancer. Thus if there is any increase in REE caused by 
the presence of cancer, it is within the limits of 
detection of indirect calorimetry and therefore is 
unlikely to be a significant cause of weight loss in 
these patients.
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The evidence of Chapters 5,7 and 8 suggesting that 
tumour bearing patients lose relatively more fat than 
lean tissue requires closer investigation. Alterations 
in fat and carbohydrate metabolism have been 
implicated in the development of cancer cachexia (9). 
For example, studies in rats have indicated increased 
endogenous fat utilisation in the presence of cancer 
(109,111,112), and although recent studies have shown 
an increase in fat utilisation in cancer patients 
compared with controls (10-12), some of the cancer 
groups have been very heterogeneous (11,12) and some 
control groups have been very small (12).
In the present study the effects of both cancer 
and weight loss on endogenous fat and carbohydrate 
oxidation rates have been investigated in patients 
with colorectal and gastric cancer, as well as in 
patients with nonmalignant illness.
PATIENTS & METHODS
Ninety three recently diagnosed patients were 
studied. Colorectal or gastric cancer was proven 
histologically in 70 patients, and a control group of 
23 patients had nonmalignant illness (Table 29). Of 
the 70 cancer patients, 43 were weight stable and 27 
were weight losing. The control group was similarly 
divided into 10 weight stable and 13 weight losing 
patients.
In the cancer patients, the presence or absence of 
hepatic métastasés was assessed by ultrasound and 
computerised tomography and confirmed at subsequent 
laparotomy. Six of the weight stable patients and 
eight of the weight losing patients had hepatic 
métastasés.
The methods used are as described in Chapter 3.
TABLE 29 CLINICAL DIAGNOSES IN WEIGHT STABLE AND
WEIGHT LOSING CANCER PATIENTS AND CONTROLS
Diagnosis Cancer
Weight stable Weight losing
(n = 43) (n = 2?)
Colorectal cancer 
Gastric cancer
31
12
17
10
Control
Weight stable Weight losing
(n = 10) (n = 13)
Duodenal ulceration 
Pyloric stenosis 
Cholelithiasis 
Benign colorectal polyp 
Diverticular disease 
Cr o h n ’s disease 
Ulcerative colitis
RESULTS
There was no significant difference in mean age 
between the groups (Table 30). The weight losing 
cancer patients had a significantly lower mean body 
weight and LBM than their weight stable counterparts. 
The weight losing controls had a significantly lower 
mean body weight but no significant difference in LBM, 
compared with their weight stable counterparts. Both 
the weight losing groups had lost 15% or more of their 
pre-illness body weight.
Anthropometric and nutritional details are shown 
in Table 31. Mean MAMC and TST measurements were 
significantly lower in both weight losing groups 
compared with their weight stable counterparts. This 
was especially evident for the TST measurements which 
were almost 30% less than expected standard values for 
both the weight losing groups. The weight losing 
cancer patients had significantly lower mean serum 
albumin and transferrin levels compared with the other 
three groups. No significant differences were detected 
in mean energy intakes, but both cancer groups had a 
significantly reduced protein intake compared with the 
weight stable controls.
REE has been expressed as kcal/kg body weight/day 
and as kcal/kg LBM/day (Table 32). When REE is 
expressed in terms of body weight, both weight losing
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groups have a significantly higher mean REE than their 
weight stable counterparts. However, there are no 
significant differences in REE between the groups when 
REE is expressed in terms of LBM. There were no 
significant differences in RQ or daily urinary 
nitrogen excretion between the groups.
Oxidation rates of endogenous fat and carbohydrate 
are shown in Table 33. As with REE, these oxidation 
rates have been expressed in terms of kg of body 
weight and kg of LBM to allow comparison between 
groups. When fat oxidation is expressed in terms of 
body weight, the weight losing cancer patients have a 
significantly increased mean fat oxidation rate 
compared with the other three groups. There are no 
significant differences between the groups when 
carbohydrate oxidation is expressed in terms of body 
weight. When fat and carbohydrate oxidation rates are 
expressed in terms of LBM, no significant differences 
are detected between the groups.
It is evident from Table 33 that both cancer 
groups have higher mean fat oxidation rates and lower 
mean carbohydrate oxidation rates than both control 
groups, irrespective of the way in which these rates 
are expressed. When fat and carbohydrate oxidation 
rates of all the cancer patients are compared with 
those of all controls (Table 34), mean fat oxidation 
rates are significantly higher and mean carbohydrate
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oxidation rates significantly lower in the cancer 
patients. Furthermore, patients with hepatic 
métastasés have significantly higher fat oxidation 
rates and significantly lower carbohydrate oxidation 
rates than those cancer patients without hepatic 
métastasés (Table 35). Patients with localised cancer 
have significantly higher mean fat oxidation rates 
(P<0.05) and significantly lower mean carbohydrate 
oxidation rates (P<0.05) than controls. No 
significant correlation was found between fat 
oxidation rates and the degree of weight loss for any 
of the groups.
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DISCUSSION
This study demonstrates that patients with 
colorectal or gastric cancer have increased rates of 
body fat oxidation compared with patients who have 
nonmalignant illness. This increase in fat oxidation 
is especially evident in those cancer patients who 
have lost weight and those who have hepatic 
métastasés. These findings are consistent with the 
observations made in previous chapters, where the body 
fat stores of cancer patients appeared to be more 
depleted than lean tissue stores, and support the 
findings of Watson and Sammon (233), referred to in 
Chapter 5.
Abnormalities of fat metabolism, including 
lipaeraia (112) and loss of body fat stores (109,113), 
have been reported in experimental animals (see 
Historical Review). However, studies of fat 
metabolism in tumour-bearing patients have been less 
well controlled. In 1917 Murphy and colleagues (29) 
reported an increased resting energy expenditure in a 
patient with leukaemia, and concluded that most of the 
calories were supplied by fat. More recently, various 
workers have reported abnormalities in fat metabolism 
in cancer patients. For example, Waterhouse and 
Kemperman (10) showed diminished suppression of free 
fatty acid oxidation in response to a glucose load in 
five metastatic cancer patients compared with
157
controls. Other workers (11,106) have reported 
increased lipolysis and increased fat oxidation rates 
in cancer patients. For example, Arbeit and colleagues 
(11) reported an increased fat oxidation rate in four 
cancer patients with diffuse metastatic disease 
compared with 11 controls. They also reported 
increased fat oxidation rates in patients with 
metastatic cancer compared with controls, but found no 
significant difference between patients with localised 
cancer and controls. They found no significant 
difference between patients with metastatic and 
localised cancer. In contrast, patients with hepatic 
métastasés in the present study had significantly 
increased fat oxidation rates and significantly 
decreased carbohydrate oxidation rates compared with 
patients with localised cancer.
Apart from the present study, only one other group 
of investigators has attempted to compare both weight 
stable and weight losing patients with cancer and 
nonmalignant illness. Edén and colleagues (12) showed 
that weight losing cancer patients had significantly 
increased glycerol turnover and concluded that this 
probably indicated an increased whole body lipolysis. 
However, their study involved only 20 patients with a 
wide variety of tumour types. Furthermore, their 
weight losing control group was not strictly 
comparable in that four of the six patients had lost 
weight several months or years previously and
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therefore were not actively losing weight. In the 
present study fat and carbohydrate oxidation rates 
have been investigated in large groups of patients who 
were well matched with respect to age and weight as 
well as the degree and rate of weight loss. Only two 
tumour types have been studied, namely colorectal and 
gastric cancer, which have been shown to behave 
similarly with respect to resting energy expenditure 
(see Chapter 7). The use of heterogeneous cancer 
groups should be viewed with caution as differences in 
the metabolic behaviour of various tumour types have 
been reported (39 + Chapter 7). In the present study, 
there were no significant differences in fat or 
carbohydrate oxidation rates between the colorectal 
and gastric cancer patients.
The low triceps skinfold thickness (TST) 
measurements in the weight losing cancer patients are 
in keeping with the observed increase in endogenous 
fat oxidation in these patients. It should be noted, 
however, =that the weight losing controls, while having 
a similar TST measurement, had normal fat oxidation 
rates. This may indicate an altered pattern of weight 
loss, with the controls having an initial rapid loss 
of body fat whereas the cancer patients have a more 
prolonged but less rapid loss.
Various workers (47,78,82) have reported altered
carbohydrate metabolism in cancer patients. An
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increased rate of anaerobic glycolysis with lactate 
production has been demonstrated in tumour cells 
(47,78), and increased glucose turnover has been found 
in tumour-bearing patients (82). These observations 
are compatible with the findings of the present study, 
since the observed decrease in carbohydrate oxidation 
rate in tumour-bearing patients could still occur 
against a background of increased Cori cycle activity 
and increased gluconeogenesis.
The inaccuracies associated with the assessment of 
dietary intake are most likely responsible for the 
lack of statistical significance between the low mean 
energy intakes in the cancer groups compared with the 
controls. Nevertheless, mean energy intake in the 
weight losing controls was greater than that of both 
the cancer groups. This suggests a degree of anorexia 
even in those cancer patients who had not lost weight 
and perhaps reflects the ability of the tumour-bearing 
host to compensate for a decreased food intake, at 
least in .the early stages of the disease. The reduced 
serum albumin and transferrin levels in the weight 
losing cancer patients are similar to the findings of 
other studies (11,150).
REE measurements in this study are similar to 
those in Chapter 4, whereby no significant differences 
in REE are seen when REE is corrected for differences 
in LBM, No significant differences were found between
160
the groups in terras of RQ, a finding similar to that 
of others (11,27,35). However, in both this study and 
that of others (11,35) the respiratory quotients of 
the cancer groups have been consistently lower than 
those of the controls.
At present, no firm explanation as to the 
mechanisms responsible for altering fat metabolism in 
cancer patients can be offered. It is likely that it 
is hormonally mediated and changes in insulin, 
glucagon, cortisol and catecholamine levels may 
deserve further study. However, recent reports that 
macrophage-derived substances such as tumour necrosis 
factor or cachectin (122,123) interfere with fat 
metabolism suggest that this putative 'defense' 
against the tumour-bearing state may be involved in 
the development of cancer cachexia.
1 6 1
CHAPTER 10
THE RELATIONSHIP BETWEEN RESTING ENERGY EXPENDITURE 
AND WHOLE BODY PROTEIN TURNOVER IN PATIENTS WITH 
BENIGN AND MALIGNANT DISEASE
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INTRODUCTION
In the previous chapter abnormalities of fat and 
carbohydrate metabolism have been demonstrated in 
patients with cancer. Abnormal protein metabolism in 
cancer patients has been reported by some workers 
(62,66,67), although there is conflicting evidence in 
the literature (68,69).
Whole body protein turnover (WBPT) has been 
estimated to account for up to 50% of resting energy 
expenditure (REE) in man (51). Consequently, 
abnormalities of WBPT may be reflected in alterations 
in REE. Few studies, however, have compared WBPT and 
REE in the same individuals.
The aim of this study was to assess the effects of 
cancer and weight loss on WBPT. The relationship 
between WBPT and REE has also been investigated. WBPT 
and REE have been measured simultaneously in weight 
stable and weight losing patients with colorectal, 
gastric and non-small cell bronchial cancer, as well 
as in patients with nonmalignant illness.
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PATIENTS AND METHODS
Ninety six recently diagnosed patients were 
included in the study. Cancer was proven 
histologically in 74 patients, and a control group of 
22 patients had nonmalignant illness. The pathological 
diagnoses and distribution of patients according to 
weight status are shown in Table 36.
The presence of hepatic métastasés in the cancer 
patients was assessed by ultrasound and computerised 
tomography and confirmed histologically in those 
patients who underwent laparotomy. Seven patients 
(three weight stable, four weight losing) with 
colorectal cancer, four patients (one weight stable, 
three weight losing) with gastric cancer and five 
patients (all weight losing) with bronchial cancer had 
hepatic métastasés.
The methods used are as described in Chapter 3.
TABLE 36 PATHOLOGICAL DIAGNOSES IN WEIGHT STABLE AND 
WEIGHT LOSING CANCER PATIENTS AND CONTROLS
Diagnosis Cancer
Weight stable Weight losing
(n = 40) (n = 34)
Colorectal cancer 24 14
Gastric cancer 8 8
Bronchial cancer 8 12
Control
Weight stable Weight losing
(n = 10) (n = 12)
Duodenal ulceration 2 5
Pyloric stenosis - 1
Cholelithiasis 2 1
Diverticular disease 1 1
Benign colorectal polyp 4 2
Ulcerative colitis 1 -
Crohn's disease - 2
6 4
RESULTS
There was no significant difference in mean age 
between the groups (Table 37). The weight losing 
gastric cancer, bronchial cancer and control patients 
had a significantly lower mean body weight and LBM 
than that of their weight stable counterparts. There 
were no significant differences between the weight 
losing and weight stable colorectal cancer patients 
with respect to body weight and LBM, although the 
weight losing colorectal cancer patients had lost more 
than 15% of their pre-illness body weight. The degree 
of weight loss was similar in each of the weight 
losing groups.
Rates of whole body protein synthesis and whole 
body protein degradation (which is equivalent to whole 
body protein turnover since patients were studied in 
the fasting state) are shown in Table 38- Results have 
been expressed in terms of the isotopic enrichment of 
both urinary ammonia and urinary urea. Rates of 
protein degradation were all greater than the 
corresponding rates of protein synthesis because 
patients were studied following an overnight fast.
Rates of protein synthesis and degradation were 
not affected significantly by the presence of weight
loss in any of the cancer patients or controls,
although in most cases mean rates of synthesis and
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degradation were slightly higher in the weight losing 
patients. Patients with bronchial cancer had 
significantly higher rates of protein synthesis and 
degradation than gastric cancer patients and controls. 
Patients with colorectal cancer had significantly 
higher rates of protein synthesis and degradation than 
patients with gastric cancer. There were no 
significant differences in protein synthesis and 
degradation rates between gastric cancer patients and 
controls. The pattern and significance of results were 
similar whether ammonia or urea values were used.
When WBPT and REE were expressed in terms of LBM 
(Table 39), the pattern of results was similar to that 
shown in Table 38. There were no significant 
differences in REE between the groups. The presence 
of hepatic métastasés had no significant effect on 
protein synthesis and degradation rates (Table 40), 
although most patients with hepatic métastasés had 
higher mean rates compared with those patients who had 
localised disease.
There was no correlation between WBPT and REE in 
any of the groups (Figure 15). There was also no 
correlation between WBPT and weight loss (Figure 16).
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Figure 15
The relationship between resting energy expenditure 
and whole body protein turnover in weight stable and
losing cancer patients and controls
stable cancer patients - solid circle
losing cancer patients - open circle
weight stable controls - solid square
weight losing controls - open square
There are no significant correlations in any of the
groups.
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Figure 16
The relationship between weight loss and whole body 
protein turnover in weight stable and weight losing 
cancer patients and controls
weight stable cancer patients 
weight losing cancer patients 
weight stable controls 
weight losing controls
solid circle 
open circle 
solid square 
open square
There are no significant correlations in any of the
groups.
DISCUSSION
The present study has demonstrated that patients 
with colorectal or non-small cell bronchial cancer 
tend to have elevated rates of WBPT compared with 
patients who have gastric cancer or nonmalignant 
illness. These findings were unaffected by weight loss 
and were consistent, irrespective of whether WBPT was 
expressed with reference to the patients’ total body 
weight or lean body mass. Thus, independent of weight 
loss or altered body composition WBPT was increased in 
patients with bronchial and colorectal cancer.
Edén and colleagues (67) suggested that elevated 
WBPT may increase energy expenditure in the cancer 
patient and thus initiate or worsen a negative energy 
balance. In the present study no correlation was found 
between rates of WBPT and REE for any of the patient 
groups examined. Furthermore, there were no 
significant differences in the rates of REE between 
the groups of cancer patients and controls. Thus, 
although patients with colorectal and bronchial cancer 
had an elevated rate of WBPT, this was not associated 
with a detectable increase in REE. In Chapter 7 it 
was noted that the relationship between REE and 
various indices of body size was similar for patients 
with colorectal and gastric cancer, yet in the present 
study patients with colorectal cancer had WBPT rates 
which were more than 507 greater than unose oi the
gastric cancer patients. This finding supports the 
contention that changes in WBPT do not affect REE 
measureably.
It should be remembered that in the present study 
measurements of protein turnover and energy 
expenditure represent whole body rates. It is possible 
that in the presence of an increased WBPT, certain 
energy-requiring processes are reduced to compensate 
for the energy cost incurred, thereby maintaining a 
normal REE. It is also possible that although certain 
patients have an elevated rate of tracer flux, this 
may represent regional changes of protein turnover 
rather than a uniformly elevated rate throughout the 
body. It has been demonstrated that protein synthesis 
can be depressed in skeletal muscle and elevated in 
the liver of patients with cancer (63,68,70). 
Furthermore, the efficiency of energy conversion and 
of protein synthesis may vary from one tissue to 
another. Thus, since WBPT and REE are measurements 
derived, from all tissues of the body it would be wrong 
to assume that these two variables should necessarily 
change in parallel.
Rates of protein turnover have been shown to 
decrease during uncomplicated starvation (62,246) and 
it has been proposed that this may be one mechanism of 
energy conservation. Since anorexia and decreased 
food intake are a major cause of weight loss in cancer
patients (3) it might be expected that protein 
turnover would show an adaptive fall with increasing 
weight loss. A recent study by Edén and colleagues 
(67) suggested that rates of WBPT were inversely 
related to the severity of weight loss in patients 
with cancer. However, the opposite result was obtained 
by Heber and colleagues (66) who showed a direct 
correlation between increased rates of WBPT and 
increasing weight loss. The small numbers of patients 
with different types of cancer, and the different 
labelled amino acids infused, may account for these 
contradictory results. The results of the present 
study indicate that there is no correlation between 
WBPT and weight loss in patients with colorectal, 
gastric and bronchial cancer, or in controls. If the 
patients ’ weight loss was predominantly due to a 
decrease in their food intake this study suggests that 
the normal adaptation to semistarvation is compromised 
in the presence of malignant disease.
Carmichael and colleagues (52), in a study of 11 
patients with colorectal cancer, claimed that protein 
turnover, synthesis and degradation increased with 
advancing disease, while Ward and colleagues (247) 
demonstrated a similar finding in the immediate 
postoperative period in patients with disseminated 
cancer and hepatic métastasés. In the present study, 
patients with hepatic métastasés showed a small but 
insignificant increase in protein turnover, synthesis
and degradation compared with those patients without 
hepatic métastasés.
It is possible that a small rise in REE may occur 
in the presence of an elevated WBPT, but that this may 
not be detected by the methods used. From 
stochiometry it can be estimated that the minimum 
energy required for the synthesis of 1 gram of protein 
is about 0.86 kcal (248). Using the isotopic 
enrichment of urinary urea to calculate rates of 
protein synthesis, the mean rate of protein synthesis 
for the colorectal and bronchial cancer patients was 
5.0gP/kg/day compared with 3.6gP/kg/day for controls. 
This represents an increase of 1 .4gP/kg/day. Since the 
mean weight of the patients was about 60kg, these 
cancer patients were synthesising approximately 84g 
more protein per day. This extra protein synthesis 
would require the expenditure of 72.2 kcal which 
represents approximately 5% of the patients' mean REE. 
A change of this magnitude would be at the limit of 
detection of the method used to measure REE. Moreover, 
REE can vary between normal individuals by up to 50% 
(249). Thus, if the above minimum estimates for the 
energy cost of protein synthesis are correct, the 
expected increase in REE may be undetectable.
Trauma and sepsis are the two main pathological 
states normally associated with increased whole body 
protein flux (250). In the present study WBPT rates
in the colorectal and bronchial cancer patients were 
up to 80% greater than those of the control patients, 
yet none of the patients had evidence of trauma or 
sepsis. The rate of protein synthesis in human tumours 
is approximately the same as the tissue of origin
(251), and human cancers rarely exceed 1% of body mass
(252). Thus, it is unlikely that the tumour itself 
could have caused the observed increase in WBPT. One 
possible explanation for the increased rates of WBPT 
may be the presence of an inflammatory response in 
these cancer patients.
An acute phase protein response can be 
demonstrated in the majority of individuals with 
progressive neoplasia (253,254). The acute phase 
protein response is a characteristic alteration in the 
serum concentration of certain circulating proteins 
which usually accompanies the body's inflammatory 
response to injury (255). Tumour necrosis, destruction 
of normal tissue, and infection of adjacent tissue are 
some of- the factors independent of tumour type that 
could elicit such an acute phase protein response. The 
synthesis of acute phase proteins is thought to be 
mediated by the peptide monokine interleukin-1 (256).
Recent studies have also suggested that circulating 
peptides which may be cleavage products of 
interleukin-1 can influence the protein metabolism of 
skeletal muscle (257). Thus, the immune response of 
the host may participate in the production of some of
I I
the metabolic abnormalities seen in the tumour-bearing 
h o s t .
In conclusion, WBPT appears to be elevated in 
patients with certain tumour types. This abnormal 
protein metabolism does not appear to be related to 
weight loss and has no detectable effect on REE. The 
possibility of an acute phase protein response 
contributing to an elevated WBPT requires further 
investigation.
CHAPTER 11
THE EFFECTS OF PERIPHERALLY-ADMINISTERED INTRAVENOUS 
NUTRITION ON THE METABOLIC RESPONSE TO TRAUMA IN 
PATIENTS FOLLOWING SURGERY FOR COLORECTAL CANCER
INTRODUCTION
In the preceding chapters various abnormalities in 
the substrate metabolism of patients with cancer have 
been demonstrated, and their possible relationship to 
the development of cancer cachexia has been discussed. 
There is evidence to suggest that debilitated patients 
who have lost weight have increased morbidity and 
mortality following surgical procedures 
(13,14,258-260). Thus, attempts to minimise the 
postoperative loss of body protein which is 
characteristic of the metabolic response to trauma 
(144,145) may be of value in debilitated cancer 
p atients.
In this and the following two chapters, the 
metabolic response to surgery has been investigated in 
patients undergoing surgery for colorectal or gastric 
cancer. Attempts to modify this response using 
nutritional support (Chapters 11 and 12) and 
pharmacological manipulation (Chapters 12 and 13) are 
reported.
In the first of these studies, three 
peripherally-administered intravenous regimens have 
been compared in patients following surgery for 
colorectal cancer. A standard dextrose-saline regimen 
has been compared with an amino acid regimen as well 
as a more complete nutritional mixture containing
glucose, amino acids and fat. The effects of these 
regimens on postoperative fat and carbohydrate 
oxidation rates and nitrogen balance is reported.
PATIENTS & METHODS
Forty two patients about to undergo elective 
surgery for colorectal cancer were randomised to 
receive on the first four postoperative days one of 
the following fluid regimens:
(1) Dextrose-saline (DS) - consisting of 2 litres
dextrose 5% and 1 litre 
normal saline per day.
(2) Amino acid (AA) - consisting of 1.5 litres
of Vamin N (Kabi-Vitrum) 
diluted with 1.5 litres 
sterile water.
(3) Glucose-amino acid-fat (GAF) - Vitrimix
(Kabi-Vitrum).
Solution (3) consists of 750ml Vamin Glucose which 
is mixed with 250ml Intralipid 20% in the ward using a 
simple vacuum device supplied with the solutions 
(Figure 17). Two litres of this solution were 
administered over each 24 hour period, in addition to 
0.5 litres of dextrose 5% and 0.5 litres of normal 
saline. The amino acid profiles of the AA and GAF 
solutions were identical. Potassium supplements were 
added to each solution to provide 50mmol of potassium 
per day. Each regimen was infused continuously so 
that the delivery of amino acids, fat or carbohydrate 
remained constant over each 24 hour period. The 
calorie and nitrogen content of each of these fluid
Figure 17
The contents of the two bottles which constitute the 
glucose-amino acid-fat (GAF) regimen are mixed in the 
ward immediately prior to administration
regimens are shown in Table 41. Of the 1700 
non-protein kcals in the GAF group, 1000 kcal were 
provided by fat (Intralipid 20%; Kabi-Vitrum) and 700 
kcal were provided by carbohydrate. These solutions 
were administered through a peripheral vein via a 
peristaltic infusion pump. On the day of operation, 
fluid balance was maintained with blood products and 
crystalloid solutions as required. Fluid requirements 
in excess of 3 litres/day were provided in the form of 
either blood products or normal saline.
Preoperatively and on each of the first four 
postoperative days a 24 hour urine collection was 
obtained for total urinary nitrogen, urea, ammonia and 
3-methylhistidine estimation, and blood samples were 
obtained for urea and electrolytes, liver function 
tests, plasma glucose, plasma insulin, serum albumin 
and serum transferrin. Approximate nitrogen balance 
was calculated by subtracting daily urinary nitrogen 
excretion from intravenous nitrogen input. This value 
was corrected for changes in total body urea nitrogen 
which occurred during the study period. Total body 
urea was calculated from blood urea and total body 
water measurements (see below) preoperatively and on 
the 4th postoperative day. A record of fluid input 
and output was made for each study day. No allowance 
was made for non-urinary loss of nitrogen, which was 
assumed to be constant in each group, since no patient 
had excessive nasogastric or drain losses.
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Resting energy expenditure (REE) and respiratory 
quotient (RQ) were measured between 09.00 and 12.00 
hours on the first preoperative day and on the second 
and fourth postoperative days as described in Chapter 
3. Carbohydrate and fat oxidation rates were 
calculated using the formulae of Frayn (see Chapter 
3).
Lean body mass (LBM) was derived from measurements 
of total body water made during the preoperative and 
fourth postoperative day calorimetry runs (see Chapter 
3).
Peripheral venous cannulae sites were examined 
daily and the cannula was moved to another site if 
signs of inflammation were detected. Episodes of 
inflammation or phlebitis were recorded for each 
regimen.
RESULTS
Sixteen patients received the dextrose-saline (DS) 
regimen, 12 received the amino acid (AA) regimen and 
14 received the glucose-amino acid-fat (GAF) regimen. 
There were no significant differences between the 
groups with respect to mean age, body weight, 
percentage weight loss and lean body mass (Table 42). 
The types of operation performed are shown in Table
43.
There were no significant differences in 
preoperative urinary nitrogen excretion between the 
groups (DS = 4.8 + 0.4gN/d, AA = 7.1 ± 1.3gN/d, GAF = 
4.5 ± 0.4gN/d). The cumulative nitrogen balance for 
the four postoperative days in the AA group (-10.3 ± 
3-8gN) was significantly better than the DS group 
(-25.3 ± 3.1gN, P<0.01), while that of the GAF group 
(+7.7 ± 2.3gN) was significantly better than both the 
AA and DS groups (P<0.01). Nitrogen balance for each 
of the postoperative days is shown in Figure 18. 
Nitrogen balance in the AA group was significantly 
better than the DS group on the first (P<0.01) and 
second (P<0.01) postoperative days only. Nitrogen 
balance in the GAF group was significantly better than 
the AA group on the second, third and fourth 
postoperative days (P<0.01), and significantly better 
than the DS group on each of the postoperative days 
(P<0.01). There was a significant fall in nitrogen
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Figure 18
Mean daily nitrogen balance (+ s.e.ra.) for the first 
four postoperative days in patients receiving 
dextrose-saline, amino acid or glucose-amino acid- 
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balance in the AA group (P<0.05) and a significant 
improvement in the DS group (P<0.01) between the first 
and fourth postoperative days.
There were no significant differences between the 
groups in preoperative REE (Figure 19) and RQ (Figure 
20). Postoperatively, REE increased significantly in 
the AA (P<0.01) and GAF (P<0.01) groups. On the second 
postoperative day, REE in the AA group was 
significantly greater than in the other two groups 
(P<0.05). RQ fell significantly on the second 
(P<0.05) and fourth (P<0.01) postoperative days in the 
AA group.
There were no significant differences between the 
groups in preoperative fat and carbohydrate oxidation 
rates. Carbohydrate oxidation rates are shown in 
Figure 21. The trends in this figure are very similar 
to those of Figure 20. Carbohydrate oxidation fell 
significantly (P<0.01) in the AA group 
postoperatively. Six patients in this group had 
negative values of carbohydrate oxidation on the 
second and fourth postoperative days. Carbohydrate 
oxidation was significantly lower in the AA group 
compared with the other two groups on the fourth 
postoperative day (P<0.01). Fat oxidation increased 
significantly (P<0.05) in the AA group postoperatively 
(Figure 22). On the second and fourth postoperative 
days, fat oxidation was significantly lower in one uA:
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Figure 19
Mean resting energy expenditure (± s.e.m.) 
preoperatively and on the 2nd and 4th postoperative 
days in patients receiving dextrose-saline (DS), 
amino acid (AA) or glucose-amino acid-fat (GAF)
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Figure 20
Mean respiratory quotient (+ s.e.m.) preoperatively 
and on the 2nd and 4th postoperative days in patients 
receiving dextrose-saline (DS), amino acid (AA) or 
glucose-amino acid-fat (GAF)
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Figure 21
Mean carbohydrate oxidation rates (+ s.e.m.) 
preoperatively and on the 2nd and 4th postoperative 
days in patients receiving dextrose-saline (DS), amino 
acid (AA) or glucose-amino acid-fat (GAF)
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Figure 22
Mean fat oxidation rates (+ s.e.m.) preoperatively and 
on the 2nd and 4th postoperative days in patients 
receiving dextrose-saline (DS), amino acid (AA) or 
glucose-amino acid-fat (GAF)
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group compared with the other two groups (P<0.01).
Measured fluid balance for each of the 
postoperative days is shown in Figure 23- There were 
no significant differences in fluid balance between 
the groups. The cumulative fluid balance over the 
four postoperative days was significantly higher in 
the GAF group (+5.2 + 0.62 litres) compared with the 
DS group (+3.4 ± 0.58 litres; P<0.05). Fluid balance 
in the AA group (+4.2 + 0.44 litres) was not 
significantly different from the other two groups.
This contrasts with the total body water measurements 
which showed a fall between the preoperative and 
postoperative measurements in the AA group (-2.07 ± 
0.71 litres) which was significantly different from 
the DS (+1.94 + 0.59 litres; P<0.01) and GAF (+1.30 + 
0.85 litres; P < 0 .01 ) groups. The number of patients 
requiring postoperative diuretic therapy was not 
significantly different between the groups (DS = 2 
patients, AA = 1 patient, GAF = 2 patients).
Preoperatively there were no significant 
differences between the groups with respect to the 
urinary excretion of the metabolites shown in Table
44. Postoperatively, urinary nitrogen and urea 
excretion in the DS group was significantly lower than 
in the other two groups (P<0.01). Urinary nitrogen and 
urea excretion in the AA group was significantly 
higher than in the GAF group (P<0.01). There were no
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Figure 23
Mean daily fluid balance (+ s.e.m.) for the first four 
postoperative days in patients receiving dextrose- 
saline, amino acid or glucose-amino acid-fat
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significant differences between the groups in the 
urinary excretion of nitrogen in forms other than that 
of urea and ammonia, nor in 3-methylhistidine 
excretion.
There were no significant differences between the 
groups with respect to preoperative serum urea and 
pre- and postoperative serum creatinine (Table 45). 
Postoperatively, serum urea fell significantly in the 
DS group (P<0.01) and increased in the other two 
groups (P < 0 .01).
Preoperatively, there were no significant 
differences between the groups with respect to plasma 
glucose and insulin (Table 45). Postoperatively 
plasma glucose increased significantly in the DS 
(P<0.01) and GAP (P<0.01) groups, and was 
significantly higher than that of the AA group 
(P<0.01), while plasma insulin increased significantly 
in all three groups (P<0.Q1). There were no 
significant differences in plasma insulin between the 
DS and AA groups, but plasma insulin levels in the OAF 
group were significantly greater than those of the 
other two groups (P<0.05).
Serum albumin and serum transferrin (Table 46) 
fell postoperatively in each group (P<0.01), and 
haematocrit fell in the DS (P<0.05) and GAP (P<0.01 ) 
groups.
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Ten episodes of cannula site inflammation or mild 
phlebitis occurred in the GAP group compared with four 
in the AA group and three in the DS group (no 
significant differences). There were no significant 
differences between the groups with respect to 
postoperative complications and hospital stay (Table 
47).
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DISCUSSION
In 1973, Blackburn and colleagues (165) claimed 
that the infusion of amino acid solutions in the 
absence of glucose could improve nitrogen balance and 
conserve visceral proteins. Isotonic dextrose 
solutions had previously been shown to spare nitrogen 
(163,164), but Blackburn hypothesised that infused 
glucose stimulated insulin secretion and hence 
inhibited lipolysis. He suggested that the infusion of 
amino acids alone resulted in reduced insulin 
production with consequent enhancement of fat 
mobilisation and ketone production, thereby sparing 
the body's protein stores. However, various workers 
(166-168), comparing amino acid infusions alone with 
amino acid plus dextrose, have shown that the protein 
sparing effects of peripheral amino acids are due to 
the infused amino acids themselves, and are 
independent of plasma insulin levels and ketosis.
In the present study, the patients receiving amino 
acids alone (AA group) had a significantly improved 
nitrogen balance compared with those patients 
receiving dextrose-saline (DS group). This 
improvement, however, was apparent only on the first 
and second postoperative days, after which there was 
no significant difference in nitrogen balance between 
these two groups. This finding is similar to that of 
Garden and colleagues (170), who reported a
184
significant improvement in nitrogen balance on only 
the first postoperative day in patients receiving 
amino acid infusions providing lOg of nitrogen per day 
compared with patients receiving dextrose-saline.
Other studies have shown a more prolonged improvement 
in nitrogen balance in patients receiving amino acid 
solutions containing 10-14g nitrogen per day(169,171). 
In these studies, the mean daily nitrogen balance was 
approximately -7g nitrogen per day. In the present 
study, mean daily nitrogen balance was less than -3g 
nitrogen per day. The type of amino acid solution 
used, and the balance of essential to non-essential 
amino acids, may be partly responsible for these 
differences in nitrogen balances.
A finding of note in the present study was the 
significant improvement in nitrogen balance with time 
in those patients receiving dextrose-saline, while 
nitrogen balance became more negative in the patients 
receiving amino acids. There was also a deterioration 
in nitrogen balance with time in those patients 
receiving a combination of glucose, amino acids and 
fat. The provision of this more complete nutrient 
mixture, however, resulted in a positive nitrogen 
balance on each of the study days. Even when 
allowances are made for non-urinary nitrogen loss of 
approximately 2g/day, these patients were virtually in 
nitrogen balance throughout the study period. 
3-methylhistidine excretion reflects skeletal muscle
13
breakdown (261), although it has been shown that it is 
released from tissues other than skeletal muscle 
(262). In the present study, the similar 
postoperative excretion of 3-methylhistidine in each 
group suggests that any effect on nitrogen sparing is 
due to improved protein synthesis rather than 
decreased breakdown.
The significant postoperative rise in fat 
oxidation and fall in carbohydrate oxidation and RQ in 
the patients receiving amino acids, together with the 
significantly lower plasma glucose levels, appear 
initially to support the fat mobilisation theory of 
Blackburn (165). However, the similar postoperative 
plasma insulin levels in the DS and AA groups suggest 
that any nitrogen sparing effect of the amino acids 
occurs independently of plasma insulin levels, a 
finding supported by the work of Greenberg and 
colleagues (166). It should also be noted that there 
were no significant differences in postoperative RQ or 
fat oxidation between patients receiving amino acids 
and those receiving dextrose-saline. The negative 
carbohydrate oxidation rates in the amino acid group 
most probably represent gluconeogenesis, which might 
be expected to occur in the absence of infused 
glucose. It is unlikely, however, that these patients 
receiving amino acids were in a state of net glucose 
production throughout each 24 hour period. A possible 
explanation lies in the timing of the indirect
calorimetry measurement. It may be that following a 
period of sleep when REE would be lowest, these 
patients were in a state of maximal fat mobilisation 
and amino acid utilisation, with net glucose 
production. The stress associated with the nursing and 
physiotherapy activities which followed the 
calorimetry measurement may return these patients into 
a state of net glucose oxidation. This hypothesis 
would seem reasonable, as a persistent state of net 
glucose production would result in glycogenesis, which 
would be unlikely to occur in these patients.
The carbohydrate oxidation rates in the 
dextrose-saline and glucose-amino acid-fat groups were 
similar to the daily amount of infused glucose (see 
Figure 21). The high fat oxidation rates in the amino 
acid and dextrose-saline groups, in the absence of 
infused fat, indicate mobilisation of body fat stores. 
In contrast, those patients receiving llOg fat/day 
(GAF group) had fat oxidation rates which were 
significantly lower ( 60-75g/day ). Thus, the amount of 
fat administered may be in excess of requirements.
The significant increase in postoperative REE in 
the AA and GAF groups (18-19% of preoperative REE) 
most probably reflects a combination of the 
postoperative metabolic response to trauma and the 
specific dynamic action of the infused nutrients 
(182,263). This increase was greatest in the AA group
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and may reflect the energy cost associated with the 
metabolism of these amino acids. This high energy cost 
may contribute to the poor nitrogen balance in this 
group. The postoperative rise in REE of only 7% in the 
DS group is similar to the 9% rise reported by Harris 
and colleagues (182) whose patients received a similar 
low calorie fluid regimen.
The increases in serum and urine urea in the AA 
and GAF groups, together with the similar values for 
the non-urea non-ammonia urinary nitrogen, indicate 
that most of the infused amino acids in these groups 
has been metabolized and not simply excreted in the 
urine.
The discrepancy between the fluid balance and 
total body water measurements emphasises the fluid 
shifts which occur in the perioperative period. The 
fluid balance data commence on the first postoperative 
day and therefore do not take account of fluid 
administration on the day of surgery, so a comparison 
with the total body water measurements is not strictly 
justified. The mean daily fluid balance for each group 
was approximately +1 litre/day, a proportion of which 
will have been lost as insensible water loss. The fall 
in serum albumin and transferrin is mirrored by the 
fall in haematocrit, which reflects the positive fluid 
balance in each group.
The achievement of positive nitrogen balance using 
a peripherally-infused combination of glucose, amino 
acids and fat is important. Similar results have been 
obtained using a peripheral regimen containing 14.1g 
nitrogen and more than 3000 non-protein calories per 
day (173). The patients in that study, however, had 
not been subjected to major surgery immediately prior 
to commencing the nutritional support. Furthermore, 
although the solution was described as one for 
peripheral administration, half the patients received 
the solution through central venous cannulae. In the 
present study, the GAF regimen contained no additional 
trace elements or vitamins. If peripheral vein feeding 
were to continue for more than 3-4 days, these 
additives should be included. The stability of the 
mixture is unlikely to be affected, but this would 
require further investigation.
The episodes of mild phlebitis which occurred in 
all groups probably would be minimised by the daily 
resiting of peripheral venous cannulae. Messing and 
colleagues (264) demonstrated a reduction in venous 
complications due to the peripheral infusion of a 
similar GAF regimen (osmolarity 960 mOsm/1) when 
heparin was added to the solution. They also 
recommended daily resiting of the cannulae. The 
infusion of amino acids, with or without fat and 
glucose calories, is best given via the larger forearm 
veins, where few phlebitic episodes occurred in the
189
present study.
It is not surprising that there were no 
significant differences between the groups in 
postoperative morbidity and mortality. This study was 
designed to investigate the effects of different fluid 
regimens on the metabolic and biochemical changes 
which occur in the early postoperative period. The 
provision of calories and nitrogen for such a short 
duration would not be expected to have a demonstrable 
effect on clinical outcome.
In conclusion, this study demonstrates that a 
combination of glucose, amino acids and fat 
administered via a peripheral vein in the 
postoperative period can result in positive nitrogen 
balance. The infusion of amino acids alone only 
transiently improves postoperative nitrogen balance 
and has little to offer compared with the standard 
dextrose-saline regimen. Where the provision of 
peripheral intravenous nutritional support is desired, 
the use of a more complete nutritional mixture, 
namely, a combination of amino acids and both glucose 
and fat calories, is recommended.
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CHAPTER 12
THE EFFECTS OF AN ANABOLIC STEROID AND PERIPHERALLY- 
ADMINISTERED INTRAVENOUS NUTRITION ON TH^ METABOLIC 
RESPONSE TO TRAUMA IN PATIENTS FOLLOWING SURGERY FOR
COLORECTAL CANCER
INTRODUCTION
Various attempts have been made to manipulate the 
metabolic response to surgery by pharmacological 
agents. For example, the administration of insulin 
(188,189), growth hormone (20), naftidrofuryl (21) and 
anabolic steroids (196) each have been shown to 
influence postoperative nitrogen losses but not all 
studies have demonstrated this effect (190,191,197).
In some studies a combination of intravenous nutrition 
and an anabolic steroid have resulted in a reduction 
in nitrogen excretion (192,193), while in others no 
effect on nitrogen balance was seen (197).
In the present study, the anabolic steroid 
stanozolol was given to determine its effect on the 
metabolic response to surgery in patients with 
colorectal cancer. The effects of combining the 
anabolic steroid with each of the postoperative 
nutritional regimens descibed in the previous chapter 
has also been investigated.
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PATIENTS & METHODS
Sixty patients about to undergo elective surgery 
for colorectal cancer were included in the study. The 
study was stratified to include equal numbers of males 
and females in each treatment group. They were 
randomised to receive either a single intramuscular 
injection of 50mg stanozolol (Stromba, Sterling 
Research Laboratories) 24 hours prior to surgery or to 
a control group which received no injection. The 
patients were further randomised to receive on the 
first four postoperative days one of the fluid 
regimens described in Chapter 11, namely, 
dextrose-saline (DS), amino acid (AA) or glucose-amino 
acid-fat (GAF ).
The methods used are as described in Chapters 3 
and 11.
19
RESULTS
Each of the six groups consisted of five male and 
five female patients. There were no significant 
differences between the groups with respect to mean 
age, body weight, percentage weight loss and lean body 
mass (Table 48). The types of operation performed are 
shown in Table 49.
There were no significant differences in 
preoperative urinary nitrogen excretion between the 
groups (DS/stanozolol = 4,4 + 0.4gN/d, DS/control =
5.3 ± 0.8gN/d; AA/stanozolol = 6.5 ± 1.5gN/d, 
AA/control = 5.3 ± 0.9gN/d; GAF/stanozolol = 4.1 + 
0.6gN/d, GAF/control = 4.2 ± 0.3gN/d). The cumulative 
nitrogen balance for the four postoperative days is 
shown in Figure 24. Nitrogen balance in those patients 
receiving amino acids alone was significantly improved 
(P<0.05) by the administration of stanozolol. 
Stanozolol did not significantly influence the 
cumulative nitrogen balance in those patients 
receiving either the dextrose-saline or glucose-amino 
acid-fat regimens. The cumulative nitrogen balance in 
both the AA groups was significantly better than that 
of both the DS groups (P<0.01), and that of the two 
GAF groups was significantly better than in the two AA 
and the two DS groups (P<0.01).
Cumulative nitrogen balance, displayed separately
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Figure 24
Mean cumulative nitrogen balance (± s.e.m.) in the 
stanozolol and control groups of patients receiving 
dextrose-saline (DS), amino acid (AA) or 
glucose-amino acid-fat (GAF)
for males and females, is shown in Figure 25- 
Stanozolol significantly improved nitrogen balance in 
female patients who received amino acids alone 
(P<0.01). Cumulative nitrogen balance in female 
patients was significantly better than in male 
patients in both the DS groups (P<0.01), and in the 
stanozolol treated AA group (P<0.05).
Nitrogen balance for each of the postoperative 
days is shown in Figure 26. It was significantly 
better in the stanozolol treated AA group (P<0.05) 
than in the AA control group on the third 
postoperative day. There was a significant 
improvement in nitrogen balance in both the DS groups 
between the first and fourth postoperative days 
(P<0.01), whereas over the same period nitrogen 
balance fell significantly (P<0.05) in the two AA 
groups. Nitrogen balance was more positive on each 
day in the stanozolol treated GAF group compared with 
the GAF control group, but this did not reach 
statistical significance. In the two AA groups 
nitrogen balance was significantly better than in the 
two DS groups on the first two postoperative days only 
(P<0.01). On the third postoperative day, nitrogen 
balance in the stanozolol treated AA group was 
significantly better than in both the DS groups 
(P<0.01). Nitrogen balance in the two GAF groups was 
significantly better than the two DS groups on each of 
the postoperative days (P<0.01), and significantly
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Figure 25
Mean cumulative nitrogen balance (+ s.e.m.) in males 
and females in the stanozolol and control groups of 
patients receiving dextrose-saline (DS), amino acid 
(AA) or glucose-amino acid-fat (GAF)
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Mean daily nitrogen balance (+ s.e.m.) for the first 
four postoperative days in the stanozolol and control 
groups of patients receiving dextrose-saline (DS), 
ajnino acid (AA) or glucose-amino acid-fat (GAF)
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better than the two AA groups on the second and fourth 
postoperative days (P<0.01).
There were no significant differences between the 
groups in preoperative REE (Figures 27a and 27b) and 
RQ (Figures 28a and 28b). REE increased significantly 
(P<0.05) in all groups except for the DS control 
group. Stanozolol had no significant effect on 
postoperative RQ. RQ fell significantly in both the 
AA groups postoperatively (P<0.01), and was 
significantly lower than that of the two GAF groups 
(P<0.01).
Stanozolol had no significant effect on 
postoperative carbohydrate (Figures 29a and 29b) or 
fat (Figures 30a and 30b) oxidation rates.
Carbohydrate oxidation rates fell significantly in 
both the AA groups (P<0.01). Three patients in the AA 
control group and five in the stanozolol treated AA 
group had negative values of carbohydrate oxidation on 
the second and fourth postoperative days. Carbohydrate 
oxidation rates were significantly lower (P<0.01) in 
both these groups compared with the other groups on 
the fourth postoperative day. Fat oxidation increased 
significantly in the AA control group postoperatively 
(P<0.05). On the fourth postoperative day, fat 
oxidation was significantly lower in both the GAF 
groups (P<0.01) compared with the other groups.
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Stanozolol had no significant effect on measured 
fluid balance in any of the groups (Figure 31). There 
was no significant difference between the groups in 
the number of patients requiring postoperative 
diuretic therapy. The cumulative fluid balance 
results (Figure 32) contrast with the total body water 
measurements which showed a fall between the 
preoperative and postoperative measurements in the two 
AA groups (AA/stanozolol = -2.10 + 0.75 litres; 
AA/control = -1.61 + 0.68 litres). These results were 
significantly different from the two DS groups 
(DS/stanozolol = +1.65 + 0.83 litres; DS/control = 
+1.35 + 0.73 litres - P<0.01) and the two GAF groups 
(OAF/stanozolol = +1.11 + 0.85 litres; GAF/control = 
+1.52 + 1.12 litres - P<0.01).
Preoperatively there were no significant 
differences between the groups with respect to the 
urinary excretion of the metabolites shown in Tables 
50 and 51. Stanozolol had no significant effect on 
any of these indices postoperatively. Urinary nitrogen 
and urea excretion in the two DS groups was 
significantly lower postoperatively than in the two AA 
and two GAF groups (P<0.01). Urinary nitrogen and urea 
excretion in both the AA groups was significantly 
higher than in the two GAF groups (P<0.01). There 
were no significant differences between the groups in 
the urinary excretion of nitrogen in torms other than 
that of urea and ammonia, nor in 3-Methylhistidine
2500
2000-
1500-
u_
GOO­
DS AA GAF 
1
08 AA GAF
4 Postoperative day2 3
Control Stanozolol
Figure 31
Mean daily fluid balance (+ s.e.ra.) for the first four 
postoperative days in the stanozolol and control 
groups of patients receiving dextrose-saline (DS), 
amino acid (AA) or glucose-amino acid-fat (GAF)
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Figure 32
Meap cumulative fluid balance (+ s.e.m.) in the 
stanozolol and control groups of patients receiving 
dextrose-saline (DS), amino acid (AA) or 
glucose-amino acid-fat (GAF)
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excretion.
Stanozolol had no significant effect on 
postoperative serum urea and serum creatinine levels 
(Table 52). Serum urea fell significantly in the two 
DS groups (P<0.05) and increased in the two AA groups 
(P<0.01) and the two GAF groups (P<0.01).
Preoperatively there were no significant 
differences between the groups with respect to plasma 
glucose and insulin (Table 52). The stanozolol 
treated amino acid group had a significantly lower 
plasma glucose than the AA control group on the third 
(P<0.05) and fourth (P<0.05) postoperative days.
Plasma glucose increased significantly in the two DS 
groups (P<0.01) and in the stanozolol treated GAF 
group (P<0.01). On the second and third postoperative 
days, plasma glucose was significantly lower in the 
two AA groups (P<0.01) compared with the two DS and 
two GAF groups. Stanozolol had no significant effect 
on postoperative plasma insulin. Plasma insulin 
increased significantly in the two DS groups (P<0.05) 
and the two GAF groups (P<0.01 ). There were no 
significant differences in plasma insulin between the 
DS and AA groups, whereas plasma insulin levels in the 
two GAF groups were significantly greater (P<0.05) 
than those of the DS and AA groups postoperatively.
Serum albumin and serum transferrin (Table 53)
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fell postoperatively in all groups (P<0.05), and 
haematocrit fell in the two DS groups (P<0.05) and the 
GAF control group (P<0.01). Stanozolol had no 
significant effect on serum albumin, serum transferrin 
or haematocrit.
Four episodes of mild phlebitis occurred in 80 
patient days in the DS groups (DS/stanozolol = 4, 
DS/control = 0), compared with five episodes in the AA 
groups (AA/stanozolol = 3, AA/control = 2) and 13 
episodes in the GAF groups (GAF/stanozolol = 6, 
GAF/control = 7 ) .  These differences were not 
statistically significant. There were no significant 
differences between the groups with respect to 
postoperative complications and hospital stay (Table 
54).
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DISCUSSION
The effects of the three nutritional regimens on 
the metabolic response to surgery were very similar to 
those reported in the previous chapter, therefore this 
discussion will be limited to those aspects of the 
metabolic response which have been influenced by 
stanozolol.
It appears that preoperative administration of the 
anabolic steroid stanozolol may improve postoperative 
nitrogen balance significantly in patients receiving 
amino acid infusions. This finding is consistent with 
that of Michelsen and colleagues (193), who reported 
improved nitrogen balance on each of the first three 
postoperative days following the administration of 
nandrolone decanoate and isotonic amino acids to 
patients undergoing total hip replacement. In the 
present study, stanozolol did not improve nitrogen 
balance in patients receiving amino acid infusions 
until the third postoperative day. In patients 
receiving the more complete nutritional regimen, 
glucose-amino acid-fat, nitrogen balance was more 
positive on each of the postoperative days in the 
stanozolol treated patients, but these differences did 
not reach statistical significance.
There have been conflicting results regarding the 
effect of anabolic steroids in the presence of an 
adecuate nutritional input. Tweeaie and coworKers
20!
(192) showed that a combination of nandrolone 
decanoate and TPN improved nitrogen balance moreso 
than nandrolone decanoate alone, whereas Yule and 
colleagues (197) showed that anabolic steroids had no 
significant effect on nitrogen balance in patients 
receiving postoperative TPN. In contrast to the 
findings of the present study, previous work by Blamey 
and colleagues from this centre (196) showed that 
stanozolol had a significant effect on postoperative 
nitrogen balance in patients receiving a 
dextrose-saline regimen. The patient population in 
that study, however, consisted mainly of patients with 
benign disease whereas all patients in the present 
study had colorectal cancer. Furthermore, mean daily 
nitrogen balance in Blamey's control group was -10.9gN 
while in the present study the control patients 
receiving dextrose-saline had a mean daily nitrogen 
balance of only -6.3gN. Blamey's stanozolol treated 
group had a mean daily nitrogen balance of -S.OgN 
while in the present study the stanozolol treated 
patients receiving dextrose-saline had a mean daily 
nitrogen balance of -6.8gN.
The underlying pathology may influence the effect 
of anabolic steroids on the metabolic response to 
surgery. Most studies of anabolic steroids have 
involved either groups of patients with benign 
diseases only (18,192,194,195,198,199) or groups where 
the majority of patients had benign disease
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(196,200-203), whereas all the patients in the present 
study had colorectal cancer. The differing patient 
population, and differences in the type, dose and 
timing of anabolic steroid administration, make direct 
comparison of results difficult. The dose of 
stanozolol used in the present study was identical to 
that shown to be effective both in Blamey's study 
(196) and in the prevention of fibrinolytic shutdown 
in a previous study (265).
The virilising effects of anabolic steroids limit 
their use in clinical studies, especially in females 
(18). The high anabolic to androgenic ratio (100:1) of 
stanozolol has resulted in no evidence of virilisation 
in the 30 females in the present study. Furthermore, 
its long duration of action enables stanozolol to be 
administered as a single intramuscular dose (266).
The anabolic to androgenic ratio of many other 
anabolic steroids such as testosterone (1:1), 
methandienone (1:1) and nandrolone decanoate (10:1) 
has prevented their widespread use (18). In the 
present study, the improved nitrogen balance seen in 
the stanozolol treated amino acid group was due 
largely to a significant improvement in nitrogen 
balance in female patients, all of whom were 
postmenopausal. In contrast, male patients were found 
to benefit more in Blarney's study (196) where 
dextrose-saline was administered rather than amino 
acids.
The minimal, delayed rise in REE in the 
dextrose-saline control group cannot readily be 
explained- A proportion of the postoperative REE in 
the AA and GAF groups will be due to the specific 
dynamic action of the infused nutrients (263), but it 
is unlikely that the significant difference in 
postoperative REE in the two DS groups is due to 
stanozolol, since it had no apparent effect on REE in 
the AA and GAF groups.
Stanozolol did not influence serum protein levels 
postoperatively, although serum albumin on the fourth 
postoperative day was lower in the stanozolol treated 
AA group than in the AA control group. Blamey and 
colleagues (196), noting a trend towards lower serum 
transferrin levels in the stanozolol treated group, 
speculated that improved protein synthesis in skeletal 
muscle may be at the expense of liver protein 
synthesis. This is unlikely to be the explanation in 
the present study since the half life of serum albumin 
is approximately 16 days. The similar postoperative 
excretion of 3-methylhistidine in each of the groups 
suggests that any effect on nitrogen sparing is more 
likely to be due to improved protein synthesis rather 
than decreased breakdown. The fall in serum albumin 
and transferrin in all groups is mirrored in most by a 
fall in haematocrit. Transfer of proteins and fluid 
between body compartments, as well as changes in 
protein synthesis and catabolism, are known to
infuence changes in serum proteins (267).
Fluid retention due to anabolic steroids has been 
reported previously (196,197,268), but in the present 
study there was no evidence of fluid retention due to 
stanozolol. The discrepancy between the fluid balance 
and total body water measurements has been discussed 
in the previous chapter. Stanozolol had no 
significant effect on renal function irrespective of 
the type of postoperative nutritional regimen 
infused. The increases in serum and urine urea in the 
AA and GAF groups indicate metabolism of the infused 
amino acids. The similar values for the urinary 
excretion of nitrogen in forms other than that of urea 
and ammonia indicate that the infused amino acids have 
been metabolized to a similar extent in both groups.
In conclusion, preoperative administration of the 
anabolic steroid stanozolol has been shown to improve 
postoperative nitrogen balance in cancer patients 
receiving amino acid infusions. This improvement was 
most marked in female patients. It appears to have 
little or no effect in postoperative patients 
receiving either a combination of glucose, amino acids 
and fat or a simple dextrose-saline regimen. It is 
possible that alteration in the dose and timing of 
administration of stanozolol may enhance its effect on 
nitrogen balance.
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CHAPTER 13
THE EFFECTS OF AN ANABOLIC STEROID AND NAFTIDROFURYL 
ON THE METABOLIC RESPONSE TO TRAUMA IN PATIENTS 
FOLLOWING SURGERY FOR GASTRIC CANCER
2Ub
INTRODUCTION
The administration of naftidrofuryl in the 
postoperative period has yielded conflicting results 
(21,190,191). Burns and colleagues (21) demonstrated 
an improvement in postoperative nitrogen balance using 
this agent, and suggested that its effect may have 
been due to stimulation of carbohydrate and fat 
catabolism, thus conserving tissue protein.
In the previous chapter, the administration of 
stanozolol failed to improve postoperative nitrogen 
balance in patients with colorectal cancer receiving a 
standard dextrose-saline regimen. In the present 
study, the effects of combining naftidrofuryl with 
stanozolol have been assessed in a randomised study of 
patients undergoing surgery for gastric cancer. These 
patients have been compared with similar patients who 
received either stanozolol alone or no pharmacological 
a g e n t .
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PATIENTS & METHODS
Thirty patients about to undergo elective surgery 
for gastric cancer were randomised to one of the 
following treatment groups or to a control group:
(1) Stanozolol group - Patients in this group
received a single intramuscular injection of 
50mg stanozolol (Stromba - Sterling Research 
Laboratories) 24 hours prior to surgery.
(2) Stanozolol/naftidrofuryl group - Patients in
this group received stanozolol as above plus 
slow bolus intravenous infusions of 
naftidrofuryl (Praxilene - Lipha Laboratories) 
200mg twice daily commencing on induction of 
anaesthesia and continuing until the end of 
the fourth postoperative day.
(3) Control group - Patients in this group
received neither stanozolol nor naftidrofuryl.
For the first four postoperative day all patients 
received a constant infusion of dextrose 5% (2 
litres/day) plus one litre normal saline/day 
administered via a peripheral vein using a peristaltic 
infusion pump.
Other methods used are as described in Chapters 3 
and 11 .
2UY
RESULTS
Each group consisted of ten patients. There were 
no significant differences between the groups with 
respect to mean age, body weight, percentage weight 
loss and lean body mass (Table 55). The types of 
operation performed are shown in Table 56.
There were no significant differences in 
preoperative urinary nitrogen excretion between the 
groups (control = 6.2 + 1.3gN/d; stanozolol = 3.9 ± 
0.5gN/d; stanozolol/naftidrofuryl = 4.5 ± 0.7gN/d). 
Postoperatively, there were no significant differences 
between the groups in the cumulative nitrogen balance 
for the first four postoperative days (control = -32.7 
± 3.0gN; stanozolol = -23.6 + 3.1gN; 
stanozolol/naftidrofuryl = -27.1 ± 3-7gN). Daily 
nitrogen balance for each of the groups is shown in 
Figure 33- There were no significant differences 
between the groups on the first three postoperative 
days, but on the fourth postoperative day, nitrogen 
balance in the stanozolol (P<0.01) and 
stanozolol/naftidrofuryl (P<0.05) groups was 
significantly better than in the control group. 
Nitrogen balance improved significantly between the 
first and fourth postoperative days in the 
stanozolol/naftidrofuryl group only (P<0.05).
Cumulative nitrogen balance, displayed separately
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Figure 33
Mean daily nitrogen balance (+ s.e.m.) for the first 
four postoperative days in the control, stanozolol 
and stanozoiol/naftidrofuryl groups of patients
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for males and females, is shown in Figure 34. An 
analysis of variance shows no significant differences 
within the groups of males or females, but the 
cumulative nitrogen balance for females was 
significantly less negative than that for males in the 
control (P<0.05) and stanozolol (P<0.01) groups.
There were no significant differences between the 
groups in pre- and postoperative REE (Figure 35) and 
RQ (Figure 36). Postoperatively in the 
stanozolol/naftidrofuryl group, REE increased 
significantly (P<0.05) and RQ fell significantly 
(P<0.05), compared with preoperative values.
There were no significant differences between the 
groups in pre- and postoperative carbohydrate and fat 
oxidation rates (Figures 37 and 38). However, 
postoperative fat oxidation rates were significantly 
greater than preoperative values in the stanozolol 
(P<0.05) and stanozolol/naftidrofuryl (P<0.01) 
g roups.
There were no significant differences between the 
groups in measured fluid balance on any of the 
postoperative days (Figure 39), nor in the cumulative 
fluid balance over the four postoperative days 
(Control = +3.7 + 0.6 litres; Stanozolol = +2.3 + 0.5 
litres; Stanozolol/naftidrofuryl = +3.4 + 0.6 
litres). These cumulative fluid balance results
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Figure 34
Mean cumulative nitrogen balance (+ s.e.m.) in male 
and female patients in the control, stanozolol and 
stanozolol/naftidrofuryl groups
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Mean resting energy expenditure (± s.e.m.) 
preoperatively and on the 2nd and 4th postoperative 
days in the control (C), stanozolol (S) and 
stanozolol/naftidrofuryl (S/N) groups of patients
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Figure 36
Mean respiratory quotient (+ s.e.m.) preoperatively 
and on the 2nd and 4th postoperative days in the 
control (C), stanozolol (S) and stanozolol/ 
naftidrofuryl (S/N) groups of patients
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Mean carbohydrate oxidation rates (+ s.e.m.) 
preoperatively and on the 2nd and 4th postoperative 
days in the control (C), stanozolol (S) and 
stanozolol/naftidrofuryl (S/N) groups of patients
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Figure 38
Mean fat oxidation rates (+ s.e.m.) preoperatively and 
on the 2nd and 4th postoperative days in the control 
(C), stanozolol (S) and stanozolol/naftidrofuryl (S/N) 
groups of patients
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Figure 39
Mean daily fluid balance (+ s.e.m.) for the first four 
postoperative days in the control, stanozolol and 
stanozolol/naftidrofuryl groups of patients
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contrast with the total body water measurements which 
showed a loss in total body water in the 
stanozolol/naftidrofuryl group (-0.02 ± 1.1 litres) 
and a gain in the other two groups (control = +1.1 ± 
0.6 litres; stanozolol = +0,07 + 0.7 litres). The 
number of patients requiring postoperative diuretic 
therapy was not significantly different between the 
gr o u p s .
Preoperatively there were no significant 
differences between the groups with respect to the 
urinary excretion of the metabolites shown in Tables 
57 and 58. Postoperatively, cumulative urinary urea 
excretion and the percentage of urinary nitrogen 
excreted in the form of urea were significantly lower 
in the stanozolol group than in the control group 
(P<0.05). There were no significant differences 
between the groups in postoperative 3-methylhistidine 
excretion.
There were no significant differences between the 
groups with respect to pre- and postoperative serum 
urea, serum creatinine, plasma glucose and plasma 
insulin (Table 59). Postoperatively, serum albumin, 
serum transferrin and haematocrit fell significantly 
(P<0.05), but there were no significant differences 
between the groups (Table 60).
There were no significant differences between the
Qs:
<
O
o
N
O
S
<
H
OQ
O
S
O
H
H
W
CK
O
%
W
>H
PC
<
z
H
CC
>-
LO
ÙJ
CÛ
<C
I—I 
>, 
ÎH
3
Cm
0 
S-, 
"O 
•H 
- O  
Cm 
CÜ 
C
1
I—I
O
I—I
O
N
O
C
cd
-P
OQ
r— e n  r— T— CM T -
• en • • O • • •
o - : # - en K O • PO LO r-
z f  C\J r- OO C\J CM OO
-H -H -H -H -H +» ■H -H
T- O ^  OO K O  e n C— r-
C\i o nn cTv • K O • ^
e n  T— r -  [>- CM r- O
1—
PC LO CO OO CM CT> CM
E-t 1---1 • o • • CM • • •
Z O [> - en LO LO • KO ^  n -
O 1---1 en CM T- (X en r - r -  KO
CJ O
(SI -H -H ■H -H +) -H +1 -H
w o
X OQ c KO X " X -  LO O  CM (YQ CM
H CL, cd 0 -  CM o  T- • LO • X
X X CM !>- r— KO t>- ^ O  en
X O OQ r — T— LO
M PC
o
<C
1-4 X
S
o PC
s X
s Cij
< o
PC
Q Q e n KO CJYOO
S M • 00 • CM CM • » •
■=i: H X r -  X " X o • O O  KO
X o e n  CM (YQ T- tn- (Y i CM LO
< C Î-.
[ i ] X X ■H -H -H -H ■H -H -H -H
ce c
X X o O  LO LO O KO n- r -  OO
o X X -  tn - P -  < X • o • OO
w X X -  X - r -  e n en CM C— CM
Z o CM CM KO
W N
Ü O
O X
K - <
H E-<
M OQ
Z
(X
o
w CO 
L, U 
3  3
O O
x: x: 
:=r X  
c\j en
(0 CO 
L, P 
3  3  
O O 
X X 
^  vO 
C\J (3\
CO W 
^ L, 
3  3  
O O 
X X 
vO
C\J
C W CO 
(ü S-, s- 
bû 3  3  
O O O 
S-. X X 
X zj- kO 
•H c\j en
1—11—1 1-11—1 1-1,— 1 1—11— 1
o o O O O O G G GS s s S s e •H S S
s e s s s E C Ë S
G
S
CL X X X X X S X X
O G o o o G G G G
<D X G X G X 1 G X
C. CO P G L, en C G G
X O X O X G G X G
X X X C X
c « • G
<D G G
W •H O
O • ■ C 3
CD 1
X G G
G
<
S 
D 
CO 
+ 1
W 1—1z >5
M G
Q 3
M z
H O
CO S_
M Z X  en LO o LO OO
Z •H • » • • « t
Z X on T- o  T - T- CM>H Z
Z G +1 -H -H -H + 1 +1
H C
W OO CO CM ^ OO ^
2 CO 1--1 • » « » « «
1 PC O X  LO X  OO O- f-
m z 1—1 OO n- T- on
Q
S
Z
W
üo
PC
H
M
z:
>H
PC<
z
M
PC
Z)
Ù-to
OQ
zo
2
2<
Q
Z<
<W
ce
z
Xo
zo
H
H
H
ce
o
%
w
PC<
z
M
PC
z
CO
LO
w
z
m<
H
o
ceo
z
cez
Ù-i
O
ce
Q
MH
X
<z
zozoNO
Z<
H
OQ
O
Z<
ZOzo
tsi
o
Z•X
H
OQ
ZO
ce
Hzo
o
w
zH
ON
O
CGX
CQ
ON
OC
G
X
OQ
OU
XCOO
OO [— CM T - X  T -
X  o n o n  CM o n  o n
-H -H -H -H +1 +1
OO o n LO X CM LO
o n  e n OO o O  O
I Z lO r— CM o n
o n  LO LO o n X CO
o n  CM 0 - CM -
-H •H -H -H + 1 +1
m- o coco LO
o O X  00 T— 0 0
OO OO CM CM
G G
G G
3 3
0 0
Z Z
X  LO
CM OY
G G
• • G G
•H Z
C G G
• • G •H Z
/—s bO X X
c 0 G G
G G G G
àû X G G
O •H Ü Ü
L, ■5^ G 3%.3$. • •
X G Z 1—1
•H Z G 0 0
C X X 0 X X •H Ë Ë
o 0 0 0 Z Ë Ë
Z G X o®- G X •H
O G G G G X Z Z
PC 0 G X 0 G 0 0
■gÇ. X G X Z Ë Ë
Z 3 3
G 1—1
G G
•H Z X X
C X 0 0
G 0 G G X
G e G G
G g ! X 0
,'Y'l
Ë 
0 
G 
+ 1
C
GG
S
Z
ec
z
s
M
CO
H CO
Z X
[ l ] z
H o
H oc
< CJ
X
z
Z z
H PCz
S X
M oZ PC
Z Q
CO M
Z: H
M . X
<
Q Z
2 \
< zo
W z
CO o
O N
O O
Z Z
Z <
Ü H
CO
<S Q
CO Z
=G <
ZX ZozW o
Z N
M O
Z Z
M <Z E-i
< CO
W
OC
CJ Z
O
Q XZ H
< Z
O
< oW
OC
Z
2
Z
OC
( Z
CO
e n
LO
[i]
Z
m
H
G
3
Z
0 
G 
Z 
•H  
X 
Z  
G 
C
1
O
N
O
G
G
X
OQ
O
N
O
G
G
X
OQ
O
G
X
G
O
O
POLO X  
O  O 
+1 +1 +1
0 0  X  o n  
LO X  m
LO 0 0  LO
o  o  o  
+1 +1 +1
T— o
m x  o n
tn - LO LO
o  o  o  
+1 +1 +1
T - o n  CO 
L o x  o n
00 t>-
• • o
o  o  •
T— T— OO
+ 1 +1 +1
m- LO m- 
OY e n o o
X  
e n  • r- 
• o n  •
LO r- LO
+1 +1 +1
e n  e n  X  
0-00 t>-
OO o  LO
X  LO LO
+1 +1 +1
o n  e n  tn - 
00 Cn- 10-
o n  LO o n  ou 
o  o  o  o  
+1 +1 +1 +1 
OY OY C-- [>-
LO LO LO LO
o n  LO o n  o n  
o  o  o  o  
+1 +1 +1 +1
X  o n L O  ou 
LO LO LO LO
0- x  o n  LO 
o  o  o  o  
+ 1  + 1  -f-l + 1
OO o  X  X  
lO  0 -  lO  LO
o - o  LO ou
+1 +1 +1 +1
—^ ou o n  1— 
OO OY e n o o
o  LO OO o n  
o n  ou T - ou
+1 +i +1 +1
LO r -  LO o -
ou X  o  '—
OO OO X  t z  
X  on ou r- 
+1 +1 +1 +1
OO LO Z O O
z  z  o n  o
I—1
X 1—1 • •
O
• * S 1—1 ,—1
/—s 3 O
t—1 S
a
Z
a
rH G
o G
S •H G G
s G W •H
•H
X
O
Ü
X
3
G G 3 G
G G i—! G
G G bO X
3 X O U  X G X  OU X X  X o n  X
GO O G o
S G Z Z S G Z Z a G Z Z z a
3 G G G 3 G G G G G G G G G
G X Q Q G X O Q G X Q a Q G
G G 1—! 1—!
CO CO X X
X  ou o n  X  
o
G z z z
G G G G 
CL, Q  Z  Q
e
G
G
+ 1
G
G
G
S
zo
OC
E-i
Zo
CJ
w
z
H
Z
M
CO
H
Z
W
M
H
<
X
Z
M
H
M
X
CJ
O
H
<C
2
M
<C
Z
Û
Z
<
X
X
w
X
COz
<
X
H
2
Z
X
X
CO
CO
Xzo
X
ü
z
z
Xz
X
o
X
Q
H
H
X
<z
zozo
N
O
Z
<
H
CO
Q
Z
<
Z
ozo
N
O
Z
<
H
CO
Z
G
3
X
O
G
Z
•H
Z
X
G
G
O
NI
O
G
G
Z
CO
O
NI
O
G
G
Z
CO
O
G
Z
G
O
O
m c o  X X î— V- X T—LO
r -  o T- o o o
+1 +1 +1 +1 +1 +1 +1 +  1+1
t z o o  OO o LO o n r- T-CO
X  OYOO 
o n  X  X
X T- T- OO LO X  
o n  o n  o n
o  o n  T— X  '— '— OO r— O
X  ^  r - o  o  o
+  1 + 1  + 1 + 1  + 1  + 1 + 1  + !  + 1
T—  r -  CO o n  LO LO X  LO o n
X  OO LO X  r -  '— OO LO X
o n  X  X o n  o n  o n
Z -  LO t Z X T— t— o n o o  10-
o o o
+1 +1 +1 +1 +1 +1 +1 +1 +1
O LO X X LO LO z- LO o n
LO o o  to­ X r- T- LO o n  o n
o n  X  X en en en
2
Z
Z
Z
<
2
Z
X
X
CO
o
LO
Xz
m
<
H
bO
G
•H
s
3
Z
X C M  X  
O
G  Z  Z  
G  G  G  
X  Z  Z
bû
G
•H
G
G
G
X
G
G
G
G
Z X X X
O
G  Z  Z  
G  G  G  
X  Z  Z
Z
•H
G
ü
O  X X  X  
Z  O
G  G  Z  Z  
S  G  G  G  
O  X  Z  Z  
G
Z
G  
G  
+ 1
G
G
G
21 c
groups with respect to postoperative complications and 
hospital stay (Table 6l).
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DISCUSSION
This study shows that stanozolol, whether given 
alone or in combination with naftidrofuryl, has little 
nitrogen sparing effect in postoperative patients 
receiving a simple dextrose-saline regimen. However, 
over the four postoperative days, nitrogen excretion 
in the stanozolol and stanozolol/naftidrofuryl groups 
tended to decrease, such that, by the fourth 
postoperative day, nitrogen excretion in these groups 
was significantly less than in the control group.
This late effect on nitrogen excretion appears to be 
due solely to the administration of stanozolol, as the 
addition of naftidrofuryl provided no additional 
benefit in terms of nitrogen excretion.
This late effect of stanozolol contrasts with the 
findings of the previous chapter, where stanozolol had 
no significant effect on nitrogen excretion in 
colorectal cancer patients receiving the same 
dextrose-saline regimen. It also contrasts with the 
study of Blarney and colleagues (196), who demonstrated 
improved nitrogen balance on the first three 
postoperative days in patients receiving the same 
anabolic steroid and postoperative fluid regimen. The 
differences in the patient populations in the various 
studies of anabolic steroids have been discussed in 
the previous chapter. There are also differences in 
the patient populations used in studies of
naftidrofuryl. Most of these studies have consisted 
of patients with mainly benign disease (21,190,191). 
Furthermore, Burns and colleagues (21) excluded 
patients with weight loss while Jackson and colleagues 
(191) excluded nearly one third of their patients, 
including those with considerable weight loss, 
metastatic disease and postoperative sepsis. In the 
present study, 12 patients had lost more than 10% of 
their pre-illness weight, seven had liver métastasés 
and three developed postoperative fistulae. No patient 
was excluded.
These differences in patient populations and in 
the dose and method of administration of the 
pharmacological agents used make comparison of the 
present results with those of other studies difficult. 
In the present study, naftidrofuryl was administered 
by slow bolus, similar to the method used by Burns and 
colleagues (21) and Jackson and colleagues (191). The 
latter group of workers were unable to demonstrate any 
significant effect on nitrogen excretion using this 
method, while Inglis and colleagues (190), using a 
continuous infusion of naftidrofuryl, also were unable 
to demonstrate a significant effect.
The significant increase in postoperative fat 
oxidation in the stanozolol and
stanozolol/naftidrofuryl groups suggests that these 
agents may influence substrate metabolism. The
greater increase occurred in the
stanozolol/naftidrofuryl group, and was associated 
with a significant fall in RQ. These findings are 
consistent with the hypothesis of Burns and colleagues 
(21), who suggested that naftidrofuryl may increase 
the utilisation of fat and carbohydrate, thus sparing 
body protein stores. Johnson and colleagues (191) 
demonstrated changes in lactate and total ketone 
concentrations in postoperative patients receiving 
naftidrofuryl which would support this hypothesis, but 
as in the present study, were unable to demonstrate 
any significant nitrogen-sparing effect.
In conclusion, there is some evidence to suggest 
that the preoperative administration of the anabolic 
steroid stanozolol influences postoperative nitrogen 
excretion in patients undergoing surgery for gastric 
cancer. While naftidrofuryl has had no demonstrable 
effect on nitrogen excretion, both this agent and 
stanozolol may influence postoperative fat oxidation, 
which could indirectly affect nitrogen excretion. The 
effect of these agents on energy substrate metabolism 
thus appears to warrant further investigation-
CHAPTER 14
CONCLUSIONS
Energy expenditure
Over the past 70 years many authors reported that 
patients with cancer had a raised resting energy 
expenditure (REE), and suggested that this could 
contribute significantly to the development of cancer 
cachexia. However, many of the early studies were 
anecdotal and even some recent studies used either 
inappropriate or no control groups. The first aim of 
this thesis, therefore, was to assess whether the 
presence of cancer influenced the REE of the host.
The comparison of weight stable and weight losing 
patients with cancer and nonmalignant illness (Chapter 
4), yields no evidence to suggest that cancer results 
in a raised REE. The presence of weight loss, 
irrespective of whether the patient has cancer or not, 
is related more closely to abnormalities of REE. This 
suggests that the host response to an illness, benign 
or malignant, is a major determinant of alteration in 
REE, rather than any factor associated with the 
presence of cancer itself.
There are subtle differences in the relationship 
between REE and indices of body size depending on the 
type of cancer present (Chapter 7). This finding 
highlights the disadvantages in using heterogeneous 
groups of cancer patients in studies of REE.
The importance of expressing REE in terms of the 
metabolically active portion of body weight has been 
stressed. The REE studies of this thesis have 
demonstrated that misleading results are obtained when 
REE is expressed in terms of body weight, which makes 
no allowance for the relatively less metabolically 
active fat mass. The possible disadvantages in using 
total body water measurements for the estimation of 
lean body mass in malnourished patients have been 
discussed, but it should be noted that even total body 
potassium measurements can be inaccurate in the 
presence of weight loss.
Many authors have suggested that REE increases 
with advancing tumour burden, with major increases in 
REE occurring in patients who have hepatic métastasés. 
In the longitudinal study of patients with colorectal 
cancer (Chapter 8), no significant differences in REE 
have been found following either curative resection or 
progression of metastatic disease. This supports the 
earlier conclusion that the presence of cancer has no 
significant effect on host REE.
Prediction of resting energy expenditure
Some authors have claimed that cancer patients 
have a raised REE, basing their conclusions on a 
comoarison of measured REE with that predicted by
various predictive formulae. In Chapter 5, where four 
predictive formulae or tables have been compared with 
measured REE values, significant errors in the 
predictive ability of these formulae and tables have 
been found. Of particular importance is the inaccuracy 
of the widely-used Harris-Benedict formula in 
predicting REE in male patients, irrespective of 
disease or weight status. It is concluded that subtle 
differences in body composition between ill patients 
and the healthy volunteers used to derive these 
formulae are responsible for the inaccuracy in 
prediction of REE.
An alternative method of estimating REE in the 
absence of indirect calorimeter facilities has been 
demonstrated (Chapter 6). Close correlations between 
measured REE and mid-arm muscle circumference (MAMC) 
measurements have been demonstrated. It is noteworthy 
that the regression lines relating REE to MAMC are 
similar to those relating REE to lean body mass 
(Chapter 4). This suggests that MAMC measurements are 
representative of the metabolically active portion of 
the body. A prospective study using the regression 
equations derived from MAMC measurements would be 
required to test the accuracy of prediction of REE 
using this technique.
Substrate metabolism
Patients with cancer have been shown to have 
decreased rates of endogenous carbohydrate oxidation 
and increased rates of endogenous fat oxidation 
compared with patients with nonmalignant illness. 
These abnormalities are more pronounced in those 
cancer patients with hepatic métastasés. The studies 
of this thesis can provide no firm explanation for 
these metabolic abnormalities, but the accelerated 
rate of body fat oxidation may contribute 
significantly to the development of cancer cachexia. 
Furthermore, these abnormalities of fat oxidation are 
consistent with the recent discovery that tumour 
necrosis factor, or cachectin, which is produced by 
the macrophages of some patients with cancer, 
interferes with fat metabolism.
Some authors have suggested that whole body 
protein turnover (WBPT) is increased in patients with 
cancer, and that this may cause an increase in REE. 
The results of Chapter 10 demonstrate that patients 
with certain tumour types have increased rates of 
WBPT. However, abnormalities of WBPT are not related 
to weight loss and have no demonstrable effect on 
REE.
The possibility that an acute phase protein 
response is responsible for some of the metabolic
abnormalities seen in patients with cancer has been 
discussed. An acute phase protein response can be 
demonstrated in many patients with progressive cancer, 
and this phenomenon would be consistent with the 
observations made in Chapter 4, where it was concluded 
that the h o s t ’s response to illness appeared to be a 
major determinant of abnormalities in REE.
Furthermore, the presence of an acute phase protein 
response would be consistent with the production of 
cachectin. Studies of the immune response and the 
production of interleukin-1 in cancer patients are 
outwith the scope of this thesis, but warrant further 
investigation.
Peripherally-administered intravenous nutrition
The peripheral administration of glucose, amino 
acids and fat to patients following surgery for 
colorectal cancer has been shown to result in a 
positive nitrogen balance, with minimal phlebitic 
complications (Chapter 11). In those patients 
receiving an amino acid solution alone 
postoperatively, there was a significant fall in 
carbohydrate oxidation rate and a significant rise in 
fat oxidation rate. However, the transient improvement 
in postoperative nitrogen balance in these patients 
appears to have occurred independently of plasma 
insulin levels, and it is concluded that this solution
has little to offer compared with a standard 
dextrose-saline regimen.
This study did not address the question of whether 
debilitated patients undergoing major surgery should 
receive intravenous nutritional support. However, it 
is concluded that where the provision of postoperative 
peripherally-administered intravenous nutrition is 
desired, the use of a nutrition mixture containing 
glucose, amino acids and fat should be used.
Pharmacological manipulation of the metabolic response 
to surgery
Manipulation of the metabolic response to surgery 
using anabolic steroids has yielded conflicting 
results in the literature. The findings of Chapter 12 
suggest that the use of the anabolic steroid 
stanozolol may improve nitrogen balance in patients 
receiving intravenous amino acid solutions following 
colorectal cancer surgery. Although stanozolol had no 
significant effect on postoperative» nitrogen balance 
in those patients receiving glucose, amino acids and 
fat, the trend towards improved nitrogen balance 
suggests that alteration in the dose or timing of 
administration of stanozolol may be worthy of further 
investigation.
In the study of patients receiving a 
dextrose-saline regimen following surgery for gastric 
cancer (Chapter 13), stanozolol appeared to improve 
nitrogen balance by the fourth postoperative day. This 
finding contrasts with the results of Chapter 12, 
where stanozolol had no significant effect on nitrogen 
balance in patients receiving the same regimen 
following colorectal cancer surgery. However, it 
supports the contention that alteration in the dose or 
timing of administration of this agent may be of 
value. Naftidrofuryl had no demonstrable effect on 
postoperative nitrogen balance, but the suggestion 
that both this agent and stanozolol may have some 
effect on postoperative fat metabolism warrants 
further investigation.
Thus, there is some evidence to suggest that 
postoperative nitrogen excretion and substrate 
metabolism may be influenced by the pharmacological 
manipulation of the metabolic response to surgery. It 
is concluded that further studies of the effects of 
stanozolol and naftidrofuryl on the metabolic respone 
should be undertaken.
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APPENDIX
The indirect calorimeter was developed in the 
Department of Surgery largely by Christopher C. Goll. 
The validation of this equipment, including patient 
studies, formed a major part of his Ph.D. thesis 
(269). A schematic representation of the gas circuitry 
of the indirect calorimeter is shown in Figure 40.
Butane gas calorimetry test
A small gas camping light (Lumogaz Camping Gaz 
Ltd) which burns commercial butane gas (Camping Gaz 
Ltd) was burned inside the calorimeter canopy at 
regular intervals to test the sensitivity and accuracy 
of the whole system. This test was performed together 
with regular calibration of the gas analysers (see 
Chapter 3).
Analysis of the fuel by gas chromatography showed 
the constituents to be 93-30% butane, 0.34% propane 
and 6.36% butene. This fuel burns with an RQ of
0 .619. Regular test runs revealed the calorimeter to 
have an error of less than +5%.
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Schematic representation of the gas 
circuitry of the indirect calorimeter
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